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ABSTRACT
Background:
Due to advances in Antiretroviral Therapy (ART), people living with HIV (PLWH)
live longer in the United States. Aging prolongs exposure to HIV and antiretroviral drugs,
which could lead to an elevated risk of developing multiple age-related comorbidities [HIV
Associated Non-AIDS (HANA) conditions], earlier for PLWH. Higher comorbidity
burdens among older PLWH may require greater use of inpatient care, i.e., higher
hospitalization, inpatient resource utilization, and costs. This study examined the trends
and characteristics of comorbidities, resource utilization, and costs of hospital stays with
HIV (HSWH) compared to hospital stays without HIV (HSWOH). We also assessed trends
for resource utilization and costs for hospital stays with major HANA conditions.
Methods:
Thirteen years of pooled data of Health Care Utilization Project (HCUP) National
Inpatient Sample (NIS) data, 2003 through 2015, were analyzed to describe the trends.
Among a total of 98,754,786 inpatient discharges, 69,633,686 inpatient discharges were
analyzed. We excluded hospital stays for patients less than 18 years old, neonatal,
pregnancy, and same-day discharge from our analysis. The primary outcomes of this study
were the number of procedures, length of stay, and inpatient costs. Total hospital charges
were converted to costs using hospital-wide cost-to-charge ratios provided by HCUP from
accounting reports of the Center for Medicare and Medicaid Services. The key independent
variables were age, and hospital stays with HIV. Using SAS 9.4, univariate, bivariate, and
v

multivariable survey-weighted analyses were conducted using sampling weights to
measure national estimates. Multivariable regression analyses using a generalized linear
model (GLM) framework were conducted to determine predictors of inpatient resource
utilization and costs, controlling for the patient- and hospital-level characteristics. The
study results were interpreted using significance level at P<0.01, 99% confidence intervals
(CI), and clinical relevance of the associations.
Results:
Over the study period, the proportions of HSWH remained stable (0.81%), but the
proportions of HSWH among the older increased gradually. The mean age difference
between HSWH and HSWOH reduced substantially. Hospitalization rates decreased from
105 to 89 per 100,000 U.S. population over the years, while the rates for the older
population aged 55-64 and 65+ years increased substantially. Overall, HSWH had fewer
HANA conditions than hospital stays without HIV (HSWOH). The proportions of
cardiovascular disease (CVD) and cancer increased disproportionately over time among
HSWH; CVD and liver disease increased among aged 65+ years, and CVD and cancer
increased among aged 50-64 years.
The median number of procedures for HSWH was consistently lower than that for
HSWOH, but it increased disproportionately among older HSWH over time. While the
overall length of stay and costs for HSWH was consistently higher than that for HSWOH,
the differences narrowed down over the study period. The differences in inpatient resource
use and costs between HSWH and HSWOH also decreased for hospital stays with major
HANA conditions. Multivariable analyses showed that the procedure use was lower for
HSWH. Inpatient LOS and costs were significantly higher among HSWH and older.
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Conclusions:
Consistent with the aging, higher HSWH and HANA comorbidities were observed
among older PLWH during hospital stays, which suggest future increased hospital resource
utilization and costs for HSWH. Our study finding confirms our hypothesis of increased
length of stays and costs during HSWH and utilization of procedures among older HSWH.
As PLWH age, a close investigation of surgical procedures and comorbidities requiring
longer inpatient stays and higher costs is needed to prepare U.S. inpatient departments for
future HSWH.
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CHAPTER 1
INTRODUCTION
1.1 Background of the Study
In 39 years since Human Immunodeficiency Virus (HIV) infection first appeared
as an infectious disease, it has become a manageable chronic condition due to the
advancement of highly active antiretroviral treatment (HAART). In the United States, more
than 1 million people are currently living with HIV. One in seven of the people living with
HIV (PLWH) are unaware of their infection, and every year about 40 thousand people
become newly infected with HIV (HIV.gov, 2018). From 2012 to 2016, while the annual
number of new HIV diagnoses remained stable in the United States, the number of newly
diagnosed PLWH increased among subpopulations like young gay and bisexual men
(Center for Disease Control and Prevention, 2016a). New HIV diagnoses among people
aged 50 years or older decreased significantly from 25% of total new diagnoses in 2006
(Jacobson, 2011) to 17% in 2016 (Center for Disease Control and Prevention, 2018).
Currently, almost half of all PLWH are aged 50 years or older (Center for Disease Control
and Prevention, 2018), and this proportion will rise to more than 70% by 2030 (Wing,
2017). The widespread availability of effective antiretroviral therapy (ART) to suppress
HIV viral load helps PLWH live longer. Hence, HIV-related deaths are decreasing
worldwide. Also, the number of older PLWH are increasing in the United States as the
population age. This shift in aging brings new prevention and care challenges for the
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healthcare system, due to HIV’s transformation from a fatal illness to a manageable but
complex chronic medical condition.
There is a debate about whether HIV accelerates the aging process or acts as an
additional risk factor, which increases the likelihood of developing chronic conditions
among PLWH (Pathai, Bajillan, Landay, & High, 2013; Solomon, O’Brien, Wilkins, &
Gervais, 2014). Whatever the case, the development of geriatric conditions, such as
comorbidities, frailty, poorer cognitive functioning, depression, and other mental illness,
may be hastened with advanced aging (Center for Disease Control and Prevention, 2018;
Heslin & Elixhauser, 2006; HIV.gov, 2017). The prevalence of chronic diseases,
commonly described as HIV Associated Non-AIDS (HANA) conditions, such as
cardiovascular diseases, cancer, osteoporosis, liver disease, renal disease, and
neurocognitive decline, are increasingly common among PLWH with long-standing HIV
infection (High et al., 2012; Pathai et al., 2013; United States Senate, 2013). With the high
prevalence of physical and mental health comorbidities and lack of social supports, aging
with HIV may create higher health care demand, including increased hospital inpatient care
in the United States (Matthew Harris et al., 2015). Increasing comorbidities among older
PLWH may require greater use of inpatient care, which leads to higher resource utilization
and hospital costs (H. Krentz & Gill, 2015; Zingmond, Arfer, Gildner, & Leibowitz, 2017).
The ongoing age shift is also important because older PLWH are at increased risk for
readmission, prolonged hospitalizations (Yehia et al., 2010), and of remaining
underdiagnosed (Blaylock & Wortmann, 2015; Sankar, Nevedal, Neufeld, Berry, &
Luborsky, 2011). Moreover, age-related comorbidities may appear as more severe for
PLWH aging with HIV even on ART compared to others (Gras et al., 2007). Therefore, it
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is vital to explore how existing health care infrastructure can meet the increasing demand
for clinical and non-clinical services for this growing aging population.

1.2 Statement of the Problems
With the advent of highly active antiretroviral treatment (HAART), the incidence
of AIDS-defining illnesses and HIV-related mortality has reduced significantly (High et
al., 2012). These successes, combined with a growing aging population (45% of the PLWH
were aged 50 or older in 2015), bring new prevention and treatment challenges for HIV
care (United States Senate, 2013). HANA conditions, like cardiovascular disease, cancer,
osteoporosis, liver disease, renal disease, and neurocognitive decline, are common among
PLWH with long-standing HIV infection (High et al., 2012; Pathai et al., 2013; United
States Senate, 2013). Multiple projections suggest that the demand for health care services
by older adults will rise considerably in the coming decades due to long-term ART
toxicities and multiple comorbidities.
While it is difficult to determine whether HIV accelerates the aging process, or is
merely an additional risk factor for chronic conditions, research shows the development of
geriatric clinical conditions is hastened with advanced aging (High et al., 2012; Pathai et
al., 2013). HIV induced chronic immune activation and inflammation is referred to as a
factor of accelerated or early aging, and that leads to PLWH developing multiple
comorbidities at a younger age than the general population (Ahn et al., 2019; Desai &
Landay, 2010; Guardigni & Montano, 2018). High prevalence of physical and mental
health comorbidities and lack of social supports significantly affect the quality of life of
PLWH, which leads to higher health care demand, including increased hospital inpatient
care in the United States. Studies show that PLWH aged 50 years have higher
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hospitalization rates and length of stay (LOS) compared to younger PLWH in the United
States (S. A. Berry, Fleishman, Moore, & Gebo, 2012; Fleishman et al., 2005; Tadros,
Shaver, Davis, & Davidov, 2012). Also, the overall cost of HIV management has increased
in recent years, and it is projected to increase further as PLWH are living longer with more
HANA conditions (Ward et al., 2020).
Therefore, the rapid increase in the number of PLWH aging with HIV in the United
States may have important implications for the demand and the availability of inpatient
resources. Also, other demand pressures could affect infrastructure, patient-management,
and hospital-based long-term care treatment outcomes. However, it remains unclear
whether the existing health care infrastructure can meet increasing specialized demand for
clinical and non-clinical services for the aging HIV population (High et al., 2012).

1.3 Significance of the Study
Assessing the changing patterns of hospital admissions, comorbidity burdens,
resource utilization, and inpatient costs of PLWH during hospital stays is essential to
planning for future inpatient care resource demand posed by the aging PLWH. However,
there is a lack of research addressing the complicated relationship of age, comorbidities,
and outcomes of the patients during hospital stays with HIV diagnosis in the United States.
Few studies have investigated hospital resource utilization and costs with the aging of
PLWH compared to non-PLWH using U.S. national inpatient data. To our knowledge,
studies focusing on age-related medical conditions using the national-level inpatient data
are scarce. This study adds to the literature and the field by examining and describing
HANA comorbidities associated with the aging of patients during hospital stays, using
thirteen years of national inpatient sample (NIS) data (2003-2015). Studying recent trends
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of the patient and facility-level factors, inpatient resource utilization, and costs associated
with HIV hospital stays are important. Hospital inpatient cost analysis is critical in HIV
and aging research for optimizing scarce resource allocation by both public and private
payers.
The purpose of this study is to examine trends and characteristics of inpatient stays,
resource utilization, and costs during hospital stays with HIV compared to hospital stays
without HIV, and across patients’ age. This study hypothesized that the aging of PLWH is
associated with increased hospital admission and a higher presence of HANA conditions
among older HIV patients compared to non-HIV patients during their inpatient stays. This
study also hypothesized that the comorbidity burdens of older patients are associated with
increased resource utilization and costs of care during their hospital stays than their nonHIV counterparts.

1.4 Research Questions
Question 1. What are the differences in characteristics and comorbidities between hospital
stays with HIV and hospital stays without HIV, from 2003 to 2015?
Question 2. What are the age-specific trends in HANA comorbidities, resource utilization,
and costs of hospital stays with HIV and hospital stays without HIV, from 2003-2015?
Question 3. What are the variations in inpatient resource utilization and costs of care
between hospital stays with HIV and hospital stays without HIV by age of the patients?
Question 4. What are the variations in inpatient resource utilization and costs of care
between hospital stays with HIV and hospital stays without HIV by age of the patients
hospitalized with select major HANA conditions?
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1.5 Research Objectives
The overall goal of this study is to describe, compare, and examine the patient- and
hospital-level characteristics, comorbidity burdens, inpatient resources utilization, and
costs of hospital stays with HIV diagnosis compared to that with non-HIV diagnoses, from
2003 through 2015. The specific aims and hypotheses have been arranged based on related
publications and are described below.
Paper 1
Paper 1 is a descriptive study which focuses on the specific aims:
Aim 1. Describe the overall and age-specific rates of hospital stays with HIV in the United
States, 2003 to 2015.
Null hypothesis (H0): The rates of hospital stays with HIV did not change over the
study period.
Alternative hypothesis (H1): The rates of HIV hospitalization decreased over the
study period.
Aim 2. Compare the changes in the patient- and hospital-level characteristics between
hospital stays with HIV and hospital stays without HIV, 2003 to 2015.
H0: There were no changes in the patient- and hospital-level characteristics between
hospital stays with HIV and hospital stays without HIV over the study period.
H1: There were changes in the patient and hospital-level characteristics between
hospital stays with HIV and hospital stays without HIV over the study period.
Aim 3. Describe the changes in the top primary diagnoses and procedures of hospital stays
with HIV compared to that of hospital stays without HIV over the years, 2003 to 2015.
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H0: There were no changes in the top primary diagnoses between hospital stays
with HIV and hospital stays without HIV over the years.
H1: Hospital stays with HIV had higher proportions of age-related conditions in the
primary diagnoses than hospital stays without HIV over the years.
Aim 4. Describe the prevalence of major HANA comorbidities during hospital stays with
HIV compared to that during hospital stays without HIV, 2003 to 2015.
H0: There were no differences in the proportions of major HANA conditions
between hospital stays with HIV and hospital stays without HIV over the years.
H1: Hospital stays with HIV had higher proportions of major HANA conditions
than hospital stays without HIV over the years.
Aim 5. Examine the HANA comorbidity patterns across the different age groups during
hospital stays with HIV compared to that during hospital stays without HIV, 2003 to 2015.
H0: There were no differences in the age-specific proportions of HANA conditions
between hospital stays with HIV and hospital stays without HIV over the years.
H1: Hospital stays with HIV had higher proportions of HANA conditions among
older patients than hospital stays without HIV over the years.
Paper 2
Paper 2 focuses on the resource utilization, and costs of hospital stays with HIV
compared to that of hospital stays without HIV in the United States for the select major
HANA condition(s). This paper compares yearly trends of inpatient resource utilization
(number of procedures and LOS) and costs of care between these two types of hospital
stays. Moreover, it discusses variations in resource utilization and costs across different
age groups. The specific aims are:
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Aim 1. Describe the differences in inpatient resource utilization (number of procedures and
LOS) and costs between hospital stays with HIV and hospital stays without HIV over the
years, 2003 to 2015.
H0: There were no changes in resource utilization and costs between hospital stays
with HIV and hospital stays without HIV over the years.
H1: Hospital stays with HIV had higher resource utilization and costs than hospital
stays without HIV over the years.
Aim 2. Estimate the variations in inpatient resource utilization (number of procedures and
LOS) and costs between hospital stays with HIV and hospital stays without HIV over the
years for patients hospitalized with select major HANA conditions, 2003 to 2015.
H0: There were no changes in resource utilization and costs between hospital stays
with HIV and hospital stays without HIV over the years for patients hospitalized
with select major HANA conditions.
H1: Hospital stays with HIV had higher resource utilization and costs than hospital
stays without HIV over the years for patients hospitalized with select major HANA
conditions.
Aim 3. Compare the inpatient resource utilization, and costs between hospital stays with
HIV and hospital stays without HIV across different age groups of the patients, 2003 to
2015.
H0: There were no changes in the age-specific resource utilization and costs
between hospital stays with HIV and hospital stays without HIV over the years.
H1: Hospital stays with HIV had higher resource utilization and costs than hospital
stays without HIV over the years with the increasing age of the patients.
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Aim 4. Assess the association of inpatient resource utilization and costs with the HIV and
age of the patients during hospital stays, controlling for patient and facility-level factors.
H0: There is no association of inpatient resource utilization and costs with the HIV
and age of the patients during hospital stays, controlling for patient and facilitylevel factors
H1: There are significant associations of inpatient resource utilization and costs
with the HIV and age of the patients during hospital stays, controlling for patient
and facility-level factors.
Aim 5. Examine the effect of HIV and patients’ age on resource utilization and costs of
care during hospital stays with the select major HANA conditions, controlling for patients’
demographic and facility-level factors.
H0: There are no effects of HIV and age on inpatient resource utilization and costs
during hospital stays, controlling for patient and facility-level factors.
H1: There are significant effects of HIV and age on inpatient resource utilization
and costs during hospital stays, controlling for patient and facility-level factors.
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CHAPTER 2
LITERATURE REVIEW
2.1 Aging in the United States
The United States’ population pyramid (Figure 2.1) clearly shows that a large
portion of the American population is aging (U.S. Census Bureau, 2019) due to the postWorld War II baby boomers because babies born in between 1946 to 1964 are currently at
least 55 years old. A rapid change in age structure may have significant social and
economic consequences, including a major impact on the organization and delivery of
health care (Wiener & Tilly, 2002). With aging, multiple chronic health conditions appear,
which sometimes turn into disabilities requiring long-term care services, such as home
health, nursing homes, personal care, and congregate housing (Wiener & Tilly, 2002).
Multiple projections suggest that the demand for health care services by older adults will
rise considerably in the coming decades. This additional demand will create immense
pressure on the healthcare workforce to deliver those services (Institute of Medicine, 2008).
Thus, priority should be given to strengthening care delivery for co-occurring chronic
conditions through the widespread adoption of evidence-based practices targeting older
adults in the areas of disease prevention, long-term care, palliative care, and effective care
management (Rowe, Fulmer, & Fried, 2016).
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Figure 2. 1 Population pyramid of the United States, 2019.

2.2 HIV Infection in the United States
More than 1 million people are living with HIV (PLWH) today in the United States.
One in seven PLWH is unaware of their infection, and every year about 40 thousand people
become newly infected with HIV (HIV.gov, 2018). In 2018, a total of 37,832 people
received an HIV diagnosis in the United States and six dependent areas, and the annual
number of new HIV diagnoses decreased by 9 percent from 2010 to 2017 (Center for
Disease Control and Prevention, 2019a). New HIV infections (HIV incidence) refers to the
estimated number of people who are newly infected with HIV during a year, which is
different from the number of people diagnosed with HIV during a year. HIV can be
diagnosed through blood or saliva testing in multiple ways, such as antigen/antibody tests,
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antibody tests, or nucleic acid tests (NATs). The stage of HIV infection (early, acute, and
chronic infection and AIDS) can be determined by measuring CD4 T Cell count, viral load
(HIV RNA), and drug resistance tests. AIDS is the late stage of HIV infection that occurs
when the body’s immune system is severely damaged due to the destruction of white blood
cells. HIV infection is identified as AIDS (stage 3) when PLWH have fewer than 200 CD4
cells per cubic millimeter of blood (<200 cells/mm3), or having one or more opportunistic
infections regardless of their CD4 counts (Castro et al., 1993). In 2018, a total of 17,032
PLWH were diagnosed with AIDS in the United States and six dependent areas. Since the
beginning of the HIV epidemic, more than 700,000 people have died of HIV/AIDS in the
United States, and nearly 15,000 people die each year from AIDS (Center for Disease
Control and Prevention, 2016b).
The HIV/AIDS epidemic has seen dramatic shifts since its first cases were
identified in 1981. Today, a previously fatal infection has become a manageable chronic
condition due to the advancement of HIV/AIDS treatment. The advent of combination
antiretroviral therapy (cART) prevents HIV from growing inside the body and keeps the
virus at a very low level or ‘suppressed’ (HIV.gov, 2019b). The viral load (HIV RNA) tests
are done to check the status of HIV after diagnosis and to monitor the success of HIV
treatments. Viral suppression, which keeps the immune system working and prevents
illness, is measured as a viral load test result of fewer than 200 copies/mL at the most recent
viral load tests (Centers for Disease Control and Prevention, 2019). PLWH on ART can
achieve viral suppression with reduced risk of transmitting HIV to their HIV-negative
sexual partners (Centers for Disease Control Prevention, 2018a). Therefore, ART is
recommended for all PLWH irrespective of how long they have had the virus or how
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healthy they are (Center for Disease Control and Prevention, 2019d). According to the
CDC, an estimated 62% of persons with diagnosed HIV in the United States were virally
suppressed in 2016 (Center for Disease Control and Prevention, 2019d).
Despite these successes, while the number of newly diagnosed PLWH fell by 19%
between 2005 to 2014, the prevalence of HIV infection has increased among some
subpopulations like young gay and bisexual men (Center for Disease Control and
Prevention, 2016a). The increased HIV incidence among gay and bisexual men might be
explained by the lower access to diagnosis, care, retention, and viral suppression due to
societal barriers like stigma and discrimination. Thus, the progress regarding the outcomes
of advanced HIV treatment and prevention strategies remain uneven for all PLWH. Apart
from curbing HIV incidence and mortality, the quality of life of the PLWH, including
physical and emotional well-being, social support system, and life roles, has emerged as a
critical issue. Because, despite achieving virological and immunological stability, PLWH
have a significantly lower health-related quality of life (HRQoL) than do the general
population (Miners et al., 2014). A study showed that asymptomatic PLWH men have
worse perceived physical health when symptomatic PLWH have worse perceived mental
and physical health than their non-PLWH counterparts (Bing et al., 2000). A review study
noted that “existing data suggest that physical manifestations, ART, psychological wellbeing, social support systems, coping strategies, spiritual well-being, and psychiatric
comorbidities are important predictors of quality of life in the HIV population (Basavaraj,
Navya, & Rashmi, 2010).”
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2.3 Demographics of PLWH in the United States
An estimated 1.1 million people in the United States were living with HIV at the
end of 2016, however, about 14% of them do not know their HIV status and so need testing
(Centers for Disease Control and Prevention, 2018a). According to the Center for Disease
Control and Prevention (CDC), an estimated 54.6% of young PLWH aged 13-24 years
living with HIV remain unaware of their infection. More than half of the total PLWH were
older than 50 years, with the largest percentage increase in rates of PLWH by persons aged
65 years and older in 2016 (Centers for Disease Control and Prevention, 2018a). About
67% of PLWH have received some HIV care, 49% retained in care, and 53% were virally
suppressed in 2016 (Centers for Disease Control and Prevention, 2018a).
Literature shows that about 38% of new infections were transmitted by individuals
unaware of their HIV infection; whereas, 42% newly infected PLWH got HIV from PLWH
aware of their infection but not in care and 20% from those receiving care but not virally
suppressed (Li, Purcell, Sansom, Hayes, & Hall, 2019). The annual number of new HIV
diagnoses has remained stable in the United States in the last several years, however, newly
diagnosed HIV cases have increased among subpopulations like young gay and bisexual
men (Center for Disease Control and Prevention, 2016a).
African Americans and Hispanics/Latinos are disproportionately affected by HIV.
In 2017, African Americans and Hispanics/Latinos accounted for 43% and 26% of new
HIV diagnoses, when they are 13% and 18% of the U.S. population (Centers for Disease
Control and Prevention, 2018a). Survival after an AIDS diagnosis is lower for African
Americans than for other racial/ethnic groups. African Americans accounted for 43% of
deaths among PLWH in 2016 (Centers for Disease Control and Prevention, 2018a).
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Although HIV has been reported in all U.S. states, the District of Columbia, and U.S.
dependent areas, the HIV epidemic is not evenly distributed across the U.S. regions. The
South accounted for about half of new HIV diagnoses, while nearly two-thirds (64%) of
PLWH live in only ten U.S. states. These states are Florida, California, Texas, New York,
Georgia, North Carolina, Illinois, New Jersey, Pennsylvania, and Louisiana (Centers for
Disease Control and Prevention, 2018a). However, rates of new HIV diagnoses per
100,000 population are higher in District of Columbia (53.6), Georgia (30.0), Florida
(26.6), Louisiana (26.6), Maryland (20.2), Nevada (19.7), Texas (19.0), Mississippi (17.3),
South Carolina (16.9), and New York (16.4) (Centers for Disease Control and Prevention,
2018a). The overall rate of HIV incidence among women decreased by 21% from 2010 to
2015; however, the rate of HIV diagnoses is higher among women of color. African
American women accounted for 59% of new diagnoses among women (Centers for Disease
Control and Prevention, 2018a). Adolescents and young adults continue to be at high risk;
56% of new HIV diagnoses in 2017 are aged 35 years or less. Among young and gay or
bisexual men, minorities have particularly been affected more by the HIV epidemic in the
United States (Centers for Disease Control Prevention, 2018b).

2.4 Risk of HIV Transmission
HIV is mainly spread by having sex or sharing syringes and other injection
equipment with someone already infected with HIV. HIV infection is known as a sexually
transmitted disease because sexual contact is identified as the major risk factor for HIV
transmission. Primarily, risky behaviors like having vaginal or anal sex without using a
condom and sharing needles or syringes, play a significant role in HIV transmission in the
United States. Substance use may contribute to these risks indirectly because alcohol and
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other drugs can lower one’s inhibitions and make him/her less likely to use condoms.
People who inject drugs (PWID) are at high risk of getting HIV if they share needles,
syringes, or other drug-injection equipment (e.g., cookers) with others. Receiving blood
transfusions, blood products, or organ/tissue transplants that are HIV contaminated, eating
food that has been pre-chewed by a PLWH, being bitten by a PLWH, and contact between
broken skin, wounds, or mucous membranes and HIV-infected blood can be other potential
routes of HIV transmission. However, these are the relatively rare cases of HIV
transmission in the United States. Certain cultural and societal factors can also act as risk
factors in HIV transmission (Edwards & Collins Jr, 2014). These factors include poverty,
lack of education, racial/ethnic or gender discrimination, geographic location, lack of
access to care, homophobia, and stigma (Gupta, Parkhurst, Ogden, Aggleton, & Mahal,
2008; Ordóñez & Marconi, 2012).
HIV transmission patterns have shifted over time; most of the newly diagnosed HIV
cases (66%) occurred through male-to-male sexual contact in 2017 (Centers for Disease
Control and Prevention, 2018a). Although HIV transmission through heterosexual contact
is declined in recent years; the current proportion of heterosexual transmission - 24% of
new diagnoses in 2017- is much higher than the proportion at the beginning of the epidemic
(Centers for Disease Control and Prevention, 2018a; Centers for Disease Control
Prevention, 2018b). HIV diagnoses attributable to injection drug use that accounted for 6%
of new diagnoses in 2017 have also decreased in recent years. Almost half of these new
HIV diagnoses occurred among gay and bisexual men with a history of injection drug use
(Centers for Disease Control and Prevention, 2018a).
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Pre-exposure prophylaxis (PrEP) is highly useful to prevent HIV transmission.
PrEP is one tablet (Truvada), which is a combination of two antiretrovirals
(tenofovir/emtricitabine), taken every day by any person at high risk of acquiring HIV
(Huynh & Gulick, 2018). Similarly, post-exposure prophylaxis (PEP) plays a vital role to
prevent HIV transmission among individual who has already exposed to a confirmed or
suspicious HIV positive body secretion of semen, vaginal fluid, or blood. The CDC
recommends screening all patients for PrEP use, especially young MSM, sexually active
heterosexuals, and injection drug users (Huynh & Gulick, 2018).
Mother-to-child transmission during pregnancy, birth, or breastfeeding is a less
common mode of HIV transmission. Although the risk can be high if a mother is living
with HIV and not taking ART, testing all pregnant women for HIV and start HIV treatment
promptly may reduce the risk of babies born with HIV substantially. Medication therapy
for both mother and child during pregnancy, childbirth, and the postnatal period has
contributed to the decline in mother-to-child transmission rate to less than 1% (Huynh &
Gulick, 2018). In this regard, formula feeding is a good alternative to breast milk that
eliminates the risk of HIV transmission from mother to child through breastfeeding. Due
to increased testing efforts among pregnant women and ART, perinatal HIV transmission
has declined significantly in the United States (Centers for Disease Control and Prevention,
2018b).

2.5 Current Treatment of HIV Infection
The treatment of HIV disease depends on the stage of the disease and the presence
of any concurrent opportunistic infections. ART is the principal method for preventing
immune deterioration caused by HIV infection. Successful long-term ART results in a
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gradual recovery of CD4 cell counts and an improvement of immune responses that prevent
chances of other opportunistic infections. As a result, ART has substantially reduced
AIDS-related morbidity and mortality and improved long-term outcomes for PLWH. Also,
ART plays a crucial role in preventing HIV transmission when it started early. According
to the CDC, PLWH who take ART daily as prescribed, and keep an undetectable viral load
have ‘effectively no risk’ of sexually transmitting HIV to their HIV-negative partners
(HIV.gov, 2019b). When HIV viral load is so low that it does not show up in a standard
laboratory test (< 50 copies HIV RNA per mL), it is called undetectable viral load.
However, there are many PLWH who are not diagnosed with HIV, not in HIV medical
care (defined as viral load/CD4 test every 6 months, or on ART), or have viral load under
control (Centers for Disease Control and Prevention, 2018b).
Current HIV treatment guidelines recommend a rapid start (treatment sooner after
diagnosis). A person’s initial HIV regimen generally includes three HIV medicines from
at least two different HIV drug classes (U.S. Food and Drug Administration, 2018). The
most common drug classes include single-tablet regimens (STRs), Integrase Inhibitors
(INSTIs), Protease Inhibitors (P.I.s), and Nucleoside Reverse Transcriptase Inhibitors.
Detailed lists of U.S. Food and Drug Administration (FDA) approved HIV medicines are
discussed elsewhere (U.S. Food and Drug Administration, 2018). In the United States,
physicians prescribe ART based on the recommendation of the U.S. Department of Health
and Human Services (HHS) HIV/AIDS medical practice guidelines.

2.6 The ‘90-90-90’ HIV Treatment Targets
The Joint United Nations Program on HIV/AIDS (UNAIDS) set 90-90-90 goals in
2013 that 90% of all PLWH know their HIV status, 90% of all diagnosed HIV receive
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sustained ART, and 90% of all receiving ART have viral suppression by 2020 (Joint United
Nations Programme on HIV/AIDS, 2014). In the United States, 86% of all PLWH are
diagnosed, yet a large proportion of these diagnosed PLWH are not in treatment and did
not achieve the desired level of viral suppression. The CDC reported that 64% of all PLWH
(74% of all diagnosed) received care but only 49% retained in care (58% of all diagnosed),
and only 53% of all PLWH (62% of all received ART) were virally suppressed in 2016
(Figure 2.2) (Bradley et al., 2014; Center for Disease Control and Prevention, 2019d).
Beyond the viral suppression of HIV, researchers suggest a concept of the ‘fourth 90’ to
the testing and treatment target- ensure that 90% of people with viral load suppression have
a good health-related quality of life (HRQoL) (Guaraldi, Milic, & Wu, 2019). Some
researchers explained it from the perspective of aging, i.e., ensuring healthy aging for
PLWH since a large portion of PLWH are now in advanced age that makes them prone to
the elevated risk of multiple comorbidities (Harris, Rabkin, & El-Sadr, 2018; Lazarus et
al., 2016).

2.7 Health Care Delivery and Financing for PLWH
The U.S. health care system is facing enormous challenges with HIV care
management since HIV is a noncurable infection, and there are a growing number of
PLWH due to increased lifespan and new HIV infection every year. HIV requires longterm and expensive medical management and support services, heavily reliant on
prescription drugs. The central challenges for policymakers are how to ensure adequate
resources to fight HIV/AIDS and how to adapt public policies and programs with the
changes in the demographic profile of the HIV epidemic in the United States (Health Policy
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Institute, 2003). The U.S. health care system supports PLWH to engage and keep them into
the care through the following programs.

Figure 2. 2 Estimated percentage of PLWH, by outcome along the HIV care continuum in
the United States, 2016 (Center for Disease Control and Prevention, 2019d).
2.7.1 Ryan White Program
The Ryan White HIV/AIDS program, which is administered by the Health
Resource & Services Administration (HRSA), provides a comprehensive system of HIV
primary medical care, essential support services, and medications for more than half a
million low-income diagnosed PLWH each year (Health Resources and Services
Administration, 2019). Uninsured and underinsured PLWH can get HIV medical care,
access to medications, case management, substance abuse, oral health, mental health, and
other support services they need through this program (Institute of Medicine, 2011). The
program funds states, cities/counties, and local community-based organizations to provide
care and treatment services to PLWH to improve health outcomes and reduce HIV
transmission among hard-to-reach populations. Hospital-based clinics provide medical
20

care to almost half of the medical clients, when publicly-funded community health centers
(CHCs), other community-based organizations (CBOs), and health departments provide
medical care to the rest of the clients at Ryan White-funded sites (Institute of Medicine,
2011). Other providers of HIV medical care services include private doctors’ office, day
treatment programs, home care programs, skilled nursing facilities, and correctional
facilities. Ryan White HIV/AIDS program is divided into five parts, following from the
authorizing legislation (Health Resources and Services Administration, 2019).
Part A: Part A of the Ryan White HIV/AIDS Treatment Extension Act of 2009
provides assistance to Eligible Metropolitan Areas (EMAs) and Transitional Grant Areas
(TGAs) that are most severely impacted by the HIV epidemic. EMAs with 2,000+ reported
AIDS cases and TGAs with 1,000-1,999 reported AIDS cases in the past 5 years and must
have a population of at least 50,000 are eligible to receive the funds. Two-thirds of funds
are distributed by a formula based on the area’s share of living HIV (non-AIDS and AIDS)
cases, and the remainder is distributed via competitive supplemental grants based on
“demonstrated need.”
Part B: Part B of the Ryan White HIV/AIDS Treatment Extension Act of 2009
provides grants to States and Territories to improve the quality, availability, and
organization of HIV health care and support services. Recipients include all 50 states, the
District of Columbia, Puerto Rico, the U.S. Virgin Islands, and the six U.S. Pacific
territories/associated jurisdictions. Also, Part B includes grants for the AIDS Drug
Assistance Program (ADAP).
Part C: Part C of the Ryan White HIV/AIDS Program provides grant funding to
local community-based organizations to support outpatient ambulatory health service and
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support services through Early Intervention Services (EIS) program grants. Part C also
funds planning grants, which help organizations more effectively deliver HIV care and
services through Capacity Development grants.
Part D: Ryan White HIV/AIDS Program Part D grant funds public and private
organizations to provide family-centered and community-based services to children, youth,
and women living with HIV and their families, including outreach, prevention, primary
and specialty medical care, and psychosocial services. The recipients are local, communitybased organizations seeking to enhance their response to the HIV epidemic in their area
through providing family-centered primary medical care and support services when
payments for such services are unavailable from other sources. Part D also supports
activities to improve access to clinical trials and research for these populations.
Part F: Part F of the Ryan White HIV/AIDS Program provides funds to support
clinician training, technical assistance, and the development of innovative models of care
to improve health outcomes and reduce HIV transmission. These programs include the
Special Projects of National Significance Program, AIDS education and Training Centers
Program, The Dental Programs, and Minority AIDS Initiative.
Since 1990, the Ryan White HIV/AIDS program has been playing a vital role in
the United States’ public health response to HIV epidemic. The program serves as an
important source of ongoing access to HIV medication that enable PLWH to achieve close
to normal life expectancy by maintaining a very low viral load. For example, 86% of Ryan
White clients were virally suppressed in 2017, exceeding the national average of 60%
(Health Resources and Services Administration, 2019). Low-income people diagnosed
with HIV or AIDS can get primary medical care, essential support services, and
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medications through HRSA’s Ryan White HIV/AIDS program when they do not have
health insurance or their insurance does not pay for the care. Some pharmaceutical
companies provide medications to low-income PLWH who have no insurance or
prescription drug coverage (Center for Disease Control and Prevention, 2020b). Affordable
Care Act (ACA) safeguards PLWH from dropping or denying coverage because of the preexisting condition, imposing lifetime caps, and canceling coverage due to mistakes made
on an application. ACA helps people access quality, affordable coverage through the health
insurance marketplaces, and through providing financial assistance for people with low and
middle incomes in the form of tax credits. Moreover, ACA contributes to cover more
people by expanding Medicaid eligibility and lowering prescription drug costs for
Medicare recipients, which enable some PLWH to get engaged with HIV care (HIV.gov,
2019a). Finally, the Social Security Administration offers disability benefits for PLWH
who are unable to work (Center for Disease Control and Prevention, 2020b).
2.7.2 Medicare
Medicare, the federal health insurance program for people age 65 and older and
younger adults with permanent disabilities, is an important source of health coverage for
PLWH because there are a growing number of elderly with HIV due to increased lifespan.
Most PLWH on Medicare are under age 65 years because many PLWH do qualify for it
due to their disability. About one-quarter of PLWH in care get their health insurance
through Medicare, and it is now the single largest source of federal financing for HIV care
and treatment (Bradley et al., 2014). In 2016, Medicare spending on HIV totaled $10
billion, which is 51% of federal spending on HIV care, and it has increased over time in
recent years due to the addition of Medicare Part D prescription drug benefit (Kaiser
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Family Foundation, 2016). Medicare provides broad coverage of many basic health care
services, including hospital care, physician services, and prescription drugs. Among
services covered by Medicare, some vital services are expanded coverage for HIV testing,
prescription drug, and facial wasting (lipoatrophy) treatments (Kaiser Family Foundation,
2016). The majority of PLWH under Medicare are dually eligible for Medicare and
Medicaid and receive low-income subsidies from Part D.
2.7.3 Medicaid
It is the largest public health insurance program in the United States, jointly
financed by the federal and state governments, which has played a critical role in HIV care
since the epidemic began. Currently, it is covering 73 million low-income individuals (13%
of the overall population), whereas 42% of them are with HIV (Kaiser Family Foundation,
2019). The role of Medicaid has grown over time since PLWH are living longer, new
infections continue to occur, and the program was expanded under the ACA. The number
of PLWH enrolled in Medicaid has increased in recent years due to ACA’s Medicaid
expansion, which facilitates PLWH beneficiaries to gain broad health care coverage. The
majority of the Medicaid beneficiaries with HIV (65% in 2013) qualify for coverage
through a disability status (Kaiser Family Foundation, 2019). Medicaid covers a wide range
of services, including inpatient and outpatient hospital, physician and nurse, laboratory,
nursing facility, dental care, prescription drugs services, which are paid fee-for-service
basis, through capitated managed care organizations (MCOs), or through a combination of
these (Kaiser Family Foundation, 2019).
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2.7.4 Department of Veteran Affairs
The Department of Veteran Affairs (V.A.) is the largest single provider of HIV
medical care to PLWH in the United States, serving over 31,000 Veterans with HIV across
the country in 2018 (Department of Veteran Affairs, 2019). The VA is committed to
ensuring the HIV care continuum from testing and diagnosis to linkage to care, and
treatment and prevention. The VA provides comprehensive care to veterans with complex
care needs and prevalent comorbidities. Veterans with service-connected disabilities,
including HIV, are eligible for compensation benefits regarding health care.
2.7.5 Federally Qualified Health Centers
Federally Qualified Health Centers (FQHCs) are community-based health care
providers that receive funds from the HRSA Health Center Program to provide primary
care services to high need communities that are designated as a medically underserved area
or population. FQHCs include community health centers, migrant health centers,
healthcare for homeless, and public housing primary care programs. These health centers
emphasize coordinated and comprehensive primary health care services as well as
supportive services, including education, translation, and transportation that promote
access to health care. FQHCs play a vital role in ending the HIV epidemic by serving as a
key point of entry for people undiagnosed with HIV. In 2018, more than 191,000 patients
living with HIV received medical care services at those health centers, including many sites
co-funded by the Ryan White HIV/AIDS program (Helath Resources and Services
Administration, 2019).
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2.8 HIV and Aging in the United States
The increasing availability of potent ART has allowed many PLWH to live longer,
particularly those who initiate ART therapy at early disease stages. Due to the success of
combination antiretroviral drug treatments, PLWH can expect to live a near-normal
lifespan compared to non-PLWH. Different studies show that PLWH have a similar life
expectancy to the general population if they are diagnosed early, have good access to care,
and adhere to their HIV treatment (National Institute of Allergy and Infectious Diseases,
2018; Pebody, 2018). However, even with the availability of effective ART after HIV
being diagnosed, differences in access to care, comorbidities, and substance use can widen
the survival gap; for example, tobacco use accounts for up to 8 years of potential life lost
(Marcus et al., 2016). As a result of the success in gaining a higher life expectancy, PLWH
are living longer, thus aging with HIV. Currently, almost half of all PLWH are aged 50 or
older (Center for Disease Control and Prevention, 2018), with this proportion projected to
rise to more than 70% by 2030 (Wing, 2017). The good news is that the rate of new HIV
diagnoses among the people aged 50 or older decreased significantly from 25% of total
new diagnoses in 2006 (Jacobson, 2011) to 17% in 2016 (Center for Disease Control and
Prevention, 2018). Irrespective of HIV status, the older the population, the higher the onset
of age-related health conditions, which will create a higher demand for health care services
in the United States in the upcoming decades (Institute of Medicine, 2008). The interaction
of HIV with the process of aging and aging-related comorbidities are expected as the virus
consistently activate the immune cells that make the individuals susceptible to
inflammation-induced diseases and diminishes their capacity to fight some diseases (Fauci,
Hodes, & Whitescarver, 2010). Brooks et al. summarized this interaction in their review
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paper by stating, “apart from the expected contribution of normal aging, 3 additional sets
of factors contribute to risk, to varying degrees and often in complex interplay (Brooks,
Buchacz, Gebo, & Mermin, 2012): (1) factors associated directly with chronic HIV
infection including viral replication and attendant inflammation, (2) toxicities and other
complications of treatment with antiretroviral agents, and (3) host-related factors that are
especially prevalent among HIV-infected adults, including certain coinfections (e.g.,
human papillomavirus, hepatitis B); and lifestyle factors (e.g., alcohol and tobacco use,
obesity).”

2.9 The Burden of Multiple Comorbidities among Older PLWH
PLWH with higher viral load and weaker immune systems are susceptible to
numerous infectious and noninfectious diseases. The clinical conditions of the older PLWH
get complicated due to coinfection with some other virus, like Human Papilloma Virus
(HPV), Kaposi's-sarcoma Associated Herpes Virus (KSHV/HHV-8), Epstein-Barr Virus
(EBV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (Hille, Webster‐Cyriaque,
Palefski, & Raab‐Traub, 2002; Peters et al., 2012; Pinzone, Berretta, Cacopardo, &
Nunnari, 2015).
Since PLWH are now living longer, age-related chronic conditions have
increasingly become significant health concerns despite suppression of HIV viral load to
clinically undetectable levels. Age confers higher vulnerability towards more rapidly
advancing HIV disease, including a higher risk of HIV-induced neurocognitive disorders,
AIDS-defining illness, and mortality, suggested to be caused by a variety of factors not
limited to delayed diagnosis, immune senescence, and differential response to combination
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ART (Rodriguez-Penney et al., 2013). Thus, PLWH receiving ART suffer chronic
conditions just like non-PLWH, alongside HIV infection and its treatment.
Aligned with the aging process, the longer exposure of the older PLWH to both
HIV and antiretroviral drugs may increase the risk of illness, including cardiovascular,
liver, kidney, bone, lung disease, and certain cancer not associated with HIV infection
(Gallant, Hsue, Shreay, & Meyer, 2017; Guaraldi et al., 2011; Schouten et al., 2014).
Studies found a higher prevalence of multi-morbidity among HIV patients than in the
general population (Guaraldi et al., 2011; Maciel, Klück, Durand, & Sprinz, 2018;
Rodriguez-Penney et al., 2013). Despite complete viral suppression and immune recovery,
PLWH are more vulnerable to poor health than the non-PLWH (High et al., 2012). The
vulnerability is characterized by a higher risk of some common age-related health
problems, even after adjusting established risk factors, including cardiovascular disease,
metabolic disorders, hepatic and renal diseases, a certain type of cancers, and ageassociated immunologic changes and chronic inflammation (Deeks, 2011; Fitch et al.,
2013; Guaraldi et al., 2011).

2.10 HIV, Polypharmacy, and Aging
The prevalence of polypharmacy that is commonly defined as concurrent taking 5
or more medications is higher among PLWH compared to the non-PLWH. This is because
PLWH are susceptible to multiple comorbidities and reliant on prescription drugs, and they
need to continue the medication until death. After initiation of antiretroviral treatment, that
typically requires PLWH to take three medications, many non- antiretroviral medications
are prescribed to address symptoms, side effects, and to treat or prevent comorbid diseases
(Edelman, Rentsch, & Justice, 2020). Also, the increasing number of comorbidities lead
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PLWH to a higher burden of other non-antiretroviral oral medications, enhanced risk of
side effects, and elevated risk of drug-drug interactions. PLWH are more susceptible to
medication side effects, because of interaction between antiretroviral medications and
commonly prescribed non-antiretroviral medications, and increased physiologic frailty of
PLWH (Edelman et al., 2020; Hughes, Tseng, & Cooper, 2015).
Since PLWH develop various chronic diseases at a higher rate than non-PLWH as
they age, they are more likely to be exposed to polypharmacy at younger ages, because
aging PLWH increasingly require more non-antiretroviral medications to treat chronic agerelated comorbidities (H. B. Krentz, Cosman, Lee, Ming, & Gill, 2012; Ware et al., 2018).
An estimated 15 to 39% of PLWH are exposed to polypharmacy (Guaraldi et al., 2018;
Justice et al., 2018; Ware et al., 2018), with higher rates observed in resource-rich settings
and among older persons (Livio & Marzolini, 2019). Another study showed that older men
living with HIV take a median of 13 medications, including medications for HIV infection
(Greene, Steinman, McNicholl, & Valcour, 2014). The risks of polypharmacy include
increased adverse drug events, organ system injury, hospitalization, decreased medication
adherence, and mortality (Greene et al., 2014).

2.11 HIV Infection to Accelerate and/or Accentuate Aging
Multi-morbidity is common among PLWH in the United States that occurs at an
earlier age than that in HIV-uninfected participants. The prevalence of noninfectious
comorbidities among ART-experienced PLWH was anticipated to be similar among nonPLWH who were 10 years older (Guaraldi et al., 2011). Thus, a critical question is whether
HIV infection is accelerating aging through the common mechanism of aging or acting as
an additional risk factor for comorbidity development in conjugation with traditional risk
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factors. One study suggested that the answer is organ and disease-specific; when some
processes appear to be accelerated due to HIV, many illnesses are likely to be accentuated
rather than accelerated (Pathai et al., 2013). HIV induced chronic immune activation and
inflammation are referred to as factors of accelerated or early aging, while PLWH develops
multiple comorbidities at a younger age than the general population (Ahn et al., 2019;
Desai & Landay, 2010; Guardigni & Montano, 2018). Besides, the trend toward a stronger
association between age and noninfectious disease burden among PLWH might support
premature or accelerated aging in HIV (Guaraldi et al., 2011; Schouten et al., 2014). LopezOtin el al. discussed the multiple biological mechanisms of aging, some of which may
affect HIV-positive individuals at higher rates, including genetic instability, telomere
shortening, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing,
mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered
intercellular communication (López-Otín, Blasco, Partridge, Serrano, & Kroemer, 2013).
Additional research is suggested to generate a more in-depth understanding regarding the
mutual impacts of HIV infection and aging to develop and implement effective preventive
measures for safe antiretroviral therapy among older PLWH (Sharma & Singh, 2016).

2.12 The Vulnerability of the Older PLWH
The impact of HIV infection and its treatment on the aging of PLWH may cause
premature aging and the development of multiple HANA conditions. The cumulative
burden of these complications reduces a person’s ability to compensate and respond to
many events, which jointly results in the onset of ‘frailty’ (Deeks, 2011; Justice, 2010).
Frailty is a pathologic aging syndrome, which indicates vulnerability to diverse adverse
health outcomes such as treatment toxicity, functional decline, hospitalization, surgical
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complications, and death (Desquilbet et al., 2009; High et al., 2012). Studies showed the
frailty-related phenotype was prevalent among PLWH at a younger age than those nonPLWH, especially in more-advanced HIV infection (Desquilbet et al., 2009; Piggott et al.,
2013), because HIV infection may synergistically interact with age to contribute to
functional decline (Morgan et al., 2012).
‘HIV Stigma’ is a critical issue for older PLWH, because it involves prejudice,
discounting, discrediting, discriminating, and isolation from family and friends due to
illness (Center for Disease Control and Prevention, 2019b; Gay Men’s Health Crisis Inc,
2010). It greatly affects the quality of life, self-image, and mental health and may prevent
them from seeking HIV care and disclosing HIV status (Cahill & Valadéz, 2013; Gay
Men’s Health Crisis Inc, 2010). Moreover, health care providers often do not order HIV
testing for older people because of bias about reduced exposure to risky behavior (Gay
Men’s Health Crisis Inc, 2010). Besides, older people may mistake HIV symptoms as usual
aging symptoms. Thus, older people are more likely than younger to have late-stage HIV
infection at the time of diagnosis. This leads to starting treatment late and possibly suffering
from more immune-system damage (Gay Men’s Health Crisis Inc, 2010).
The increasing population of older PLWH also face psychological challenges
regarding social engagement and interaction, adequacy of informal social supports and
caregiving resources, and utilization of community-based services to meet their growing
needs (High et al., 2012). The stigma associated with HIV and homosexuality interacts
with age-related stigma to exacerbate stress and affect the quality of life and mental health
of older PLWH. Besides, lack of social supports and networks leaves older PLWH with
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fewer resources, making them more vulnerable in terms of depression, bereavement,
mental health, and substance use in their later stages of life (Cahill & Valadéz, 2013).
Also, as PLWH age, the general progression of HIV infection may create symptoms
that are not specific to HIV-associated diseases during end-of-life care, including fatigue,
pain, insomnia, decreased libido/hypogonadism, reduced memory and concentration (HIVassociated neurocognitive disorder (HAND), depression, and distorted body image.
Palliative care can play a vital role in addressing these suffering and maximize function
and quality of life for PLWH, and for patients with HIV disease who are nearing the end
of life (Simms, Higginson, & Harding, 2012). Therefore, HIV prevention strategies need
to incorporate a comprehensive set of issues, such as non-communicable diseases, mental
health disorders, pain management and palliative care, and stigma and discrimination
(Lazarus et al., 2016).

2.13 Impact of Aging PLWH on U.S. Health Care System
With the additional risks of comorbidity, weak cognitive functioning, frailty, poor
mental health, and provider or society level stigma, the aging of the PLWH may place
enormous demands on the health care and social service systems. Some of these demands
will reflect the needs created by the general aging population, yet some were specific to
the needs of older PLWH, which may include a large number of racial and ethnic minorities
and people with low incomes (Gay Men’s Health Crisis Inc, 2010).
Due to the aging of PLWH, there would be far more demand than the supply of
healthcare industry in the future, especially the demand for both clinical and non-clinical
health care workers. With aging, multiple chronic conditions appear, which sometimes
turns into disabilities requiring long-term care services, such as home health, nursing
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homes, personal care, and congregate housing (Wiener & Tilly, 2002). Multiple projections
suggest that the demand for health care services for older adults will rise considerably in
the coming decades, which will create immense pressure on the health care workforce to
deliver those services (Institute of Medicine, 2008). Staff at long-term care facilities,
nursing homes, personal care, congregate housing, and senior centers should be trained to
support the unique experiences and needs of PLWH to ensure culturally competent and
non-discriminatory care (Gay Men’s Health Crisis Inc, 2010). However, due to social
isolation, many older PLWH are disconnected from traditional informal support networks,
thus rely heavily on formal care providers, like the emergency department, hospital
outpatient, and inpatient department (Shippy & Karpiak, 2005).

2.14 Challenges for U.S. Health Care System
However, effective HIV care delivery and management largely depend on the
capacity of health care systems, such as hospital infrastructure and the number of health
care providers focusing on managing PLWH. Infectious disease specialists, advanced
practice registered nurses, physician assistants, and primary care physicians are responsible
for providing a vast majority of medical care for PLWH (Institute of Medicine, 2011).
Registered nurses, dentists, pharmacists, and social workers are among a large number of
other providers necessary to provide quality HIV/AIDS care in a variety of settings. With
the changing pattern of the HIV epidemic, the U.S. health care system requires the broader
skills of primary care physicians, nurses, and physician assistants to address the
comorbidities of PLWH to manage HIV the epidemic successfully. However, the
projections indicate that the supply of HIV providers is not keeping up with the demand
for HIV care. Also, cuts in funding and available positions that support HIV programs,
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such as in health departments, are reflective of lacking in the health care system’s capacity
to provide care for a growing number of PLWH in the United States (Institute of Medicine,
2011). The AAMC Center for Workforce Studies projects a shortage of 45,000 primary
care physicians by 2020 (Colleges, 2010). Retirement of the health care workforce who got
trained in HIV/AIDS care management during the beginning of the HIV epidemic is
another challenge for the health care system (Institute of Medicine, 2011).
Another hospital-level challenge is reaching HIV care to the rural areas in the
United States because resources for HIV prevention and care are concentrated in urban
areas (Schafer et al., 2017). However, studies showed that the HIV epidemic has migrated
from primarily urban centers to more rural locales (Iyer, 2015; M Vyavaharkar, Glover,
Leonhirth, & Probst, 2013). The rural residence also reported lower rates of HIV testing,
delayed HIV diagnosis, later adoption of HAART, and higher HIV-related mortality
(Lahey et al., 2007; Ohl et al., 2013; Ohl et al., 2010; Weis, Liese, Hussey, Gibson, &
Duffus, 2010). Additionally, rural residents with HIV may face challenges with stigma,
social isolation, long-distance to care, limited transportation, and lack of access to
providers with HIV experts (Reif et al., 2014; Sutton, Anthony, Vila, McLellan‐Lemal, &
Weidle, 2010; Medha Vyavaharkar, Moneyham, Murdaugh, & Tavakoli, 2012). Rural
residents with HIV may face additional challenges in engagement and retention in HIV
care due to the closure of hospitals in rural counties. More than 42 rural hospitals went out
of business between 2005 to 2009 due to recession, and the trend has been accelerating
since 2010; there were 72 hospital closures between 2010 to 2016 (Wishner, Solleveld,
Rudowitz, Paradise, & Antonisse, 2016).
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2.15 Aging of PLWH and Hospital Inpatient Care
With the high prevalence of physical and mental health comorbidities and lack of
social supports, aging with HIV may create higher health care demand, including increased
hospital inpatient care in the United States (Matthew Harris et al., 2015). Increasing
comorbidities among older PLWH require greater use of inpatient care, which leads to
higher resource utilization and hospital costs (H. Krentz & Gill, 2015; Zingmond et al.,
2017). PLWH with multiple comorbidities may need more frequent hospital admission or
extended hospital stay in their later age. There are a growing number of older PLWH in
the United States due to age-shift. This ongoing age-shift is important because older PLWH
are at increased risk for readmission, prolonged hospitalizations (Yehia et al., 2010), and
of remaining underdiagnosed (Blaylock & Wortmann, 2015; Sankar et al., 2011).
Moreover, age-related comorbidities may be more severe for PLWH aging with HIV even
on ART compared to others (Gras et al., 2007). Therefore, it is crucial to explore how
existing health care infrastructure can meet the increasing demand for clinical and nonclinical services for this growing population.

2.16 Current Trends for Hospitalizations with HIV Infection
Declining hospitalizations rates were observed shortly after the widespread
availability of HAART in the United States. Hospital stays with principal HIV diagnosis
has decreased between 2006 and 2013; however, trends in hospital stays were volatile for
HIV as secondary diagnosis over the same period (Heslin & Elixhauser, 2016). The rate
of hospitalizations that included both principal or secondary diagnosis decreased for all
groups under the age of 55 years, but increased for patients aged 55 years or over, between
2006 and 2013 (Heslin & Elixhauser, 2016). Thus, it is evident that while overall
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hospitalization is decreasing due to HIV infection, there is a growing number of older
PLWH getting admitted into the hospital, which may create additional pressure on hospital
inpatient care delivery. Decreasing trends of hospitalization were found in other studies as
well (Buchacz et al., 2008; Zhao, Encinosa, & Hellinger, 2007). However, some studies
suggested stable or increasing rates of hospitalization (Fleishman & Hellinger, 2003; Gebo,
Diener-West, & Moore, 2001; H. Krentz, Dean, & Gill, 2006). The potential causes for this
lack of continued decline in hospitalization rates include aging of PLWH, toxicity from
long-term antiretroviral use, development of chronic and organ disease, development of
multi-drug resistant viruses, and high prevalence of substance use (Crum-Cianflone et al.,
2010).

2.17 Resource Utilization of PLWH in the United States
Although the introduction of HAART has substantially reduced hospitalization
among PLWH in past several decades (S. Berry, Fleishman, Moore, & Gebo, 2016;
Buchacz et al., 2008; Crum-Cianflone et al., 2010; Heslin & Elixhauser, 2016),
hospitalizations are still reported to be elevated among PLWH compared to individuals
hospitalized with non-HIV (Bachhuber & Southern, 2014; Shih, Chen, Rothman, & Hsieh,
2011). Besides, longer duration of hospital stays is more common among the PLWH
compared to their non-infected counterparts (Akgün et al., 2013; Pearce et al., 2012). A
recent study showed that symptomatic PLWH have a considerably longer duration of stay
in the hospital than non-PLWH when asymptomatic PLWH’s length of stay is similar to
non-PLWH’s hospital length of stays (Rowell-Cunsolo, Liu, Shen, Britton, & Larson,
2018). Longer inpatient length of stays places a substantive burden on hospital and health
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insurance systems (Shih et al., 2011) because it is typically associated with higher resource
utilization for treatment (Needham et al., 2003; Papi, Pontecorvi, & Setola, 2016).

2.18 Hospital Inpatient Resource Utilization by the Older PLWH
Generally, inpatient resource utilization shows a downward trend since the
introduction of HAART. Analyzing U.S. hospital records data, one study reported that
annual inpatient hospitalization rates and the number of inpatient days per year decreased
in the United States between 2002 to 2007, while there was no significant change in
hospital length of stay per admission (Yehia et al., 2010). However, while overall hospital
admission rates decreased, PLWH still experienced higher utilization of inpatient and
outpatient care compared to non-PLWH (Gebo et al., 2010). The aging of HIV in the United
States may pose an increasing demand for inpatient health care services, as PLWH has
increased risk for readmission and prolonged hospitalizations (S. Berry et al., 2016).
Expected increases in inpatient utilization due to comorbidities, and factors related to aging
may reduce as new antiretroviral treatments may have the potential to reduce the need for
hospitalization (Yehia et al., 2010). Since HIV requires life-long treatment, and chronic
use of ART, PLWH are likely to increase health care resource utilization substantially due
to long-term toxicities of ART coupled with different comorbidities (Ward et al., 2020).
Other than the direct effect of HIV infection, variations in hospital length of stays
are explained by the complications, complicated perineal closures, and the tendency for
males to remain hospitalized longer than females (Leeds et al., 2016). Moreover,
significant variations were observed in inpatient resource utilization across the patient’s
age, gender, race, and insurance (Fleishman et al., 2005; Yehia et al., 2010). Geographical
variations in utilization patterns exist; for example, hospitalization and inpatient length of
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stays are lower in Western states compared with states in the Northeast (Gornick, 1982;
Weiss & Elixhauser, 2014). Another study result indicates that inpatient cost and length of
stay vary significantly across states (Hellinger, 2004).

2.19 Costs of HIV Care in the United States
Lifetime costs of HIV care depend on the disease stage at which PLWH are
diagnosed, initiate care, take ART, and the extent of ART adherence and retention in care
(Farnham, 2010; Hellinger, 2006). As the life expectancy of PLWH increased, the
economic burden of HIV has evolved with their increasing lifespan and cumulative higher
medical costs over their lifetime (Schackman et al., 2015; Sloan et al., 2012). The estimated
annual costs of care for PLWH in the United States are $19,912 in 2006 U.S. dollars
($23,000 in 2010 U.S. dollars) (Gebo et al., 2010), and discounted lifetime HIV treatment
costs were $367,134 in 2009 U.S. dollars ($379,668 in 2010 U.S. dollars) (Center for
Disease Control and Prevention, 2019c; Schackman et al., 2006). The costs for lifetime
treatment based upon the number of new diagnoses were estimated to be $16.6 billion in
2009 (Center for Disease Control and Prevention, 2019c). Increased utilization of inpatient
and outpatient care and antiretroviral medications of PLWH results in high costs of HIV
care, and the costs increase as patients become more immunosuppressed (Gebo et al., 2010;
NORC at the University of Chicago, 2016). Cost expenditures resulted from prescription
medications are the largest part of this cost burden, and studies showed that costs of
prescription medications are increasing over time (NORC at the University of Chicago,
2016; Ritchwood, Bishu, & Egede, 2017; Schackman et al., 2015). Some of the HIV case
costs are likely due to the treatment of comorbidities not associated with HIV, especially,
the higher costs of older PLWH arise from having multiple comorbid conditions. The costs
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would likely continue to increase due to non-HIV related complications, including agerelated diseases such as cardiovascular disease, cerebrovascular disease, and malignancies
(Gebo et al., 2010).

2.20 Hospital Inpatient Costs of the Older PLWH
There are increasing concerns about the costs associated with lifetime treatment of
the HIV infection, including costs associated with accessing medical care, treating
comorbid conditions, and HIV medications. Due to the availability of HAART and fewer
hospitalization for AIDS-defining illnesses, previous studies have projected lower health
care costs (Harling & Wood, 2007; Hellinger, 1998; Meyer-Rath et al., 2013; Shapiro et
al., 1999). However, the overall cost of HIV management has increased in recent years,
and it is projected to increase further as PLWH are living longer with more HANA
conditions (Ward et al., 2020). Since HIV treatment is a life-long process, and PLWH
needs to take ART persistently, the cost of HIV management would be increased due to
long-term ART toxicities and multiple comorbidities (Ward et al., 2020). The average cost
of HIV care is consistently higher for older PLWH than younger PLWH (Gebo et al.,
2010); the estimated direct cost of noninfectious comorbidities for PLWH age 60 years or
above is two times than those aged less than 40 years ($21,280 vs. $10,588) (Guaraldi et
al., 2013). Frequent and lengthy hospitalizations are common among some PLWH, which
are associated with higher personal costs and healthcare expenditure (S. A. Berry et al.,
2012; Bozzette et al., 2001; Guaraldi et al., 2013). With the aging of PLWH, despite a CD4
count equivalent to those of younger patients, older patients will account for a
disproportionately higher burden of care and costs (H. Krentz & Gill, 2015). The reduction
of total care cost observed in the increasing CD4 count was compensated by the increase
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of total care cost with increased age (Guaraldi et al., 2013). The age-shift of PLWH in the
United States increases the percentage of non-communicable disease among PLWH, which
eventually increases the non-communicable disease treatment cost as the proportion of the
total direct cost of HIV management (Smit et al., 2017).

2.21 Theoretical Background of the Study
DesHarnais et el.’s health outcome model represents that the patient’s health
outcome is the combined results of patient’s physiological reserve, social conditions, health
conditions for which patients get admitted, and provider performance (Figure 2.3)
(DesHarnais, Chesney, Wroblewski, Fleming, & McMahon Jr, 1988). They described
patient’s demographic characteristics (e.g., age, sex) and health conditions (e.g., health
conditions, comorbid conditions) as patients’ physiological reserve, and living conditions,
financial situation, and the ability for self-care as patient’s social condition. Moreover, they
classified the reason for hospital admission (e.g., principal diagnosis, surgical prognosis)
as immediate problem or illness. They also discussed provider performances (e.g.,
adequacy of staff, plant technical performance, interpersonal relationship) as predictors of
patient’s health outcome (Figure 2.3).
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Figure 2. 3 Schematic diagram of some factors related to health outcomes (DesHarnais et
al., 1988).
From the perspective of the health care system, Donabedian structure-processoutcome relationship is linear (Figure 2.4). Donabedian believed that the ‘structure
measures’ influence ‘process measures,’ which in turn affect ‘outcome measures.’
Structure measures refer to the attributes of the service/provider, while process measures
reflect the systems and processes used to deliver to produce desired outcomes (Donabedian,
2005).

Figure 2. 4 The Donabedian model for quality of care (Donabedian, 2005).
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2.22 Conceptual Framework of the Study
The conceptual framework for this study is built upon DesHarnais et el.’s health
outcome model (DesHarnais et al., 1988) and modified for this study to incorporate the
unidirectional relationship among aging of PLWH, comorbidities, and hospital outcomes
as suggested in the literature. Inspired by the Donabedian model for quality of care
(Donabedian, 2005), instead of placing patient’s health outcomes in the center, the
proposed framework described hospital outcomes, i.e., resource utilization and costs, as
the byproduct of those linear interactions, along with patient demographics and facilitylevel characteristics.
Aging of PLWH: There are a growing number of older people due to the age-shift
in the U.S. population who are somewhat at risk of HIV infection. Besides, the advent of
HAART has substantially reduced AIDS-defining morbidity and mortality and improved
the life expectancy of PLWH. Also, PLWH who take ART daily as prescribed, and keep
an undetectable viral load have ‘effectively no risk’ of sexually transmitting HIV to their
HIV-negative partners (HIV.gov, 2019b). These successes, aligned with the growing older
at-risk population, led to the aging of PLWH in the United States (High et al., 2012; Pathai
et al., 2013). However, the current study did not examine the interaction among early ART
use, the growing at-risk older population, and the aging of PLWH. Instead, it investigates
the impact of the aging PLWH on inpatient comorbidities, resource utilization, and costs
compared to their non-PLWH counterparts. Development of some geriatric conditions,
such as comorbidities, frailty, poorer cognitive functioning, depression, and other mental
illness, might be hastened with advanced aging (Center for Disease Control and Prevention,
2018; Heslin & Elixhauser, 2006; HIV.gov, 2017).
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Comorbidities: The prevalence of age-related chronic diseases such as
cardiovascular diseases, cancer, osteoporosis, liver disease, renal disease, and
neurocognitive decline, are increasingly common among PLWH with long-standing HIV
infection (Gallant et al., 2017; High et al., 2012; Pathai et al., 2013; United States Senate,
2013). Thus, the aging of PLWH may increase the risks of multiple comorbidities during
hospital stays, which may eventually direct hospital resource utilization and costs of the
patients.
Hospital resource utilization and costs: Primary diagnosis and inpatient
comorbidity burden determine the hospital resource utilization and costs of the patients.
Patient-level characteristics such as age, gender, race/ethnicity, health insurance, location,
and type of hospitalization are essential predictors of inpatient resource use and costs of
care (Fleishman et al., 2005; Yehia et al., 2010). Similarly, hospital-level characteristics
such as teaching status, location, ownership, regions, and size of the hospital affect
inpatient resource utilization and costs (Patel et al., 2018). Besides, the length of hospital
stay, number, and types of procedures used during the hospital stay largely define the
inpatient costs (Okunji, Daniel, & Frough, 2016) (Figure 2.5).
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Figure 2. 5 Factors related to the patient’s inpatient outcomes during the hospital stays in
the United States (this study did not examine the content in the boxes with the dashed
lines).
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CHAPTER 3
METHODOLOGY
3.1 Data Source and Sample Description
The National (Nationwide) Inpatient Sample (NIS) data, 2003 through 2015, from
Healthcare Cost and Utilization Project (HCUP), sponsored by Agency for Healthcare
Research and Quality (AHRQ), were analyzed to assess comorbidity, care utilization, costs
during the hospital stays in the U.S. hospital inpatient department. The NIS is the largest
all-payer inpatient care database in the United States that collects approximately 20%
stratified sample (more than 7 million hospital stays each year) from all discharges of U.S.
community hospitals from 46 states and the District of Columbia (Agency for Healthcare
Research and Quality, 2018b). Before 2012, NIS collected all discharge records from a
20% sample hospitals from each stratum; starting in 2012, NIS collects 20% discharges
from all U.S. hospitals (Houchens, Ross, Elixhauser, & Jiang, 2014). The NIS includes
short-term, non-Federal, general, and other community hospitals, excluding long-term care
facilities, such as rehabilitation, psychiatric, and alcoholism, and chemical dependency
hospitals. In the case of the NIS, the universe is all inpatient discharges from community
hospitals in the United States, excluding rehabilitation hospitals beginning with 1998, and
excluding long-term acute-care hospitals starting with 2012.
The unit of analysis in our study is hospital discharges from the hospital inpatient
department. Discharge level weights provided with the NIS were used to produce national
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estimates (Agency for Healthcare Research and Quality, 2018d). Further information about
the sampling and dataset are available elsewhere (Agency for Healthcare Research and
Quality, 2018b). An inpatient hospital stay is designated as HIV diagnosis if the Clinical
Classification Software (CCS) code for HIV is five (5). The CCS enlisted International
Classification of Diseases, 9th Edition, Clinical Modifications (ICD-9-CM) diagnosis codes
into a smaller classification of clinically meaningful categories. For example, ICD-9-CM
diagnosis codes for different stages of HIV (042, 0420, 0421, 0422, 0429, 0430, 0431,
0432, 0433, 0439, 0440, 0449, 07953, 27910, 27919, 79571, 7958, V08) was combined
into CCS code 5, which indicates presence of HIV during hospital stays (Heslin &
Elixhauser, 2006).

3.2 Inclusion and Exclusion Criteria
Hospital stays, which indicated neonatal or pregnant issues, and by younger than
18 years old, were excluded from the study. Since the HCUP shifted from ICD-9-CM to
ICD-10-CM on October 1, 2015, this study excluded hospital discharges data from the
fourth quarter of 2015 (October to December 2015), because the Elixhauser comorbidity
index is still under development for ICD-10 coding (Hirode et al., 2020). We also excluded
hospital length of stays reported as zero (LOS=0) because, in this case, patients discharged
on the same day. Table 2.1 presents the total number of discharges collected in the NIS and
the number of observations we analyzed each year. In paper 2, we use the subpopulation
of major select HANA conditions, which are cardiovascular disease, liver disease, diabetes,
cancer, and bone loss, to compare hospital resource use and costs of hospital stays.
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Figure 3. 1 Sample selection for the study.

Table 3. 1 Sample distribution over the years, 2003 to 2015.
Year
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013

Total Unweighted
Discharge
7,977,728
8,004,571
7,995,048
8,074,825
8,043,415
8,158,381
7,810,762
7,800,441
8,023,590
7,296,968
7,119,563
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Sample Analyzed

Percentage

5,551,718
5,511,086
5,508,807
5,638,912
5,516,862
5,780,983
5,537,613
5,581,324
5,840,700
5,212,811
5,077,899

69.59
68.85
68.90
69.83
68.59
70.86
70.90
71.55
72.79
71.44
71.32

2014
2015 (Q1-Q3)
Total

7,071,762
5,377,732
98,754,786

5,030,710
3,844,261
69,633,686

71.14
71.48
70.51

3.3 Study Variables
Outcome variables: The outcome variables of the study are the length of stay
(number of days), the number of procedures used, and hospital inpatient costs. Total
hospital charges were converted to costs using hospital-wide cost-to-charge ratios provided
by HCUP from accounting reports of the Center for Medicare and Medicaid Services
(Agency for Healthcare Research and Quality, 2018a). Hospital charges refer to the amount
a hospital billed for the entire hospital stay, excluding professional (physician,
anesthesiologist) fees. Costs reflect the actual expense incurred in the production of
hospital services, including supplies, wages, and utility costs. All costs were adjusted for
the inflation to the 2015 U.S. dollars using the Personal Health Care (PHC)- Hospital Care
Index from the Centers for Medicare & Medicaid Services. The PHC-Hospital care index
for 2015 was divided by each year’s PHC index and multiplied these results with the
respective year’s costs to get the inflation-adjusted inpatient costs. The CMS Office of the
Actuary constructs the PHC Index based on components of the Consumer Price IndexMedical care (CPI-M) and the Producer Price Index (PPI), and additional composite indices
(Agency for Healthcare Research and Quality, 2019b). Moreover, various adjustments
were made to make the costs variable comparable over the years suggested by the HCUP
(Agency for Healthcare Research and Quality, 2019a).
Comorbidities: The Clinical Classifications Software (CCS), developed as part of
the HCUP, were used to identify comorbid conditions from the discharge records. The CCS
is a diagnosis and procedure categorization scheme based on the International
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Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The ICD-9CM's multitude of codes - over 14,000 diagnosis codes and 3,900 procedure codes - are
collapsed into a smaller number of clinically meaningful categories that are sometimes
more useful for representing descriptive statistics than are individual ICD-9-CM codes
(Agency for Healthcare Research and Quality, 2017a). Elixhauser Comorbidity Software
was used to describe the comorbidity burden of the patients (Agency for Healthcare
Research and Quality, 2017b). Elixhauser Comorbidity Software assigns variables that
identify comorbidities in hospital discharge records using the diagnosis coding of ICD-9CM. We used a new index that produces ‘a single numeric value’ index score (readmission
and mortality scores) that describes the comorbidity burden, and that may be more useful
for multivariable analyses purpose (B. J. Moore, White, Washington, Coenen, &
Elixhauser, 2017). With the help of an infectious disease domain expert and a detailed
literature search, we identified five major HANA conditions based on the CCS codes,
namely cardiovascular disease (CVD), cancer, diabetes, liver disease, and bone loss. A list
of diseases and respective CCS codes of the specific conditions of these five major
categories are described in Appendix A (Table A.1).
Resource Utilization: The total number of procedures used were counted as a
function of inpatient resource utilization. Types of procedures during hospital stays were
identified using ICD-9-CM procedure codes. We also describe the hospital length of stay
(LOS) as a measure of resource utilization.
Patient-level Characteristics: Many studies in the area of aging collapsed 50 years
and older into a single group (Krentz & Gill, 2015; Maciel et al., 2018; Vance, Mugavero,
Willig, Raper, & Saag, 2011). We expanded patients’ age to include more groups per
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discharge as 18-34 years, 35-49 years, 50-64 years, and 65+ years, which enables us to
examine trends between the traditional elderly group (65+ years) with the literature
identified accelerated HIV aging group (50+ years). We also used the age variable as
continuous to describe the changing likelihood of outcomes across independent variables.
Also, we included patients’ race/ethnicity, location, primary payer, median household
income for ZIP code, admission source, and types of hospital stays.
Facility-level Characteristics: Hospital level characteristics include bed size
(small, medium, large), location/teaching status (rural, urban non-teaching, urban
teaching), control/ownership (public, private nonprofit/voluntary, private for-profit),
region of the hospital (Northeast, Midwest, South, West), number of diagnoses, and
disposition of the patients.

3.4 Ethical Considerations
Ethical considerations for using NIS data are ensured by the required HCUP Data
User Agreement (DUA) training. The DUA has some requirements researchers need to
follow to preserve patient rights, and that emphasized the responsibilities of the researchers
while handling this dataset. HCUP Central Distributor removed all identifiable data from
the NIS before releasing it to the researchers. Since NIS is non-identifiable secondary data,
this study is waived from the human subject study by the University of South Carolina
Institutional Review Board (#Pro00097307).

3.5 Analytical Approach
Using the analytic guidelines outlined by HCUP-NIS (Agency for Healthcare
Research and Quality, 2018c), a survey-weighted analysis was conducted accounting for
survey design complexity by using sampling weights (discharge weight). In trend analyses,

50

we used newly generated ‘discharge trend weight’ provided by the HCUP to adjust the NIS
redesign applied in 2012 (Agency for Healthcare Research and Quality, 2015). In order to
get the consistent yearly national rates, we used these new weights for 2003 to 2011, that
are equivalent to normal discharge weights for 2012 and afterward. Data analysis was
performed using SAS version 9.4 (Carry, NC) and Stata version 15 (StataCorp LLC,
College Station, TX). The univariate, bivariate, and multivariable analyses were conducted
to describe the hospital stays, examine the bivariate relationships, and determine the
associations of HIV and age with the outcome variables, respectively.
Analysis for Paper 1: Since Paper 1 is a descriptive study, various univariate
analyses were performed and presented using tables, charts, and graphs. First, we examined
changes in patient and hospital-level characteristics of all hospital stays for the base year
(2003), middle year (2009), and recent year (2015). Second, we calculated overall and agespecific hospitalization rates (per U.S. population) and described the yearly trends from
2003 to 2015. To calculate these rates, we divided the number of hospitalizations from the
NIS by the number U.S. population in each age group collected from the U.S. Census
Bureau (U.S. Census Bureau, 2020).

We also calculated overall and age-specific

hospitalization rates per PLWH by dividing the number of hospitalizations by the number
of HIV cases (HIV prevalence) for each year, as reported by the CDC’s HIV surveillance
reports (CDC, 2020). Third, we also described yearly trends of hospital stays with HIV
among all-listed diagnoses (Dx1-Dx30) and primary diagnosis only (Dx1). The formula
for calculating the proportion of hospital stays with HIV (per 1,000) is:
Eqn. 1: Rate of hospital stays with HIV (per 1,000) = Number of hospital stays
with HIV ÷ Total number of hospital stays×1000.
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Fourth, we describe the top 20 primary diagnoses and procedures used during
hospital stays for three years (2003, 2009, 2015) by HIV status. Finally, we described
yearly trends of five major HANA conditions for all-listed diagnoses (Dx1-D30) and
primary diagnoses (Dx1). The formula for calculating the percentage of particular HANA
condition was:
Eqn. 2: Rate of particular HANA condition among hospital stays with HIV =
Number of hospital stays with HANA ÷ Number of hospital stays with HIV ×100.
Eqn. 3: Rate of particular HANA condition among hospital stays without HIV =
Number of hospital stays with HANA ÷ Number of hospital stays without HIV ×100.
We also report the age-specific percentages of HANA conditions and describe the
trends from 2003 to 2015.
Analysis for Paper 2: Survey-weighted univariate, bivariate, and multivariable
analyses were conducted using SAS version 9.4 (Carry, NC). First, we compared yearly
trends of inpatient resource utilization and costs of HSWH and HSWOH. For descriptive
analyses, we examined both mean and median to describe the overall patterns of resource
utilization and costs. We found, means to be more sensitive to the extreme value of costs
and LOS, so we reported the median values only (see Appendix B for mean charts). Second,
we compared resource utilization and costs of HSWH and HSWOH across the age groups.
For the descriptive purpose, we assessed the trends of differences between HSWH and
HSWOH in terms of resource utilization and costs. The differences were calculated by
subtracting resource utilization and costs of HSWOH from that of HSWH as shown in
equation (1):

52

Eqn. 1: Difference in inpatient resource utilization/costs = inpatient resource
utilization/costs for HSWH – inpatient resource utilization/costs for HSWOH
Third, we depicted yearly trends of differences in resource utilization and costs for
hospital stays among the major five HANA conditions. Finally, multivariable modeling
was performed to measure the association of the number of procedures, LOS, and costs for
hospital stays with HIV and age, controlling for the patient- and hospital-level
characteristics. Guided by previous studies using the NIS database (Enomoto, Gusani,
Dillon, & Hollenbeak, 2014; Molloy, Martin, Moschetti, & Jevsevar, 2017; Perera,
Armstrong, Sherrill, & Skrepnek, 2012; Zou et al., 2019), three Generalized Linear Models
(GLMs) were fitted independently with the following outcomes: 1) number of procedures;
2) length of stay; 3) inpatient costs. These models were chosen because these three outcome
variables were highly skewed and did not meet the normality assumption of the classical
linear model. As the distribution of the number of procedures was observed over-dispersed
(variance>mean) with numerous zeros (no procedures), a zero-inflated negative binomial
regression model was fitted to determine the predictors of procedures used. Inpatient costs
and length of stays were log-transformed and assessed using GLMs with gamma
distribution and log link function to estimate the predictors of hospital costs and length of
stays. We also ran and described these models for hospital stays with five major HANA
conditions separately. To check the missing values, we reran these models keeping the
missing observations considering them as ‘not missing completely at random
(NOMCAR),’ and observed no difference with the main models. Statistical significance
was assessed at alpha 0.01 due to the study’s large sample size.
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Model Equations:
Model for number of procedures:
Log (Number of procedures) = β0 + β1 HIV + β2 Age + β3 Female + β4 Race/ethnicity + β5
Primary Payer + β6 Patient’s location + β7 Income + β8 Weekend admission + β9 Elective
admission + β10 Hospital bed size + β11 Hospital teaching status + β12 Region + β13 Length
of stay + β14 Comorbidity scores + β15 Year
Model for length of stays:
Log (Length of stay) = β0 + β1 HIV + β2 Age + β3 Female + β4 Race/ethnicity + β5 Primary
Payer + β6 Patient’s location + β7 Income + β8 Weekend admission + β9 Elective admission
+ β10 Hospital bed size + β11 Hospital teaching status + β12 Region + β13 Number of
Procedures + β14 Comorbidity scores + β15 Year
Model for inpatient costs:
Log (Costs) = β0 + β1 HIV + β2 Age + β3 Female + β4 Race/ethnicity + β5 Primary Payer +
β6 Patient’s location + β7 Income + β8 Weekend admission + β9 Elective admission + β10
Hospital bed size + β11 Hospital teaching status + β12 Region + β13 Number of Procedures
+ β14 Length of stay + β15 Comorbidity scores + β16 Year
Given the nature of the data, it is plausible that patients hospitalized within one
hospital are more similar than patients within another hospital. Also, multiple inpatient
visits made by the same patients could result in correlated outcomes within the hospitals.
Therefore, to accommodate these within-subject correlations and between-subject
heterogeneity, generalized linear mixed modeling (GLMM) approach could be the best to
incorporate hospital-level random effects. However, due to very large size of the data and
complexity of survey-weighted mixed-effect modeling, it is beyond the capacity of

54

statistical software we used in this study (SAS 9.4 and Stata 15). To check how this
limitation could affect our study results, we ran GLMMs using several smaller subsamples
(10% random sample) as a sensitivity analysis and identified minimal hospital-level
random effects. Considering the circumstances, we performed survey-weighted GLMs
suggested by several previous peer-reviewed journal articles.
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CHAPTER 4

PAPER 1: AGING WITH HIV IN THE UNITED STATES: CHANGING
TRENDS OF INPATIENT STAYS AND COMORBIDITIES IN SHORTSTAY HOSPITALS, 2003 TO 20151

1

Siddiqi, K. A., Olatosi, B., Ostermann, J., Zhang, J., & Khan, M. M. To be submitted to
Journal of Acquired Immune Deficiency Syndromes.
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4.1 Abstract
Background: Due to advances in Antiretroviral Therapy (ART), people living with
HIV (PLWH) live longer in the United States. Aging prolongs exposure to HIV and
antiretroviral drugs, which could lead to an elevated risk of developing multiple age-related
comorbidities [HIV Associated Non-AIDS (HANA) conditions], earlier for PLWH. This
could also lead PLWH to have higher hospitalization with increased HANA comorbidities.
Few studies have explored the aging of PLWH and its impact on hospital stays. This study
examined trends for characteristics and comorbidities of hospital stays with HIV (HSWH)
compared to hospital stays without HIV (HSWOH).
Methods: Thirteen years of pooled data of National Inpatient Sample (NIS) from
the Health Care Utilization Project (HCUP), 2003 through 2015, were analyzed to describe
the trends. We excluded hospital stays for patients less than 18 years old, neonatal,
pregnancy, and same-day discharge from our analysis. Using SAS 9.4, we performed
survey-weighted descriptive analyses using sampling weights provided by HCUP.
Results: Over the study period, the proportions of HSWH remained stable (0.81%),
but the proportions of HSWH among the older increased gradually. The mean age
difference between HSWH and HSWOH reduced substantially. Hospitalization rates
decreased from 105 to 89 per 100,000 U.S. population over the years, while the rates for
the older population aged 55-64 and 65+ years increased substantially. Overall, HSWH
had fewer HANA conditions than hospital stays without HIV (HSWOH). The proportions
of cardiovascular disease (CVD) and cancer increased disproportionately over time among
HSWH; CVD and liver disease increased among aged 65+ years, and CVD and cancer
increased among aged 50-64 years.
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Conclusions: Consistent with the aging of PLWH, higher HSWH and HANA
comorbidities were observed among older HIV patients, which suggest increased future
hospital resource utilization for HSWH. Appropriate training of health care providers may
be essential to managing increased health burdens of older PLWH, and associated
complications during hospital stay in the United States.
Keywords: HIV, Aging, Inpatient Stay, Comorbidities, United States.

4.2 Introduction
Today, Human Immunodeficiency Virus (HIV) infection is a manageable chronic
condition due to advanced highly active antiretroviral treatment (HAART). People living
with HIV (PLWH) now live longer due to early diagnosis, engagement, and retention in
HIV medical care (National Institute of Allergy and Infectious Diseases, 2018; Pebody,
2018). This change has resulted in life expectancy gains for PLWH, with many aging and
living longer with HIV. Currently, almost half of all PLWH are 50 years or older (Center
for Disease Control and Prevention, 2018). This proportion is projected to increase to 70%
by 2030 (Wing, 2017). The interaction of HIV with the aging process and aging-related
comorbidities is expected since the virus consistently activates immune cells that make
individuals susceptible to inflammatory induced diseases and diminishes the capacity to
fight other diseases (Fauci et al., 2010).
Due to increased life expectancy for PLWH, age-related chronic conditions are
foremost health concerns after viral load suppression is achieved. Along with aging,
prolonged exposure to both HIV and antiretroviral drugs may increase the risk of agerelated chronic illnesses, commonly called HIV Associated Non-AIDS (HANA)
conditions. The HANA chronic diseases include cardiovascular, liver, kidney, bone, and
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lung disease and non-HIV associated cancers (Gallant et al., 2017; Guaraldi et al., 2011;
Schouten et al., 2014). Studies already show a higher prevalence of multimorbidity among
PLWH than in the general population (Guaraldi et al., 2011; Maciel et al., 2018; RodriguezPenney et al., 2013). The higher prevalence of HANA among PLWH raises the question
of whether HIV infection is accelerating aging or acting as an additional risk factor for
comorbidity development. While it is difficult to determine whether HIV accelerates the
aging process, or is merely an additional risk factor for chronic conditions, research shows
the development of geriatric clinical conditions is hastened with advanced aging (High et
al., 2012; Pathai et al., 2013). A previous study showed that the rates of hospitalization
with HIV diagnosis increased for the older PLWH population (Heslin & Elixhauser, 2016).
With the high prevalence of physical and mental health comorbidities and lack of social
supports, aging PLWH may demand increased inpatient care services in the United States
(Matthew Harris et al., 2015).
Assessing and describing the changing patterns of hospitalization and comorbidity
burdens of PLWH during hospital stays is essential to planning for future inpatient care
resource demand posed by the aging PLWH. Gaps in the literature exist for trends and
differences in characteristics and comorbidities for hospital stays with HIV (HSWH), and
hospital stays without HIV (HSWOH) in the United States. To our knowledge, studies
assessing the trends focused on major age-related comorbidities using nationally
representative U.S. inpatient data are few. This study examines and describes the
characteristics and trends of HSWH compared to HSWOH using the national inpatient
sample (NIS). This study also describes comorbidity trends in HSWH compared to
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HSWOH across age groups of the patients. Investigating the recent trends of HSWH and
co-occurring HANA conditions is important for planning purposes.

4.3 Methods
4.3.1 Data Source and Sample
This study pooled data from the National Inpatient Sample (NIS) data, 2003
through 2015 from the Healthcare Cost and Utilization Project (HCUP). The NIS is the
largest all-payer inpatient care database that contains hospital discharge records (more than
7 million hospital stays each year) of the U.S. community hospitals in 46 states and the
District of Columbia (Agency for Healthcare Research and Quality, 2018b). The NIS
includes short-term, nonfederal, general, and other community hospitals. It excludes longterm care facilities, such as rehabilitation, psychiatric, alcoholism, and chemical
dependency hospitals. Prior to 2012, NIS collected all discharge records from a 20%
sample hospitals from each stratum; starting in 2012, NIS collects 20% discharges from all
U.S. hospitals (Houchens et al., 2014). This was modified again in 2015 to reflect new
ICD-10 codes. Further information about the sampling and dataset changes are available
elsewhere (Agency for Healthcare Research and Quality, 2018b).
The unit of analysis in this study is hospital stay from the U.S. inpatient department.
We used discharge level weights, available through the HCUP-US website, to produce
nationally representative estimates (Agency for Healthcare Research and Quality, 2018d).
Hospital stays, which indicated neonatal or pregnancy issues, and by younger than 18 years
old, were excluded from the study. We also excluded hospital length of stays (LOS)
reported as zero (LOS=0) because this indicated such patients got discharged on the same
day. Since the HCUP shifted from ICD-9-CM to ICD-10-CM on October 1, 2015, this
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study excluded hospital discharges data from the fourth quarter of 2015 (October to
December 2015) because the Elixhauser comorbidity index is still under development for
ICD-10 coding (Hirode et al., 2020).
4.3.2 Study Variables
We used the Clinical Classifications Software (CCS) developed for HCUP to
identify comorbidities and procedures from hospital stays. The CCS is a diagnosis and
procedure categorization scheme based on the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) (Healthcare Cost and Utilization Project,
2017). An inpatient hospital stay was designated an HIV associated hospital stay if the CCS
code for HIV is 5 (ICD-9-CM codes: 042, 0420, 0421, 0422, 0429, 0430, 0431, 0432, 0433,
0439, 0440, 0449, 07953, 27910, 27919, 79571, 7958, V08) (Heslin & Elixhauser, 2006).
With the help of an infectious disease domain expert and literature search, we identified
five major HANA conditions based on the CCS codes, namely cardiovascular disease
(CVD), cancer, diabetes, liver disease, and bone loss. The name and CCS codes for specific
conditions of these five major categories are described in Appendix A (Table A.1).
Patient-level Characteristics: Many HIV related aging studies collapsed 50 years
and older into a single age group (H. Krentz & Gill, 2015; Maciel et al., 2018; Vance,
Mugavero, Willig, Raper, & Saag, 2011). We expanded the patient's age to include more
groups per hospital stay as 18-34 years, 35-49 years, 50-64 years, and 65+ years. We also
included patients' sex, race/ethnicity, location, primary payer, and median household
income by ZIP code.
Facility-level Characteristics: Hospital level characteristics examined included
admission source, type of admission, the number of diagnoses, patient disposition at
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discharge, bed size (small, medium, large), location/teaching status (rural, urban nonteaching, urban teaching), control/ownership (public, private non-profit/voluntary, private
for-profit), and geographic region (Northeast, Midwest, South, West).
Resource Utilization: The total number of procedures used and hospital length of
stay (LOS) were counted as a function of inpatient resource utilization. Types of
procedures during hospital stays were identified using ICD-9-CM procedure codes. The
average costs per hospital stay were also measured by converting total charges to costs
using hospital-wide cost-to-charge ratios provided by HCUP from accounting reports of
the Center for Medicare and Medicaid Services (Agency for Healthcare Research and
Quality, 2018a). Charges and costs were adjusted for the inflation to the 2015 U.S. dollars
using the Personal Health Care (PHC)- Medical Care Index from the Centers for Medicare
& Medicaid Services (Agency for Healthcare Research and Quality, 2019b).
4.3.3 Ethical Statement
Ethical considerations for using NIS data are ensured by the required HCUP Data
User Agreement (DUA) training. HCUP Central Distributor removed all identifiable data
from the NIS before releasing it to the researchers. This study was deemed a non-human
subject study by the University of South Carolina Institutional Review Board
(#Pro00097307).
4.3.4 Data Analysis
Using the analytic guidelines outlined by HCUP-NIS (Agency for Healthcare
Research and Quality, 2018c) (Healthcare Cost and Utilization Project, 2018b), a surveyweighted analysis was performed accounting for survey design complexity by using
sampling weights (discharge weight). To adjust the NIS redesign applied in 2012, we used
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newly generated ‘discharge trend weight’ provided by the HCUP for 2003 to 2011 to get
the consistent yearly national rates (Agency for Healthcare Research and Quality, 2015).
Descriptive analyses were conducted using SAS version 9.4 (Carry, NC). First, we
examined changes in patient- and hospital-level characteristics of all hospital stays for the
base year (2003), middle year (2009), and recent year (2015). Second, we calculated overall
and age-specific hospitalization rates (per U.S. population) and described the yearly trends
from 2003 to 2015. To calculate these rates, we divided the number of hospitalizations
from the NIS by the number U.S. population in each age group collected from the U.S.
Census Bureau (U.S. Census Bureau, 2020). We also calculated overall and age-specific
hospitalization rates per PLWH by dividing the number of hospitalizations by the number
of HIV cases for each year (HIV prevalence), as reported by the CDC’s HIV surveillance
reports (Center for Disease Control and Prevention, 2020a). Third, we also described yearly
trends of hospital stays with HIV among all diagnoses (Dx1-Dx30) and principal diagnosis
only (Dx1). The formula for calculating the proportion of HSWH (per 1,000) is:
Eqn. 1: Rate of HSWH (per 1,000) = Number of hospital stays with HIV ÷ Total
number of hospital stays×1000.
Fourth, we described the top 20 principal diagnoses and procedures used during
hospital stays for three years (2003, 2009, 2015) by HIV status. Finally, we described
yearly trends of five major HANA conditions for all diagnoses (Dx1-D30) and principal
diagnoses (Dx1). The formula for calculating the percentage of particular HANA condition
was:
Eqn. 2: Rate of particular HANA condition among HSWH = Number of hospital
stays with HANA ÷ Number of hospital stays with HIV ×100.
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Eqn. 3: Rate of particular HANA condition among HSWOH = Number of hospital
stays with HANA ÷ Number of hospital stays without HIV ×100.
We also report the age-specific percentages of HANA conditions and describe the
trends from 2003 to 2015.

4.4 Results
Table 4.1 shows patient and hospital-level attributes of the hospital stays with- and
without HIV (HSWH and HSWOH) for the baseline year (2003), middle year (2009), and
final year (2015) of the study period. Some variables which were not available throughout
the study period are presented in a supplement table in Appendix A (Table A.2).
4.4.1 Patient-level Characteristics of Hospital Stays
In table 4.1, the proportion for HSWH increased slightly in 2009 (0.85%) compared
to baseline 2003 (0.81%) and 2015 (0.81%). The overall mean age difference between
HSWH and HSWOH decreased over the study period. The change in mean age difference
was 19 years (61.82 vs. 43.09) in 2003, 15 years (61.83 vs. 46.49) in 2009, and 13 years
(62.25 vs. 49.17) in 2015. The proportion of HSWH for older age groups increased from
2003 to 2015 but decreased for the younger age groups. From 2003 to 2015, HSWH
increased by 22.25% for ages 50-64 years and 6.52% for ages 65 or older. Males constituted
the majority of HSWH, and the proportions were unchanged across most study years.
Differential changes were also observed by race and ethnicity. The proportion of Whites
with an HSWH increased in 2015 compared to baseline. Conversely, decreases were
observed for Hispanics for 2015 compared to baseline. Overall, the percentage of HSWH
for lowest-income area residents (0-25th percentile) increased slightly from 2003 to 2015.
Medicare payments for HSWH increased from the baseline year 2003 (27.10%) to 34.87%
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for 2015. By rurality, HSWH increased for both small metropolitan areas and rural
residents (Table 4.1).
4.4.2 Hospital-level Characteristics of Hospital Stays
In table 4.1, the median number of diagnoses increased over the study period for
both types of hospital stays. Overall, the proportion of discharges to long-term care (home
health care, and SNF, intermediate care, and other) increased, while home discharge
(routine), and death during hospital stay decreased for both types of hospital stays. The
proportion of HSWH decreased in government (nonfederal) hospitals but increased in
private non-profit hospitals. HSWH also decreased in rural and urban non-teaching
hospitals but increased in urban teaching hospitals. HSWH in Northeast hospitals
decreased from 2003 to 2015; compared to increases experienced in other regions.
Compared to 2003, the proportion of hospital stays in 'small bed size' hospitals increased
in 2015 for all hospital stays; but decreased in 'large bed size' hospitals.
In terms of hospital resource use, slight changes occurred in the median number of
procedures used during hospital stays from 2003 to 2015. However, the median length of
stay (LOS) decreased for both types of hospital stays over the study period, with the most
substantial decrease observed for HSWH. The median total hospital charges per hospital
stay increased for both types of hospital stays over the years from 2003 to 2015 in terms of
U.S. dollars, but the increases were relatively lower among HSWH. Inpatient costs per
hospital stay increased for HSWOH, while it was decreased slightly for HSWH over the
study years (Table 4.1).
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4.4.3 Population-based Hospitalization Rates, 2003 to 2015
Figure 4.1 presents the yearly trends of hospital inpatient stays with HIV diagnosis
per 100,000 U.S. adult population by age groups, 2003 to 2015. Overall hospitalization
rates decreased over time (105 to 89 per 100,000), while hospitalization rates among older
age groups increased. Hospitalization rates increased from 70 to 126 hospitalizations per
100,000 among ages 55-64 years and from 17 to 42 hospitalization per 100,000 among
ages 65+ years.
Figure 4.2A represents the yearly trends of the estimated prevalence of HIV cases,
the total number of hospitalizations by PLWH, and rates of hospitalization among PLWH
(per 100 PLWH). Figure 4.2B shows yearly trends of hospitalization rates for PLWH by
age groups. In Figure 4.2A, the prevalence of HIV increased over the study period, while
hospital stays decreased over time. Hospitalization rates decreased from 51 hospitalizations
per 100 PLWH in 2003 to 21 hospitalizations per 100 PLWH in 2015. Figure 4.2B shows
the hospitalization rate per 100 PLWH decreased among all age groups, and the decreases
were a little higher among older age groups (50-64 and 65+years).
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Figure 4. 1 Trends of hospital inpatient stays including HIV per 100,000 adult
population by age group (years), 200 3 to 2015
*Total number of hospitalizations in 2015 is for the first three quarters (January to
September), however, the approximate rates were calculated by multiplying the
number of hospital stays by 4/3 to make the rates consistent with other years.
a

Excludes hospital stays by less than 18 years old, same-day discharges (LOS=0),
and that with a diagnosis code for pregnancy, labor, delivery, or neonatal cases.
b

Source: Population estimates, U.S. Census Bureau.
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Table 4. 1 Patient and hospital-level characteristics of hospital stays, 2003, 2009 and 2015.
2003
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HIVCharacteristics
Unweight Weighted
ed n
%
Overall
5,505,953
99.19
Patient-level characteristics
Age (years): mean
61.82
Age groups
18-35 years
557,279
10.12
36-49 years
960,111
17.39
50-64 years
1,281,050
23.23
65+years
2,707,513
49.26
Sex
Male
2,449,236
44.61
Female
3,045,870
55.39
Race/ethnicity
White
2,919,208
72.38
African American
550,959
13.43
Hispanic
393,636
9.66
Others
180,402
4.53
Median Household
Income (by ZIP) a
0-25th percentile
1,487,772
27.90

2009

HIV+
Unweight Weighted
ed n
%
45,765
0.81
43.09

HIVUnweight Weighted
ed n
%
5490815
99.15
61.83

HIV+
Unweight Weighted
ed n
%
46798
0.85
46.49

10,068
24,864
9,683
1,150

21.74
54.53
21.21
2.52

549,244
876,843
1,437,936
2,626,792

9.99
15.95
26.14
47.92

7,919
20,529
15,981
12,086

16.69
43.97
34.27
5.07

30,368
15,384

66.41
33.59

2,521,382
2,962,828

45.97
54.03

31,952
14,840

68.17
31.83

10,277
21,367
6,057
1,525

26.32
53.73
15.84
4.11

3,351,372
613,423
410,878
280,300

71.88
13.22
8.79
6.11

12,068
21,835
5,776
15,859

27.93
51.11
13.69
7.27

22,535

50.84

1,527,832

28.69

17,289

47.35
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26th to 50th percentile
1,443,833
(median)
51st to 75th percentile
1,345,908
76th to 100th percentile
1,092,732
Primary Payer
Medicare
2,889,719
Medicaid
514,786
Private including HMO
1,650,985
Self-pay
235,008
Others (incl. No charge)
179,581
Patients’ location
(rurality)b
Large metropolitan
2,980,732
Small metropolitan
1,461,439
Micropolitan
583,022
Rural
449,097
Hospital-level characteristics
Weekend admission
No
4,475,102
Yes
1,030,851
Elective admission
Non-elective
4,041,645
Elective
1,443,258
# of Diagnoses
6.43
(median)
Disposition of patient

27.03

10,677

23.80

1,440,380

26.90

8,955

24.42

24.87
20.20

7,223
4,048

16.22
9.14

1,262,138
1,100,768

23.61
20.79

6,350
3,964

17.34
10.90

52.67
9.44
29.94
4.25
3.28

12,368
18,325
8,052
3,721
2,346

27.10
40.64
17.67
8.09
5.06

2,829,843
575,094
1,536,599
316,757
220,649

51.74
10.55
27.95
5.77
3.99

13,923
18,017
7,143
5,172
2,460

29.57
39.13
15.18
10.88
5.24

53.96
26.18
11.33
8.54

35,173
7,386
1,955
834

77.60
16.09
4.44
1.87

2,815,152
1,467,281
653,931
422,670

52.81
27.18
12.06
7.95

26,687
6,986
1,609
847

73.85
19.27
4.51
2.37

81.25
18.75

36,124
9,641

78.94
21.06

4,430,866
1,059,949

80.68
19.32

36,833
9,965

78.74
21.26

73.75
26.25

40,579
5,097
6.98

88.95
11.05

4,199,449
1,279,180
9.25

76.75
23.25

42,158
4,538
9.59

90.31
9.69
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Routine
Transfer to short term
hospital
Other transfers: SNF,
intermediate care, and
other
Home health care
AMA
Died in hospital
Bed size
Small
Medium
Large
Control/ownershipc
Government, nonfederal
Private, non-profit
Private, invest-own
Location/teaching
status
Rural
Urban non-teaching
Urban teaching
Region
Northeast
Midwest
South

3,756,366
137,019

68.37
2.53

32740
754

71.63
1.68

3,499,873
128,877

63.63
2.37

33,186
812

70.90
1.74

869,655

15.90

4,680

10.21

963,251

17.62

4,881

10.45

511,715
49,899
156,802

9.37
0.91
2.85

3,171
2,312
1,996

6.94
5.11
4.38

703,418
56,715
131,828

12.86
1.05
2.40

3,968
2,461
1,404

8.51
5.36
2.98

669,941
1,441,946
339,1421

11.55
25.67
62.78

3,535
11,456
30,774

7.41
25.08
67.51

687,422
1,271,362
3,433,043

12.56
23.85
63.60

4,366
10,852
30,662

9.04
23.47
67.48

685,391
3,932,248
774,188

12.73
72.74
14.53

10,668
29,356
5,856

23.16
63.77
13.07

Same category not available

815,094
2,417,692
2,270,522

16.22
42.38
41.39

1,800
14,057
29,908

4.31
29.44
66.24

687,160
2,316,809
2,387,858

12.67
43.76
43.57

1,449
12,246
162,922

3.16
27.22
69.61

1,127,753
125,5442
221,1067

20.86
23.56
38.39

15,546
4,790
21,468

35.38
10.87
44.23

1,074,789
1,313,733
2,096,444

20.51
23.80
38.13

16,507
5,718
19,578

37.40
11.88
40.35
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West
911,691
17.19
3,961
9.53
1,005,849
17.56
4,995
10.36
Hospital resource use (median)
# of Procedures
0.41
0.38
0.45
0.33
Length of stay
3.0
4.09
2.90
3.66
(# of days)
Total charges per
19,049
22,697
24,423
25,733
hospital stay (US$)
Costs per hospital stay
7530
8511
7,934
7,787
(US$)
(a) Since the quartile median income updates annually, the 4 quartiles vary by year. The 4 income quartiles indicates the poorest to
wealthiest populations: 2003 (1-35,999; 36,000-44,999; 45,000-59,999; 60,000+), 2009 (1-39,999; 40,000-49,999; 50,000-65,999;
66,000+), 2015 (1 - 41,999; 42,000 - 51,999; 52,000 - 67,999; 68,000+).
(b) Large metropolitan areas include central counties of metro areas (>1 million) and fringe counties of metro areas (≥1 million),
and small metropolitan areas contain counties in metro areas with 50,000-999,000 population. See methods section for details.
(c) Categories were dissimilar, therefore incomparable over the study periods.
ꝉ This study analyzed data for quarter 1 to quarter 3 (January to September 2015), to avoid the transition in ICD codes from ICD-9CM to ICD-10-CM effective on October 1, 2015.

Table 4. 1 Patient and hospital-level characteristics of hospital stays, 2003-2015 (continued).
2015 (Q1-Q3)ꝉ

2009
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HIVCharacteristics
Unweight Weighted
ed n
%
Overall
5,490,815
99.15
Patient-level characteristics
Age (years): mean
61.83
Age groups
18-35 years
549,244
9.99
36-49 years
876,843
15.95
50-64 years
1,437,936
26.14
65+years
2,626,792
47.92
Sex
Male
2,521,382
45.97
Female
2,962,828
54.03
Race/ethnicity
White
3,351,372
71.88
African American
613,423
13.22
Hispanic
410,878
8.79
Others
280,300
6.11
Median Household
Income (by ZIP) a
0-25th percentile
1,527,832
28.69

HIV+
Unweight Weighted
ed n
%
46,798
0.85
46.49

HIVUnweight Weighted
ed n
%
3,813,082
99.19
62.25

HIV+
Unweight Weighted
ed n
%
31,179
0.81
49.17

7,919
20,529
15,981
12,086

16.69
43.97
34.27
5.07

380,277
510,302
1,047,744
1,874,759

9.97
13.38
27.48
49.17

4,672
10,092
13,583
2,832

14.98
32.37
43.56
9.08

31,952
14,840

68.17
31.83

1,816,785
1,995,853

47.65
52.35

21,046
10,127

67.51
32.49

12,068
21,835
5,776
15,859

27.93
51.11
13.69
7.27

2,555,019
542,448
331,731
192,682

66.94
14.98
9.16
5.32

8,929
16,399
3,608
1,489

29.35
53.90
11.86
4.89

17,289

47.35

1,171,158

31.35

13,642

52.69
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26th to 50th percentile
1,440,380
(median)
51st to 75th percentile
1,262,138
76th to 100th percentile 1,100,768
Primary Payer
Medicare
2,829,843
Medicaid
575,094
Private including HMO
1,536,599
Self-pay
316,757
Others (incl. No charge)
220,649
Patients’ location
(rurality)b
Large metropolitan
2,815,152
Small metropolitan
1,467,281
Micropolitan
653,931
Rural
422,670
Hospital-level characteristics
Weekend admission
No
4,430,866
Yes
1,059,949
Elective admission
Non-elective
4,199,449
Elective
1,279,180
# of Diagnoses
9.25
(median)
Disposition of patient

26.90

8,955

24.42

931,721

24.94

5,338

20.62

23.61
20.79

6,350
3,964

17.34
10.90

892,995
740,126

23.90
19.81

4,259
2,651

16.45
10.24

51.74
10.55
27.95
5.77
3.99

13,923
18,017
7,143
5,172
2,460

29.57
39.13
15.18
10.88
5.24

2,072,499
535,590
925,120
149,438
125,145

54.43
14.07
24.30
3.92
3.29

10,848
12,112
5,145
1,961
1,040

34.87
38.94
16.54
6.30
3.34

52.81
27.18
12.06
7.95

26,687
6,986
1,609
847

73.85
19.27
4.51
2.37

1,998,260
1,148,202
366,952
285,792

52.60
30.22
9.66
7.52

18,541
5,938
1,128
658

70.59
22.61
4.29
2.51

80.68
19.32

36,833
9,965

78.74
21.26

3,031,049
782,033

79.49
20.51

24,286
6,893

77.89
22.11

76.75
23.25

42,158
4,538
9.59

90.31
9.69

3,008,362
791,065
12.28

79.18
20.82

27,939
3,159
13.09

89.84
10.16
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Routine
Transfer to short term
hospital
Other transfers: SNF,
intermediate care, and
other
Home health care
AMA
Died in hospital
Bed size
Small
Medium
Large
Control/ownershipc
Government, nonfederal
Private, non-profit
Private, invest-own
Location/teaching
status
Rural
Urban non-teaching
Urban teaching
Region
Northeast
Midwest
South

3,499,873
128,877

63.63
2.37

33,186
812

70.90
1.74

2,262,064
79,269

59.37
2.08

21,209
547

68.06
1.76

963,251

17.62

4,881

10.45

740,064

19.42

3,794

12.18

703,418
56,715
131,828

12.86
1.05
2.40

3,968
2,461
1,404

8.51
5.36
2.98

588,553
49,785
89,970

15.45
1.31
2.36

3,433
1,421
751

11.02
4.56
2.41

687,422
1,271,362
3,433,043

12.56
23.85
63.60

4,366
10,852
30,662

9.04
23.47
67.48

712,289
1,121,600
1,979,193

18.68
29.41
51.91

4,629
8,675
17,875

14.85
27.82
57.33

685,391
3,932,248
774,188

12.73
72.74
14.53

10,668
29,356
5,856

23.16
63.77
13.07

455,238
2,773,865
583,979

11.94
72.75
15.32

5,766
21,117
4,296

18.49
67.73
13.78

687,160
2,316,809
2,387,858

12.67
43.76
43.57

1,449
12,246
162,922

3.16
27.22
69.61

372,376
1,054,430
2,386,276

9.77
27.65
62.58

951
5,221
25,007

3.05
16.75
80.20

1,074,789
1,313,733
2,096,444

20.51
23.80
38.13

16,507
5,718
19,578

37.40
11.88
40.35

733,871
871,084
1,505,618

19.25
22.84
39.49

8,726
4,131
14,827

27.99
13.25
47.55
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West
1,005,849
17.56
4,995
10.36
702,509
18.42
3,495
11.21
Hospital resource use
(median)
# of Procedures
0.45
0.33
0.40
0.40
Length of stay
2.90
3.66
2.94
3.55
(# of days)
Total charges per
24,423
25,733
31,310
31,498
hospital stay (US$)
Costs per hospital stay
7,934
7,787
8,449
8,332
(US$)
(a) Since the quartile median income updates annually, the 4 quartiles vary by year. The 4 income quartiles indicates the poorest to
wealthiest populations: 2003 (1-35,999; 36,000-44,999; 45,000-59,999; 60,000+), 2009 (1-39,999; 40,000-49,999; 50,000-65,999;
66,000+), 2015 (1 - 41,999; 42,000 - 51,999; 52,000 - 67,999; 68,000+).
(b) Large metropolitan areas include central counties of metro areas (>1 million) and fringe counties of metro areas (≥1 million),
and small metropolitan areas contain counties in metro areas with 50,000-999,000 population. See methods section for details.
(c) Categories were dissimilar, therefore incomparable over the study periods.
ꝉ This study analyzed data for quarter 1 to quarter 3 (January to September 2015), to avoid the transition in ICD codes from ICD-9CM to ICD-10-CM effective on October 1, 2015.
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4.2B . RAT E O F H O S PITAL IZAT IO N b FO R
H S WH B Y AGE GRO UP
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Figure 4. 2 (A) Trends of HIV prevalence (10,000), total number of hospitalization
(10,000), and rates of hospitalization (per 100) for people living with HIV; (B)
Hospitalization per 100 PLWH by age groups (years).
*Total number of hospitalizations in 2015 is for the first three quarters (January to
September), however, the approximate rates were calculated by multiplying the
number of PLWH by ¾ to make the rates consistent with other years.
a

Source: HIV surveillance report, vol. 16-28, Center for Disease Control and
Prevention (CDC).
b

Excludes hospital stays by less than 18 years old, same-day discharges (LOS=0),
and that with a diagnosis code for pregnancy, labor, delivery, or neonatal cases.

4.4.4 Trends of Hospital Stays with HIV (HSWH)
Figure 4.3A shows the trends of age-specific HSWH (out of all hospital stays) for
all diagnoses with an HIV diagnosis. Figure 4.3B represents the trends for only the
principal diagnosis with an HIV diagnosis. The overall proportions of HSWH are mostly
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constant, but variations exist by age. Among all diagnoses, the proportion of HSWH
decreased over the study years for younger age groups (18-35 and 36-49 years) but
increased for older age groups (50-64 and 65+ years). Besides, the proportions of HSWH
as principal diagnosis decreased for all age groups except the elderly (65+ years), whose
proportions showed slight increases over time (Figure 4.3).
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4.3B . PRINCIPAL DIAGNO S E S
W IT H A H IV DIAGNO S IS
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Figure 4. 3 Age-specific proportions of hospital stays with HIV diagnosis (per 1,000
hospital stays), 2003 to 2015. (A) HIV diagnosis as all diagnoses, (B) HIV as the
principal diagnosis.
4.4.5 Top Principal diagnoses for Hospital Stays
Table 4.2 displays the top 20 principal diagnoses for hospitals stays in the base year
(2003), middle year (2009), and the final year (2015). Chronic heart disease was the top
principal diagnosis among HSWOH in 2003 and 2009 but changed to septicemia in 2015.
The top principal diagnoses for HSWH was pneumonia in 2003 (8.29%) and 2009 (6.70%)
and septicemia in 2015 (8.18%). The proportion of age-related chronic conditions
increased over the study years for both types of hospital stays. For example, osteoarthritis
increased from 2.20% (2003), 3.30% (2009) to 4.22% (2015) among HSWOH. Among
HSWH, proportions for chronic conditions (acute and unspecified renal failure, congestive
heart failure, diabetes, and hypertension), mental illness (schizophrenia and other psychotic
disorders), and septicemia increased from 2003 to 2015. However, the proportions of
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pneumonia, skin and subcutaneous tissue infections, asthma, and pancreatic disorders
decreased over time. The percentage of substance-related mental disorders decreased,
whereas the percentage of alcohol-related disorders increased slightly from 2003 to 2015
among HSWH (Table 4.2).
4.4.6 Top Principal Procedures Used During Hospital Stays
Table 4.3 displays the top 20 procedures for HSWH and HSWOH in the base year
(2003), middle year (2009), and the final year (2015). Major procedures performed during
hospital stays were slightly different for the HSWH compared with HSWOH. We observed
that the percentages of hemodialysis, respiratory intubation and mechanical ventilation,
and cancer chemotherapy increased over the study period among HSWH. The percentage
of psychological and psychiatric evaluation and therapy increased in 2009 from 2003 but
decreased in 2015. While the proportions of hip replacement (total and partial), diagnostic
cardiac catheterization (coronary arteriography) were not among the top 20 procedures for
HSWH in 2003, these proportions placed in the top 20 procedures in 2009 and increased
in magnitude in 2015. Proportions for diagnostic bronchoscopy and biopsy of bronchus
and colonoscopy decreased among HSWH over the study period (Table 4.3).
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Table 4. 2 Top 20 principal diagnoses ꝉ for hospital stays (weighted percentage), 2003, 2009, and 2015.

2003
Rank
1
2
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3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

HIVCoronary atherosclerosis and other heart
diseases
Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Congestive heart failure; nonhypertensive
Nonspecific chest pain
Acute myocardial infarction
Genitourinary incontinence procedures
Arterial blood gases
Chronic obstructive pulmonary disease and
bronchiectasis
Osteoarthritis
Complication of device; implant or graft
Acute cerebrovascular disease
Rehabilitation care, fitting of prostheses, and
adjustment of devices
Diabetes mellitus with complications
Fluid and electrolyte disorders
Arthroscopy
Urinary tract infections
Complications of surgical procedures or
medical care

%
4.60

%
8.29

4.28

HIV+
Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Affective disorders (~ mood disorder)

4.18
3.00
2.74
2.58
2.43
2.30

Skin and subcutaneous tissue infections
Substance-related mental disorders
Pancreatic disorders (not diabetes)
Schizophrenia and related disorders
Complication of device; implant or graft
Congestive heart failure; nonhypertensive

3.80
3.09
2.82
2.59
2.42
2.07

2.20
2.11
2.07
1.71

Fluid and electrolyte disorders
Alcohol-related disorders
Nonspecific chest pain
Septicemia (except in labor)

2.05
1.99
1.91
1.74

1.69
1.69
1.67
1.63
1.60

Asthma
Diabetes mellitus with complications
Epilepsy; convulsions
Other liver diseases
Anemia

1.78
1.59
1.53
1.48
1.48

5.81

18
29

Skin and subcutaneous tissue infections
Septicemia (except in labor)

1.56
1.37

20

Gastrointestinal hemorrhage

1.27

Urinary tract infections
Hypertension with complications and secondary
hypertension
Acute and unspecified renal failure

1.37
1.34

%
6.70

1.33

2009
HIVCongestive heart failure; nonhypertensive

%
3.62
3.54
3.30
2.90

Skin and subcutaneous tissue infections
Substance-related disorders

3.99
3.19

2.85
2.80
2.74
2.58

Schizophrenia and other psychotic disorders
Septicemia (except in labor)
Complication of device; implant or graft
Congestive heart failure; nonhypertensive

3.08
2.98
2.38
2.36

9
10
11
12

Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Osteoarthritis
Coronary atherosclerosis and other heart
diseases
Septicemia (except in labor)
Genitourinary incontinence procedures
Mood disorders
Chronic obstructive pulmonary disease and
bronchiectasis
Complication of device; implant or graft
Arterial blood gases
Nonspecific chest pain
Acute myocardial infarction

HIV+
Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Mood disorders

2.28
2.28
2.27
2.21

2.27
2.12
2.01
1.99

13
14
15

Skin and subcutaneous tissue infections
Acute cerebrovascular disease
Urinary tract infections

1.97
1.93
1.93

Alcohol-related disorders
Nonspecific chest pain
Acute and unspecified renal failure
Chronic obstructive pulmonary disease and
bronchiectasis
Asthma
Fluid and electrolyte disorders
Pancreatic disorders (not diabetes)

1
2
3
4
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5
6
7
8

5.42

1.99
1.93
1.61

16
17
18
29
20

Diabetes mellitus with complications
Complications of surgical procedures or
medical care
Arthroscopy
Fluid and electrolyte disorders
Rehabilitation care, fitting of prostheses, and
adjustment of devices

1.76
1.74

Maintenance chemotherapy; radiotherapy
Diabetes mellitus with complications

1.50
1.50

1.64
1.50
1.45

Epilepsy; convulsions
Urinary tract infections
Intestinal infection

1.39
1.29
1.20

%
8.18
5.66
4.35

2015
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1
2
3
4
5
6
7
8
9
10
11

HIVSepticemia (except in labor)
Osteoarthritis
Congestive heart failure; nonhypertensive

%
6.68
4.22
3.67

Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Mood disorders
Cardiac dysrhythmias
Complication of device; implant or graft
Acute myocardial infarction
Acute cerebrovascular disease
Chronic obstructive pulmonary disease and
bronchiectasis
Acute and unspecified renal failure

3.08

HIV+
Septicemia (except in labor)
Mood disorders
Pneumonia (except that caused by tuberculosis
or sexually transmitted disease)
Schizophrenia and other psychotic disorders

2.83
2.57
2.42
2.38
2.38
2.25

Skin and subcutaneous tissue infections
Acute and unspecified renal failure
Complication of device; implant or graft
Congestive heart failure; nonhypertensive
Substance-related disorders
Fluid and electrolyte disorders

3.20
2.65
2.56
2.38
2.38
2.14

2.09

Alcohol-related disorders

2.10

3.20

12
13
14

Skin and subcutaneous tissue infections

2.05

Chronic obstructive pulmonary disease and
bronchiectasis
Diabetes mellitus with complications
Asthma
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Diabetes mellitus with complications
2.05
Spondylosis; intervertebral disc disorders;
2.04
other back problems
15
Urinary tract infections
1.83
Pancreatic disorders (not diabetes)
16
Complications of surgical procedures or
1.68
Hypertension with complications and secondary
medical care
hypertension
17
Respiratory failure; insufficiency; arrest (adult)
1.63
Acute myocardial infarction
18
Rehabilitation care; fitting of prostheses; and
1.55
Complications of surgical procedures or
adjustment of devices
medical care
29
Schizophrenia and other psychotic disorders
1.51
Maintenance chemotherapy; radiotherapy
20
Coronary atherosclerosis and other heart
1.46
Intestinal infection
disease
ꝉ Principal diagnosis for hospital stays with HIV excludes HIV-infection
Formula: Percentage of a particular condition = (# of a particular disease ÷ # of total hospital stays)×100

2.10
1.86
1.71
1.64
1.53
1.49
1.46
1.48
1.41

Table 4. 3 Top 20 principal procedures during hospital stays (weighted percentages), 2003, 2009, and 2015.

2003
Rank
1
2

%
4.36
4.29

HIV+
Diagnostic spinal tap
Other therapeutic procedures

%
7.13
7.05

4.28

Blood transfusion

6.13

4

HIVUpper gastrointestinal endoscopy; biopsy
Percutaneous transluminal coronary angioplasty
(PTCA)
Diagnostic cardiac catheterization; coronary
arteriography
Hysterectomy; abdominal and vaginal

3.74

5.84

5
6
7
8

Blood transfusion
Respiratory intubation and mechanical ventilation
Arthroplasty knee
Other vascular catheterization; not heart

2.95
2.88
2.71
2.44

9

Cholecystectomy and common duct exploration

2.42

10
11

Hip replacement; total and partial
Other therapeutic procedures

2.16
2.05

12

Insertion; revision; replacement; removal of cardiac
pacemaker or cardioverter/defibrillator
Coronary artery bypass graft (CABG)
Spinal fusion

1.94

Diagnostic bronchoscopy and biopsy of
bronchus
Hemodialysis
Other vascular catheterization; not heart
Upper gastrointestinal endoscopy; biopsy
Alcohol and drug
rehabilitation/detoxification
Respiratory intubation and mechanical
ventilation
Colonoscopy and biopsy
Psychological and psychiatric evaluation
and therapy
Incision and drainage; skin and
subcutaneous tissue
Abdominal paracentesis
Computerized axial tomography (C.T.) scan
head

3
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13
14

1.86
1.84

5.76
5.71
4.92
4.75
4.05
1.71
1.63
1.60
1.57
1.60

15
16
17

Laminectomy; excision intervertebral disc
Colonoscopy and biopsy
Colorectal resection

1.77
1.76
1.74

18
29
20

Alcohol and drug rehabilitation/detoxification
Hemodialysis
Treatment; fracture or dislocation of hip and femur

1.71
1.67
1.60

Other respiratory therapy
Bone marrow biopsy
Diagnostic ultrasound of heart
(echocardiogram)
Cancer chemotherapy
Debridement of wound; infection or burn
Incision of pleura; thoracentesis; chest
drainage

1.43
1.33
1.28
1.13
1.10
1.08

2009
HIV-
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%
4.29
4.20
4.01
3.98

1
2
3
4

Blood transfusion
Respiratory intubation and mechanical ventilation
Arthroplasty knee
Upper gastrointestinal endoscopy; biopsy

5

3.77

7

Percutaneous transluminal coronary angioplasty
(PTCA)
Diagnostic cardiac catheterization; coronary
arteriography
Other vascular catheterization; not heart

8
9
10

Hysterectomy; abdominal and vaginal
Hip replacement; total and partial
Spinal fusion

2.71
2.57
2.50

6

3.36
3.32

HIV+
Hemodialysis
Diagnostic spinal tap
Blood transfusion
Respiratory intubation and mechanical
ventilation
Other vascular catheterization; not heart
Alcohol and drug
rehabilitation/detoxification
Diagnostic bronchoscopy and biopsy of
bronchus
Upper gastrointestinal endoscopy; biopsy
Other therapeutic procedures
Psychological and psychiatric evaluation
and therapy

%
6.88
6.37
6.36
5.86
5.63
5.37
4.70
4.71
3.77
2.12
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11

Cholecystectomy and common duct exploration

2.31

12
13

2.14
1.93

14

Hemodialysis
Insertion; revision; replacement; removal of cardiac
pacemaker or cardioverter/defibrillator
Alcohol and drug rehabilitation/detoxification

15

Other therapeutic procedures

1.86

16

1.75

17

Other OR procedures on vessels other than head and
neck
Colorectal resection

18

Diagnostic ultrasound of heart (echocardiogram)

1.57

29
20

Treatment; fracture or dislocation of hip and femur
Colonoscopy and biopsy

1.50
1.36

1.88

1.64

Incision and drainage; skin and
subcutaneous tissue
Cancer chemotherapy
Colonoscopy and biopsy

1.87

Other therapeutic procedures; hemic and
lymphatic system
Diagnostic cardiac catheterization; coronary
arteriography
Other OR procedures on vessels other than
head and neck
Percutaneous transluminal coronary
angioplasty (PTCA)
Diagnostic ultrasound of heart
(echocardiogram)
Abdominal paracentesis
Hip replacement; total and partial

1.41

HIV+

%
7.33
6.66

1.73
1.51

1.39
1.36
1.30
1.29
1.20
0.97

2015
1
2

HIVRespiratory intubation and mechanical ventilation
Arthroplasty knee

5.90
4.93

3
4
5
6

Upper gastrointestinal endoscopy; biopsy
Other vascular catheterization; not heart
Blood transfusion
Hip replacement; total and partial

3.89
3.71
3.59
3.47

Hemodialysis
Respiratory intubation and mechanical
ventilation
Diagnostic spinal tap
Other vascular catheterization; not heart
Blood transfusion
Other therapeutic procedures

5.79
5.17
4.79
4.70

7

Diagnostic cardiac catheterization; coronary
arteriography
Spinal fusion

2.85

Upper gastrointestinal endoscopy; biopsy

4.56

2.84

3.73

2.71

10

Percutaneous transluminal coronary angioplasty
(PTCA)
Other therapeutic procedures

11

Hemodialysis

2.48

12
13

Cholecystectomy and common duct exploration
Alcohol and drug rehabilitation/detoxification

2.01
1.74

14
15
16

Diagnostic ultrasound of heart (echocardiogram)
Treatment; fracture or dislocation of hip and femur
Incision of pleura; thoracentesis; chest drainage

1.72
1.71
1.67

17

Colorectal resection

1.59

Alcohol and drug
rehabilitation/detoxification
Diagnostic bronchoscopy and biopsy of
bronchus
Psychological and psychiatric evaluation
and therapy
Incision and drainage; skin and
subcutaneous tissue
Cancer chemotherapy
Diagnostic cardiac catheterization; coronary
arteriography
Abdominal paracentesis
Hip replacement; total and partial
Diagnostic ultrasound of heart
(echocardiogram)
Percutaneous transluminal coronary
angioplasty (PTCA)
Other OR procedures on vessels other than
head and neck
Colonoscopy and biopsy
Other respiratory therapy

8
9

88

18

2.62

Other OR procedures on vessels other than head and
1.42
neck
29
Abdominal paracentesis
1.28
20
Insertion; revision; replacement; removal of cardiac
1.27
pacemaker or cardioverter/defibrillator
Formula: Percentage of principal procedure = (# of discharges with that procedure ÷ total # of discharges with at least one
procedure) ×100

3.72
1.95
1.87
1.86
1.64
1.59
1.53
1.41
1.39
1.22
1.17
1.08

4.4.7 Major HANA Conditions during Hospital Stays, 2003 to 2015
Table 4.4 displays the yearly trends of major HANA conditions reported during
hospital stays from 2003 to 2015. The proportions of all five major conditions increased
gradually over the years among both types of hospital stays. However, disproportionate
changes occurred for CVD and Cancer between HSWH and HSWOH. From 2003 to 2015,
the proportion of CVD increased by 26.76% (37.06% to 63.82%) for HSWH, compared to
an increase of 9.21% (67.33% to 76.54%) for HSWOH. The difference in proportions of
hospital stays with cancer between HSWH and HSWOH reduced from 4.89% (14.07%9.18%) in 2003 to 2.96% (18.11%-15.15%) in 2015. When we considered HANA
conditions as the principal diagnosis, similar patterns were observed for all HANA
conditions except CVD. The proportion of CVD increased by 3.3% for HSWH but
decreased from 4.5% for HSWOH over the study period (Table 4.4).
In table 4.5, we describe yearly trends of these five major HANA conditions across
age groups. The proportion of CVD increased among all age groups irrespective of the
types of hospital stays; however, the increases were most substantial for older HSWH.
Disproportionate increases were also observed for hospital stays with cancer among 36-49
and 50-64 years old HSWH, and for liver disease among elderly aged 65 years or more.
Diabetes increased disproportionately among HSWOH for patients aged 36-49 and 50-64
years. Interestingly, disproportionate increases in liver disease were observed for younger
(18-35 and 36-49 years) HSWOH. The bone loss increased over the years among all age
groups for both types of hospital stays (Table 4.5).
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Table 4. 4 Trends of major HANA conditionsa during hospital stays (weighted percentage), 2003 to 2015.

All Diagnoses
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2003
HIV- HIV+
CVD
67.33 37.06
Cancer
14.07 9.18
Diabetes
22.54 10.94
Liver Disease 7.28 25.39
Bone Loss
19.54 5.15
2010
HIV- HIV+
CVD
73.13 54.61
Cancer
16.85 13.40
Diabetes
28.61 16.88
Liver Disease 9.36
29.93
Bone Loss
25.76 10.52

2004
HIV- HIV+
68.05 38.36
14.20 9.65
22.94 11.34
7.64 25.24
20.40 5.79
2011
HIV- HIV+
74.62 58.43
17.30 13.63
29.94 18.05
9.85
30.35
26.94 12.42

2005
HIV- HIV+
69.41 40.65
14.66 10.02
23.50 11.24
7.82 25.67
21.28 6.45
2012
HIV- HIV+
74.91 59.48
17.53 14.57
30.33 18.93
10.26 29.90
27.31 13.41

2006
HIV- HIV+
70.83 45.15
14.46 9.94
24.63 12.82
7.97 25.70
21.49 7.26
2013
HIV- HIV+
75.53 60.61
17.77 14.55
30.92 19.24
10.66 29.61
27.82 13.90

2007
HIV- HIV+
71.16 47.06
15.71 11.03
26.05 14.29
7.90 27.23
22.82 7.51
2014
HIV- HIV+
75.93 61.97
17.99 15.09
31.49 20.03
11.31 29.73
28.69 15.28

2008
HIV- HIV+
72.12 50.55
15.85 12.63
26.55 15.31
8.42 27.20
24.04 9.42
2015
HIV- HIV+
76.54 63.82
18.11 15.15
31.98 20.99
11.64 29.35
28.96 15.83

2009
HIV- HIV+
73.07 52.50
16.35 12.13
28.23 16.58
9.05
28.60
25.22
9.83
All years
HIV- HIV+
72.40 51.00
16.16 12.24
27.38 15.66
9.09
27.91
24.51 9.95

Principal diagnosis

CVD

2003
2004
2005
2006
2007
2008
2009
HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+
23.00 7.07
22.23 6.89
21.46 6.89
22.12 7.67
20.78 7.89
20.49 8.39
20.30 8.64

Cancer
Diabetes
Liver Disease
Bone Loss

4.68
1.75
2.43
6.53

2.01
1.13
2.36
1.25

4.61
1.78
2.42
6.65

1.94
1.13
2.18
1.33

4.71
1.75
2.39
6.99

2.01
1.07
1.86
1.50

4.41
1.82
2.37
6.77

1.89
1.12
1.82
1.47

4.78
1.83
2.13
7.11

2.22
1.07
1.67
1.69

4.60
1.79
2.17
7.34

2.31
1.15
1.80
1.86

4.33
1.82
2.21
7.34

2.14
1.22
1.96
1.98

2010
2011
2012
2013
2014
2015
All years
HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+
CVD
19.20 8.41
19.15 8.91
19.16 9.33
18.86 9.41
18.61 9.64
18.57 10.04 20.35 8.32
Cancer
4.43
2.52
4.29
2.28
4.20
2.47
4.16
2.47
4.08
2.40
3.95
2.18
4.41
2.21
Diabetes
1.90
1.31
1.95
1.31
1.95
1.41
2.01
1.38
2.05
1.53
2.08
1.60
1.88
1.25
Liver Disease 2.21
1.80
2.22
1.73
2.25
2.00
2.23
1.93
2.18
1.94
2.11
1.73
2.26
1.91
Bone Loss
7.62
1.96
7.52
2.22
7.68
2.20
7.98
2.52
8.22
2.68
8.10
2.63
7.35
1.91
Formula:
Percentage of a HANA condition for HSWH = (# of hospital stays with HANA ÷ # of hospital stays with HIV)×100.
Percentage of a HANA condition for HSWOH = (# of hospital stays with HANA ÷ # of hospital stays without HIV)×100.
a
The HANA conditions are not mutually exclusive categories.
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Table 4. 5 Trends of major HANA conditions a (all diagnoses) across age groups (weighted percentage), 2003 to 2015.

CVD
Age
(years)
18-35
36-49
50-64
65+
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18-35
36-49
50-64
65+

2003
HIV- HIV+
18.55 23.00
41.12 34.18
68.85 54.76
85.89 71.57
2010
HIV- HIV+
26.07 34.93
51.21 48.45
74.11 66.67
90.21 84.26

2004
HIV- HIV+
19.58 24.22
42.66 34.54
69.70 55.07
86.69 70.39
2011
HIV- HIV+
27.17 37.77
52.55 52.08
74.96 69.78
90.71 85.91

2005
HIV- HIV+
20.95 26.55
43.96 36.43
70.25 57.29
87.44 75.95
2012
HIV- HIV+
27.84 36.29
53.45 53.11
75.36 70.14
91.03 87.44

2006
HIV- HIV+
22.29 30.18
46.36 40.20
72.11 60.29
88.47 76.53
2013
HIV- HIV+
28.63 36.44
54.37 53.58
75.68 71.20
91.17 87.76

2007
HIV- HIV+
23.21 30.77
47.21 42.02
72.07 61.05
88.80 81.04
2014
HIV- HIV+
29.54 37.14
55.10 55.20
76.10 71.99
91.30 87.86

2008
HIV- HIV+
24.11 30.97
48.52 45.37
72.64 64.41
89.13 81.91
2015
HIV- HIV+
29.86 35.92
56.03 56.37
76.79 73.72
91.45 88.91

2009
HIV- HIV+
25.46 33.82
50.50 46.26
73.86 64.96
90.08 83.93
All years
HIV- HIV+
24.72 31.53
48.89 44.22
73.31 65.64
89.35 83.61

2007
HIV- HIV+
4.55
7.75
8.69
10.16
16.31 13.42
20.10 19.58
2014
HIV- HIV+
4.50
10.06
9.13
13.33

2008
HIV- HIV+
4.52
9.61
8.65
11.83
16.26 14.41
20.24 19.89
2015
HIV- HIV+
4.43
9.27
8.97
13.11

2009
HIV- HIV+
4.22
8.40
8.42
11.09
16.11 14.11
21.66 20.03
All years
HIV- HIV+
4.25
8.74
8.39
10.84

Cancer
Age
(years)
18-35
36-49
50-64
65+

18-35
36-49

2003
HIV- HIV+
3.88
7.00
7.43
8.71
14.71 11.37
18.20 19.84
2010
HIV- HIV+
4.58
10.07
8.94
12.22

2004
HIV- HIV+
3.67
6.38
7.42
9.00
14.83 12.79
18.57 18.88
2011
HIV- HIV+
4.15
10.62
8.87
11.66

2005
HIV- HIV+
4.11
7.05
7.77
9.67
15.28 12.19
18.84 19.14
2012
HIV- HIV+
4.36
10.61
8.99
12.91

2006
HIV- HIV+
3.85
8.18
7.58
9.20
14.78 11.69
18.84 16.37
2013
HIV- HIV+
4.46
10.79
9.11
12.69

50-64
65+

16.78
22.23

15.19
21.25

16.71
22.84

15.84
20.76

16.85
23.25

16.09
24.40

16.90
23.48

16.15
22.67

16.90
23.89

16.88
23.24

16.95
24.02

16.87
23.91

16.13
21.15

14.65
21.29

Diabetes
Age
(years)
18-35
36-49
50-64
65+
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18-35
36-49
50-64
65+

2003
HIV- HIV+
7.38
4.03
15.09 9.34
27.29 20.35
26.05 26.05
2010
HIV- HIV+
10.63 7.11
21.07 13.12
32.17 23.18
33.05 35.20

2004
HIV- HIV+
7.76
5.47
15.80 9.35
27.65 18.75
26.44 28.36
2011
HIV- HIV+
11.27 8.15
22.24 14.38
33.46 23.72
34.11 33.79

2005
HIV- HIV+
8.25
5.26
16.39 9.24
27.94 18.40
26.82 29.02
2012
HIV- HIV+
11.44 8.26
22.76 15.03
33.60 24.32
34.76 34.25

2006
HIV- HIV+
8.73
4.96
17.39 10.39
28.87 20.44
28.20 29.62
2013
HIV- HIV+
11.80 8.05
23.51 14.47
34.03 24.76
35.24 35.28

2007
HIV- HIV+
9.56
6.87
18.53 11.11
30.15 21.84
29.88 31.62
2014
HIV- HIV+
12.19 7.87
24.09 14.98
34.43 25.87
35.90 34.55

2008
HIV- HIV+
9.77
6.90
19.05 11.72
30.32 22.76
30.37 32.30
2015
HIV- HIV+
12.19 7.60
24.49 16.44
35.00 25.78
36.34 36.37

2009
HIV- HIV+
10.50 6.59
20.52 12.72
32.04 23.59
32.41 35.65
All years
HIV- HIV+
10.05 6.53
19.68 11.92
31.34 22.92
31.35 33.38

2007
HIV- HIV+
8.40
19.16
10.09 26.67
10.24 34.11
5.81
18.73
2014
HIV- HIV+
11.35 18.98
13.12 26.88

2008
HIV- HIV+
9.05
17.73
10.64 27.16
10.96 33.65
6.25
19.26
2015
HIV- HIV+
11.63 17.96
13.71 26.85

2009
HIV- HIV+
9.41
19.29
10.90 27.63
11.78 35.35
6.88
22.00
All years
HIV- HIV+
9.49
18.76
11.24 27.0

Liver Disease
Age
(years)
18-35
36-49
50-64
65+

18-35
36-49

2003
HIV- HIV+
7.99
17.78
10.17 27.03
9.09
30.08
5.26
16.07
2010
HIV- HIV+
9.54
18.48
11.24 28.59

2004
HIV- HIV+
8.20
20.18
10.48 25.70
9.69
29.22
5.50
18.49
2011
HIV- HIV+
10.24 20.29
11.75 28.97

2005
HIV- HIV+
8.40
18.46
10.61 26.52
10.07 31.16
5.65
14.22
2012
HIV- HIV+
10.44 19.07
12.16 27.37

2006
HIV- HIV+
8.66
18.41
10.76 25.71
10.30 31.42
5.68
17.13
2013
HIV- HIV+
10.88 17.71
12.57 26.73

50-64
65+

12.22
7.06

37.60
24.28

13.00
7.47

37.10
24.54

13.55
7.80

37.30
25.15

14.02
8.19

36.98
27.49

14.68
8.87

36.47
27.08

15.04
9.18

35.74
26.38

11.90
6.82

34.80
22.91

Bone Loss
Age
(years)
18-35
36-49
50-64
65+
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2003
HIV- HIV+
7.79
3.37
13.62 5.25
17.99 6.40
24.77 7.98
2010
HIV- HIV+
10.03 6.43
17.51 9.47
25.12 12.99
32.32 14.94

2004
HIV- HIV+
8.02
3.57
13.97 5.52
19.23 7.91
25.93 9.01
2011
HIV- HIV+
10.60 6.79
18.48 11.40
26.33 15.11
33.13 17.94

2005
HIV- HIV+
8.47
3.59
14.76 6.11
20.08 9.03
26.67 11.11
2012
HIV- HIV+
10.74 7.26
18.80 11.87
26.88 16.14
33.61 20.60

2006
HIV- HIV+
8.56
4.33
14.83 6.71
20.39 9.60
26.97 12.33
2013
HIV- HIV+
10.82 7.04
18.97 12.35
27.57 16.75
33.99 20.44

2007
HIV- HIV+
8.95
4.42
15.45 6.83
21.91 9.91
28.68 12.33
2014
HIV- HIV+
10.95 8.21
19.47 13.39
28.59 18.03
35.02 23.11

2008
HIV- HIV+
9.51
5.49
16.61 9.00
23.36 11.44
29.71 14.73
2015
HIV- HIV+
11.04 8.37
19.43 12.89
28.84 18.88
35.25 23.94

2009
HIV- HIV+
10.03 5.77
17.14 8.90
24.45 12.16
31.50 15.59
All years
HIV- HIV+
9.62
5.48
16.60 8.54
23.95 13.17
30.43 17.16

18-35
36-49
50-64
65+
Formula:
Percentage of a HANA condition for a particular age group, HSWH = (# of HANA diagnoses for a particular age group ÷ # of
hospital stays by particular age group, HSWH)×100.
Percentage of a HANA condition for a particular age group, HSWOH = (# of HANA diagnoses for a particular age group ÷ # of
hospital stays by particular age group, HSWOH)×100.
a
The HANA conditions are not mutually exclusive categories.

4.5 Discussion
This study compared the characteristics and comorbidities for different hospital
stays by the patient- and hospital-level characteristics. The study demonstrates that HIV
hospitalization rates and proportions of HSWH (out of all hospital stays) elevated among
older due to the increased number of older age hospital stays. Also, changing patterns of
some patient-level characteristics suggest the higher presence of older patients in the U.S.
inpatient department with HIV diagnosis. Finally, age-related HANA conditions, such as
CVD, liver disease, and cancer disproportionately increased by age for HSWH.
Consistent with the increasing trends of the older population (U.S. Census Bureau,
2019), hospital stays by older patients increased over the study years from 2003 to 2015.
The rates of HIV hospitalization also increased over this period among the older
population. The finding of increasing trends for HSWH by age is supported by literature;
previous studies reported increased HSWH by older patients (Crum-Cianflone et al., 2010;
Heslin & Elixhauser, 2016; Zhao et al., 2007). Due to advanced ART, PLWH live longer,
which may expose them to age-related complications and chronic diseases (Center for
Disease Control and Prevention, 2018; Institute of Medicine, 2008). The increasing number
of older PLWH may contribute to more hospital stays with HIV. Crum-Cianflone et al.
commented that the aging of the HIV population may contribute to hospitalization rates
among PLWH and may continue to impact these rates in the upcoming years (CrumCianflone et al., 2010). Moreover, factors related to aging of PLWH, including increased
comorbidities, frailty, may increase the likelihood of hospitalization and longer hospital
stay by the older population (Akgün et al., 2014; S. A. Berry et al., 2012; Fleishman et al.,
2005; Kim et al., 2012; Smit et al., 2015; Tadros et al., 2012; Wong et al., 2018).
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Declining trends of the mean age difference between the HSWH and HSWOH and
increasing proportion of Medicare payments for HSWH highlight the impact of aging
PLWH on U.S. inpatient department. Studies using NIS data found increasing trends of
Medicare as the primary payer for HSWH (Heslin & Elixhauser, 2016; Zhao et al., 2007),
and for hospital stays with other diagnoses (Asrani et al., 2018; Hirode, Saab, & Wong,
2020). Aging of PLWH and the recent addition of Medicare Part D prescription drug
benefit by the ACA made Medicare the single largest source of federal financing for HIV
care and treatment (Bradley et al., 2014).
The increasingly higher presence of age-related chronic diseases in the top principal
diagnoses among HSWH and the disproportionate increase of these conditions may be
evidence for a higher prevalence of HANA conditions during HSWH. This is consistent
with previous literature which reported a higher prevalence of HANA conditions among
older PLWH, including cardiovascular diseases, cancer, osteoporosis, liver disease, renal
disease, and neurocognitive decline (High et al., 2012; Pathai et al., 2013; United States
Senate, 2013). We observed new trends for age-related chronic conditions based on top
procedures identified during HSWH. Increased proportions of hemodialysis, respiratory
intubation and mechanical ventilation and cancer chemotherapy may reflect elevated rates
of kidney and lung disease and cancer. The increased use of hip replacement and cardiac
catheterization (coronary arteriography) procedure suggests a higher prevalence of arthritis
and cardiovascular disease among HSWH. This finding is supported by a previous study
that found the hip replacement and spinal surgery as the top procedure by the PLWH (King
et al., 2015). Since non-AIDS related comorbidities are the most common causes of
hospitalization in recent years (S. A. Berry et al., 2012; Crum-Cianflone et al., 2010),
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patients require diagnostic services and surgical procedures related to the aging of HIV
patients.
In contrast to previous studies that demonstrated a higher prevalence of age-related
chronic diseases, such as hypertension, diabetes, stroke, cancer, cardiovascular diseases,
and neurocognitive disorder, among PLWH compared to non-PLWH (Bigna, Kenne,
Asangbeh, & Sibetcheu, 2018; Guaraldi et al., 2011; Mayer et al., 2018; Ruzicka, Imai,
Takahashi, & Naito, 2019; Schouten et al., 2014), this study found that among five major
HANA categories, only liver disease was prevalent among HSWH compared to HSWOH.
This discrepancy may indicate the HSWH occurs mostly for non-HANA conditions.
Besides, declining trends of HIV infections as a principal diagnosis is expected since
advanced ART should relegate HIV as a principal diagnosis. Therefore, it is plausible that
PLWH are hospitalized primarily with certain conditions other than HIV infection or major
HANA comorbidities. Multiple studies showed that non-AIDS defining infections are the
most common reason for hospital admission (S. A. Berry et al., 2012; Crowell et al., 2015;
Crum-Cianflone et al., 2010; Fleming et al., 2019). However, CVD and cancer increased
disproportionately over the study period among HSWH compared to HSWOH. Also, this
study observed disproportionate increases in CVD, liver disease, and cancer among older
HSWH in recent years. Many recent studies evident that PLWH older than 50 years of age
are more likely to have HANA comorbidities (Kim et al., 2012; Nguyen & Holodniy, 2008;
Schouten et al., 2014; Smit et al., 2015), and HANA associated hospital stays (S. A. Berry
et al., 2012; Fleishman et al., 2005; Tadros et al., 2012; Wong et al., 2018). HIV induced
chronic immune activation and inflammation is referred to as a factor of accelerated or
early aging, and that leads to an elevated risk of developing multiple comorbidities as
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PLWH age (Ahn et al., 2019; Desai & Landay, 2010; Guardigni & Montano, 2018). Smit
et al. predict that, in the Netherlands, 84% of PLWH will have at least one chronic
condition, and 28% of PLWH will have three or more chronic conditions by 2030 (Smit et
al., 2015). Since the age profile of PLWH in the Netherlands is very similar to that of the
United States (Smit et al., 2015; Wing, 2017), these projections may suggest a potential
increase in the burden of hospital stays with HANA comorbidities in the future for the
United States. Long-term use of ARV drugs, sustained HIV-associated immune activation,
and chronic inflammation have been reported to be associated with a higher prevalence of
multimorbidity among older PLWH (Guaraldi et al., 2011; Maciel et al., 2018; RodriguezPenney et al., 2013; Schouten et al., 2014; Strategies for Management of Antiretroviral
Therapy Study Group, 2008).
Consistent with the HIV surveillance statistics of the United States (Bachhuber &
Southern, 2014; Hess, Hu, Lansky, Mermin, & Hall, 2017), the majority of the HSWH
were made by African Americans. Although HIV prevalence continues to be higher among
African Americans, the proportion of HSWH by the whites increased over time, maybe
because whites disproportionately represent a higher proportion of older U.S. people
(Schaeffer, 2019). The decreasing trends of HSWH by patients from large metropolitan
areas and the increasing trends of small metropolitan and rural areas is an important issue
that needs to be investigated further to monitor the evolving HIV care needs outside of the
urban setting. This may reflect the migration of the HIV epidemic from urban centers to
more rural areas (Iyer, 2015; M Vyavaharkar et al., 2013). This shift indicates increasing
inpatient care demand by the PLWH living in small metropolitan and rural areas. While
PLWH from small metropolitan areas may have easier access to HIV care, rural PLWH
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may face challenges accessing tertiary HIV care, because HIV prevention and care are
concentrated in urban areas (Schafer et al., 2017).

4.6 Limitations
While this study provides a detailed picture of U.S. inpatient stays by HIV status
and age of the patients, like many other studies using large claims databases, study findings
should be interpreted within the context of certain limitations (Hashimoto, Brodt, Skelly,
& Dettori, 2014; Sarrazin & Rosenthal, 2012). First, the unit of analysis of this study is
hospital stay, so all numbers and estimates represent the records of hospital stays, and does
not reflect individual-level information. NIS is not a follow-up data; thus, there may be
repeat hospitalization by an individual in a year or next (in case of pooled data) with the
same or different conditions. Patients with a high number of repeat hospital stays may have
skewed the findings. Unfortunately, the NIS did not contain unique patient identifiers that
would enable linking multiple hospitalizations by the same patient. Nevertheless, given
that the main objective of this study was to describe the characteristics and comorbidity
burdens of HSWH compared to HSWOH, these descriptive results still provide critical
facts to inform the public health community.
Second, this study excluded hospital records that were discharged on the same day,
and that indicated neonatal or pregnant issues. Thus, the results are not reflective of all U.S.
hospital stays, even though this study represent all-cause U.S. hospital stays. Also, the
results are not reflective of hospital stays in long-term care facilities, such as rehabilitation,
psychiatric, alcoholism, and chemical dependency hospitals, because the NIS collects data
from U.S. short-term U.S. community hospitals. Third, hospitalization rates of the PLWH
for the year 2003 to 2007 might be underreported, because HIV prevalence data were not
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reported for all 50 states in these years. Moreover, since there was no unique patient
identifier in the NIS databases, we were unable to measure true hospitalization rates. A
previous study showed that 31.2% of PLWH hospitalized more than once (Buchacz et al.,
2008). Using a sensitivity analysis, we computed hospitalization rates considering single
hospitalization by PLWH (68.8%) and observed lower hospitalization rates, but similar
yearly trends across the age groups (Appendix A, Figure A.1). Finally, the accuracy of
claims data depends on the quality and consistency of coding by participating hospitals.
Thus, the ICD-9-CM codes we used to characterize patients’ illnesses may not accurately
capture the primary reasons for patient's hospitalization because hospitals use these codes
primarily for billing purposes. In this study, we described the principal diagnosis as well
as all-listed diagnoses that may minimize the impact of coding biases substantially.

4.7 Conclusions
This study presents a detailed snapshot of the changing patterns of hospital inpatient
stays with the aging of PLWH in the United States. Policymakers, hospital administrators,
and other stakeholders should consider hospital stays from two perspectives: which
subpopulation of the patients shows unique attributes, and which components of the
inpatient stays are most affected. For hospital stays, the increased presence of older patients
with HIV and major age-related chronic conditions demonstrate the need for incorporating
chronic disease management programs in inpatient care delivery. Although the hospital
inpatient department is not the routine source of care for PLWH, increased HANA
comorbidities for older PLWH may require greater use of inpatient care, higher resource
utilization, and increased hospital costs. Studies investigating the impact of the aging of
PLWH on inpatient resource utilization and costs are suggested that may unveil the real
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burden of HANA comorbidities in the U.S. inpatient department. In light of the health
professional shortages, hospitals may not be prepared to deal with increased demand from
hospitals stays with HIV. Thus, an adequate number of HIV trained inpatient workforce
and geriatric care providers should be in place for the future.
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CHAPTER 5

PAPER 2: AGING WITH HIV IN THE UNITED STATES: IMPACT ON
INPATIENT RESOURCE UTILIZATION AND COSTS, 2003 TO 20152

2

Siddiqi, K. A., Olatosi, B., Ostermann, J., Zhang, J., & Khan, M. M. To be submitted to
AIDS Care.
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5.1 Abstract
Background: With the aging of PLWH, the longer exposure to HIV infections and
antiretroviral drugs may increase the risk of age-related chronic illnesses [HIV Associated
Non-AIDS (HANA) conditions]. Higher comorbidity burdens among older PLWH may
require greater use of inpatient care, i.e., higher hospital resource utilization and costs. This
study examined the impact of aging PLWH on trends for inpatient resource utilization, and
costs of hospital stays with HIV (HSWH) compared to hospital stays without HIV
(HSWOH). We also assessed resource utilization and costs for hospital stays with major
HANA conditions.
Methods: Health Care Utilization Project (HCUP) National Inpatient Sample
(NIS) data, 2003 through 2015, were analyzed using SAS 9.4. We excluded hospital stays
for patients less than 18 years old, neonatal, pregnancy, and same-day discharge from our
analysis. Univariate, bivariate, and multivariable survey-weighted analyses were
conducted using sampling weights to produce national estimates. Multivariable regression
analyses using a generalized linear model (GLM) framework were conducted to determine
predictors of inpatient resource utilization and costs, controlling for the patient- and
hospital-level characteristics.
Results: The median number of procedures for HSWH was consistently lower than
that for HSWOH, but it increased disproportionately among older HSWH over the years.
While the overall length of stay and costs for HSWH were consistently higher than that for
HSWOH, the differences narrowed down over the study period. The differences in
inpatient resource use and costs between HSWH and HSWOH were also decreasing over
the years among hospital stays with major HANA conditions. Multivariable analyses
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showed that the procedure use was lower for HSWH, but it increased significantly with
increased age compared to HSWOH. Inpatient LOS and costs were significantly higher
among HSWH and older, but LOS and costs decreased among HSWH compared to
HSWOH with the increase in age.
Conclusions: This study finding confirms our hypothesis of increased procedure
utilization by age for HSWH. A close investigation of types of surgical procedures and
comorbidities requiring longer inpatient stays and higher costs is needed to make the
inpatient department more efficient as PLWH age in the United States.
Keywords: Aging, HIV, Inpatient, Resource Utilization, Costs, United States.

5.2 Introduction
More than 1 million people are living with HIV (PLWH) today in the United States.
One in seven PLWH is unaware of their infection, and every year about 40 thousand people
become newly infected with HIV (HIV.gov, 2018). Due to the effective combination of
antiretroviral treatment (cART), HIV infection has become a chronic condition in recent
decades. Today, PLWH may expect a normal lifespan due to early diagnosis of HIV, early
linkage and retention in HIV medical care (National Institute of Allergy and Infectious
Diseases, 2018; Pebody, 2018). PLWH in the United States are aging as a result of both
life expectancy gains and an increase in newly acquired infections at older ages (McMillan,
Krentz, Gill, & Hogan, 2018). Almost half of all PLWH are 50 years or older (Center for
Disease Control and Prevention, 2018), and projected to be around 70% by 2030 (Wing,
2017). HIV induced chronic immune activation and inflammation is referred to as a factor
of accelerated or early aging, and this leads to PLWH developing various comorbidities at
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a younger age compared to the general population (Ahn et al., 2019; Desai & Landay, 2010;
Guardigni & Montano, 2018).
With the aging of PLWH in the United States, age-related chronic conditions have
become the major health concerns once the viral load suppression is achieved. The longer
exposure to HIV infections and antiretroviral drugs (ARV) may increase the risk of agerelated chronic illnesses, commonly called HIV Associated Non-AIDS (HANA)
conditions. The HANA comorbidities include, but are not limited to cardiovascular, liver,
kidney, bone, and lung disease and non-HIV associated cancers (Gallant et al., 2017;
Guaraldi et al., 2011; Schouten et al., 2014). Also, older PLWH have a higher prevalence
of multimorbidity than the general population (Guaraldi et al., 2011; Maciel et al., 2018;
Rodriguez-Penney et al., 2013). Studies also showed that aging of PLWH hastens the
development of geriatric conditions, such as comorbidities, frailty, poorer cognitive
functioning, depression, and other mental illness (Center for Disease Control and
Prevention, 2018; Heslin & Elixhauser, 2006; HIV.gov, 2017).
PLWH aging with HIV may place enormous demands on health care and social
service systems because of the additional risks of comorbidity, weak cognitive functioning,
frailty, poor mental health, provider or society level stigma, and lack of social supports
(Matthew Harris et al., 2015). Studies showed that higher comorbidity burdens among
older PLWH require greater use of inpatient care, i.e., higher hospital resource utilization
and costs (H. Krentz & Gill, 2015; Zingmond et al., 2017). However, it is unclear whether
the existing health care infrastructure and workforce are adequate to meet increasing
specialized demand for clinical and non-clinical services for this growing HIV population
(High et al., 2012). Assessing the changing patterns of inpatient resource utilization and
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costs of PLWH during hospital stays is important to estimate future demand for inpatient
care resources posed by the aging of PLWH.
It is critical to understand the changing patterns of hospital resource utilization and
costs with the changing demographic structure; yet, research describing recent trends of
resource utilization and costs for inpatient stays is lacking. Also, to the best of our
knowledge, no studies investigated the relationship between aging of PLWH and resource
utilization and costs during hospital stays using national inpatient data. This study
examined the impact of aging on inpatient resource use patterns, and costs of hospital stays
with and without HIV using the national inpatient sample (NIS) database. We also assessed
resource utilization and costs for hospital stays with major HANA conditions. Hospital
resource utilization and costs analysis is important for assessing future demand for
inpatient care delivery.

5.3 Methods
5.3.1 Data Source and Sample
This study pooled the Healthcare Cost and Utilization Project (HCUP) National
Inpatient Sample (NIS) data, 2003 through 2015. The NIS is the largest all-payer inpatient
care discharge database (more than 7 million hospital stays each year) from U.S.
community hospitals in 46 states and the District of Columbia (Agency for Healthcare
Research and Quality, 2018c). The NIS includes short-term, nonfederal, general, and other
community hospitals. It excludes long-term care facilities, such as rehabilitation,
psychiatric, alcoholism, and chemical dependency hospitals. Prior to 2012, NIS collected
all discharge records from a 20% sample hospitals from each stratum; starting in 2012, NIS
collects 20% discharges from all U.S. hospitals (Houchens et al., 2014). This was modified
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again in 2015, to reflect new ICD-10 codes. More information about the sampling and
dataset changes are available elsewhere (Agency for Healthcare Research and Quality,
2018c).
The unit of analysis in this study is hospital stay from the U.S. inpatient department.
Discharge level weights, provided with the datasets, were used to produce nationally
representative estimates (Agency for Healthcare Research and Quality, 2015). Hospital
stays, associated with neonatal or pregnancy issues, and by younger than 18 years old, were
excluded. Hospital length of stays (LOS) reported as zero (LOS=0) were also excluded
since it indicated same-day discharge. Due to the shift from ICD-9-CM to ICD-10-CM on
October 1, 2015, this study excluded hospital discharge data from the fourth quarter of
2015 (October to December 2015) because the Elixhauser comorbidity index remains
under development for ICD-10 coding (Hirode et al., 2020).
Five subpopulations for hospital stays with five major select HANA conditions
(cardiovascular disease, liver disease, diabetes, cancer, and bone loss) were also used to
compare hospital resource utilization and costs for hospital stays with different
comorbidities. An infectious disease domain expert and detailed literature search guided
the identification of five major HANA conditions based on the Clinical Classifications
Software (CCS) codes. CCS is a diagnosis and procedure categorization scheme based on
the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9CM) (Healthcare Cost and Utilization Project, 2017). A list of diseases and respective CCS
codes of the specific conditions of these five major categories are described in Appendix
A (Table A.1).
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5.3.2 Study Variables
Outcome Variable: The outcome variables of the study are the number of
procedures used, the length of stay (number of days), and inpatient costs (U.S. Dollar).
Total hospital charges were converted to costs using hospital-wide cost-to-charge ratios
(CCR) provided by HCUP from accounting reports of the Centers for Medicare and
Medicaid Services (Agency for Healthcare Research and Quality, 2018a). When all-payer
inpatient cost-to-charge ratios (APICC) were not available, the weighted group average
(GAPICC) were used as CCR, as suggested by HCUP data documentation (Agency for
Healthcare Research and Quality, 2019a). Hospital charges refer to the amount a hospital
billed for the entire hospital stay, excluding professional (e.g., physician) fees. Costs reflect
the actual expense incurred in the production of hospital services, including supplies,
wages, and utility costs. All costs were adjusted for the inflation to the 2015 U.S. dollars
using the Personal Health Care (PHC) - Hospital Care Index from the Centers for Medicare
& Medicaid Services (Agency for Healthcare Research and Quality, 2019b). The PHCHospital care index for 2015 was divided by each year’s PHC index and multiplied these
results with the respective year’s costs to get the inflation-adjusted inpatient costs. The
CMS Office of the Actuary constructs the Personal Health Care Index based on
components of the Consumer Price Index- Medical care (CPI-M) and the Producer Price
Index (PPI), and additional composite indices (Agency for Healthcare Research and
Quality, 2019b). Moreover, costs of each stratum of the Northeast region were multiplied
by some adjustment factors to minimize overestimation due to the absence of one large
state (Pennsylvania) in 2004 NIS, as suggested by the HCUP data documentation (Agency
for Healthcare Research and Quality, 2019a).
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Key Independent Variable: The key independent variable is hospital stay status
with two levels, namely hospital stay with HIV (HSWH) and hospital stay without HIV
(HSWOH). An inpatient hospital stay was designated an HIV associated discharge if the
CCS code for HIV is 5 (ICD-9-CM codes: 042, 0420, 0421, 0422, 0429, 0430, 0431, 0432,
0433, 0439, 0440, 0449, 07953, 27910, 27919, 79571, 7958, V08) (Heslin & Elixhauser,
2016). Patient’s age during hospital stays is another key independent variable. We describe
age groups as 18-34 years, 35-49 years, 50-64 years, and 65+ years. We also used age as a
continuous variable to describe the changing likelihood of outcomes across independent
variables.
5.3.3 Covariates of the study
Patient-level Characteristics: Patients’ sex, race/ethnicity, location, primary payer,
and median household income by ZIP code were included as covariates. Elixhauser
Comorbidity Software was used to adjust the comorbidity burden of the patients (Agency
for Healthcare Research and Quality, 2017b). We used a new index of Elixhauser
Comorbidity Software that produces ‘single numeric value’ index scores (readmission and
mortality scores) that describe the comorbidity burden, and that may be more useful for
multivariable analyses purpose (B. J. Moore et al., 2017).
Hospital-level Characteristics: Hospital level characteristics examined included
elective admission, weekend admission, bed size (small, medium, large), location/teaching
status (rural, urban non-teaching, urban teaching), and hospital geographic region
(Northeast, Midwest, South, West).
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5.3.4 Ethical Statement
Ethical considerations for using NIS data are ensured by the required HCUP Data
User Agreement (DUA) training. HCUP Central Distributor removed all identifiable data
from the NIS before releasing it to the researchers. Since NIS is non-identifiable secondary
data, this study was deemed a non-human subject study by the University of South Carolina
Institutional Review Board (#Pro00097307).
5.3.5 Data Analysis
Using the analytic guidelines outlined by HCUP-NIS (Agency for Healthcare
Research and Quality, 2018d), a survey-weighted analysis was performed accounting for
survey design complexity by using discharge level weights. To adjust the NIS redesign
applied in 2012, we used newly generated ‘discharge trend weight’ provided by the HCUP
for 2003 to 2011 to get the consistent yearly national rates (Agency for Healthcare
Research and Quality, 2015). Univariate, bivariate, and multivariable analyses were
conducted using SAS version 9.4 (Carry, NC).
First, we compared yearly trends of inpatient resource utilization and costs of
HSWH and HSWOH. For descriptive analyses, we examined both mean and median to
describe the overall patterns of resource utilization and costs. We found, means to be more
sensitive to the extreme value of costs and LOS, so we reported the median values only
(see Appendix B for mean charts). Second, we compared resource utilization and costs of
HSWH and HSWOH across the age groups. For the descriptive purpose, we assessed the
trends of differences between HSWH and HSWOH in terms of resource utilization and
costs. The differences were calculated by subtracting resource utilization and costs of
HSWOH from that of HSWH as shown in equation (1):
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Eqn. 1: Difference in inpatient resource utilization/costs = inpatient resource
utilization/costs for HSWH – inpatient resource utilization/costs for HSWOH
Third, we depicted yearly trends of differences in resource utilization and costs for
hospital stays among the major five HANA conditions. Finally, multivariable modeling
was performed to measure the association of the number of procedures, LOS, and costs for
hospital stays with HIV and age, controlling for the patient- and hospital-level
characteristics. Guided by previous studies using the NIS database (Enomoto et al., 2014;
Molloy et al., 2017; Perera et al., 2012; Zou et al., 2019), three Generalized Linear Models
(GLMs) were fitted independently with the following outcomes: 1) number of procedures;
2) length of stay; 3) inpatient costs. These models were chosen because these three outcome
variables were highly skewed and did not meet the normality assumption of the classical
linear model. As the distribution of the number of procedures was observed over-dispersed
(variance>mean) with numerous zeros (no procedures), a zero-inflated negative binomial
regression model was fitted to determine the predictors of procedures used. Inpatient costs
and length of stays were log-transformed and assessed using GLMs with gamma
distribution and log link function to estimate the predictors of hospital costs and length of
stays. We also ran and described these models for hospital stays with five major HANA
conditions separately. To check the missing values, we reran these models keeping the
missing observations considering them as ‘not missing completely at random
(NOMCAR),’ and observed no difference with the main models. Statistical significance
was assessed at alpha 0.01 due to the study’s large sample size.
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5.4 Results
5.4.1 Trends of Hospital Resource Utilization and Costs (median), 2003 to 2015
Figure 5.1 depicts the trends of resource usage during hospital stays in terms of the
median number of procedures and length of stay (LOS). Although there were some
variations in the median number of procedures, similar yearly trends were observed for
both HSWH and HSWOH. The median number of procedures were mostly stable over time
for both types of hospital stays with frequent fluctuations among HSWH. Median
procedures were lower for HSWH most of the years, yet differences were diminishing over
the years. The median LOS for HSWH was consistently higher than HSWOH, but the
median decreased over the years (Figure 5.1).
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Figure 5. 1 Trends of median resource utilization during hospital stays, 2003 to 2015.
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Figure 5.2 illustrates the yearly trends of median inpatient costs during hospital
stays, adjusted in 2015-U.S. dollars. Regular fluctuations were observed in median costs
for HSWH, which ended with a consistent increase of median costs from 2012 to 2015,
while median costs consistently increased for HSWOH except for a drop in 2009. The
median costs were consistently higher for HSWH at the beginning of the study period but
became lower than HSWOH in 2009 and afterward (Figure 5.2).
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Figure 5. 2 Trends of median inpatient costs (US$) during hospital stays, 2003 to 2015
5.4.2 Trends of Age-Specific Resource Utilization and Costs (median), 2003 to 2015
Table 5.1 shows the median inpatient resource utilization (#procedures and LOS)
and costs across age groups over the years. The median number of procedures decreased
for both types of hospital stays for all age groups except patients aged 65+ years. Among
patients of 65+ years old, the median number of procedures increased for both types of
stays from 2003 to 2015, but the increase was higher for HSWH. The median inpatient
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LOS decreased for HSWH among all age groups, while it increased among younger adults
(18-35 and 36-49 years) but decreased among elderly (65+ years) for HSWOH. The median
inpatient costs decreased among all age groups of patients during HSWH except for the
elderly, compared to the over the year increase among all age groups for HSWOH (Table
5.1).
Figure 5.3 describes the differences between HSWH and HSWOH in terms of
hospital resource utilization and costs. In figure 5.3A, differences in the median number of
procedures for younger (18-35 years) and elderly (65+ years) were positive over the years,
which indicates higher median procedure usages for HSWH. Procedure usages were lower
for HSWH among aged 36-49 years and 50-64 years, which produces negative differences
(HSWH<HSWOH) over the years. Increasing trends in difference lines suggest that the
gap in procedure usage increased over the study period among aged 18-35, 36-49, and 65+
years, while the differences were almost stable among 50-64 years old patients.
In figure 5.3B, differences in median LOS between HSWH and HSWOH were
consistently positive (HSWH>HSWOH) but decreasing for all age groups over the years,
which indicates that median LOS for HSWH and HSWOH were getting closer over the
study period. Similarly, in figure 5.3C, differences in median inpatient costs were
decreasing over time for all age groups, which indicates that the inpatient costs were getting
similar for HSWH and HSWOH over the years. The positive cost differences
(HSWH>HSWOH)

among

the

patients

aged

50-64

years

became

negative

(HSWH<HSWOH) in 2008 and afterward, which suggests substantial changes in the
hospital costs between HSWH and HSWOH over the years.
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Table 5. 1 Inpatient resource utilization and costs (median) by age groups during hospital stays, 2003 to 2015.

# of Procedures
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2003
Age (years)
HIV- HIV+
18-35
0.26 0.32
36-49
0.49 0.35
50-64
0.65 0.54
65+
0.31 0.45
Overall (yearly) 0.41 0.38
2010
HIV- HIV+
18-35
0.25 0.45
36-49
0.52 0.42
50-64
0.71 0.56
65+
0.40 0.63
Overall (yearly) 0.49 0.48

2004
HIV- HIV+
0.28 0.34
0.66 0.34
0.66 0.49
0.33 0.51
0.44 0.38
2011
HIV- HIV+
0.20 0.43
0.49 0.44
0.67 0.57
0.38 0.74
0.45 0.50

2005
HIV- HIV+
0.24 0.32
0.49 0.30
0.65 0.46
0.34 0.48
0.43 0.35
2012
HIV- HIV+
0.17 0.32
0.48 0.35
0.66 0.49
0.39 0.60
0.45 0.42

2006
HIV- HIV+
0.25 0.43
0.50 0.40
0.69 0.58
0.37 0.69
0.46 0.46
2013
HIV- HIV0.16 0.34
0.47 0.37
0.66 0.52
0.41 0.69
0.46 0.45

2007
HIV- HIV+
0.27 0.45
0.52 0.47
0.71 0.58
0.42 0.77
0.49 0.51
2014
HIV- HIV+
0.12 0.30
0.47 0.38
0.64 0.51
0.40 0.61
0.45 0.44

2008
HIV- HIV+
0.22 0.38
0.49 0.40
0.69 0.54
0.37 0.66
0.46 0.45
2015
HIV- HIV+
0.08 0.30
0.42 0.35
0.61 0.44
0.35 0.57
0.40 0.40

2009
HIV- HIV+
0.18 0.36
0.47 0.26
0.67 0.38
0.39 0.51
0.45 0.33
All years
HIV- HIV+
0.21 0.37
0.49 0.37
0.67 0.51
0.37 0.62
0.45 0.43

2007
HIV- HIV+
2.35 3.91
2.41 3.85
2.78 3.97
3.40 4.42
2.93 3.92

2008
HIV- HIV+
2.35 3.87
2.40 3.75
2.76 3.87
3.38 4.38
2.92 3.83

2009
HIV- HIV+
2.37 3.80
2.41 3.56
2.78 3.69
3.31 3.90
2.90 3.66

LOS (days)
2003
Age (years)
HIV- HIV+
18-35
2.27 4.19
36-49
2.42 3.97
50-64
2.82 4.29
65+
3.58 4.60
Overall (yearly) 3.00 4.09

2004
HIV- HIV+
2.33 4.03
2.45 3.97
2.82 4.12
3.54 4.78
2.99 4.03

2005
HIV- HIV+
2.29 3.95
2.40 3.91
2.79 4.13
3.52 4.41
2.97 3.97

2006
HIV- HIV+
2.33 4.05
2.42 3.83
2.77 4.08
3.43 4.25
2.94 3.94

2010
HIV- HIV+
18-35
2.40 3.63
36-49
2.42 3.54
50-64
2.78 3.69
65+
3.30 4.04
Overall (yearly) 2.90 3.63

2011
HIV- HIV+
2.39 3.64
2.42 3.38
2.77 3.68
3.23 3.69
2.88 3.55

2012
HIV- HIV+
2.43 3.56
2.45 3.38
2.77 3.53
3.19 3.58
2.87 3.48

2013
HIV- HIV2.47 3.55
2.49 3.43
2.80 3.56
3.22 3.78
2.90 3.53

2014
HIV- HIV+
2.55 3.54
2.55 3.51
2.83 3.62
3.22 3.74
2.93 3.58

2015
HIV- HIV+
2.57 3.44
2.58 3.53
2.83 3.56
3.23 3.72
2.94 3.55

All years
HIV- HIV+
2.39 3.81
2.44 3.71
2.79 3.78
3.35 3.95
2.93 3.76

2007
HIV- HIV+
6094 7980
6970 8367
8652 9305
8576 10625
8006 8652
2014
HIV- HIV+
6100 7425
7365 7854
9025 8799
8820 9472
8348 8294

2008
HIV- HIV+
6224 8041
7201 8094
8946 8915
8710 10562
8198 8447
2015
HIV- HIV+
6169 7321
7396 7912
9110 8664
8934 9849
8449 8332

2009
HIV- HIV+
5935 7565
6932 7364
8556 8296
8515 9158
7934 7787
All years
HIV- HIV+
6035 7680
7001 7779
8675 8749
8549 9638
8019 8180

COSTS (U.S. Dollar)

116

2003
Age (years)
HIV- HIV+
18-35
5859 7997
36-49
6628 8255
50-64
8097 9617
65+
8084 9456
Overall (yearly) 7530 8511
2010
HIV- HIV+
18-35
6100 7687
36-49
7075 7493
50-64
8740 8273
65+
8542 9318
Overall (yearly) 8042 7890

2004
HIV- HIV+
5770 7313
6561 7697
8135 8641
8224 9796
7575 7895
2011
HIV- HIV+
6089 7923
7204 7634
8796 8878
8552 9263
8112 8231

2005
HIV- HIV+
6004 7635
6792 7891
8385 9250
8357 10632
7789 8233
2012
HIV- HIV+
6064 7467
7205 7470
8806 8390
8628 8898
8147 7929

2006
HIV- HIV+
6041 8018
6884 8018
8537 9047
8514 10080
7912 8215
2013
HIV- HIV+
6096 7402
7288 7609
8946 8616
8776 9654
8286 8085
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Figure 5. 3 Differences in inpatient resource utilization and costs (median) between
hospital stays with and without HIV (HSWH-HSWOH), 2003 to 2015; (A) Number of
procedures, (B) Length of stay (LOS), and (C) Inpatient costs.
5.4.3 Resource Utilization and Costs for Hospital Stays with Major HANA
Conditions
Figure 5.4 shows trends of the differences between HSWH and HSWOH in terms
of median resource utilization and costs of care during hospital stays with five major
HANA conditions. In figure 5.4A, differences in the median number of procedures over
the years for five major HANA conditions were similar to the overall trends (all-cause
hospital stays). Like overall trends, trends of differences in procedure usage for bone loss,
diabetes, and cancer were mostly unchanged over the study period, after some fluctuations.
However, differences in procedure usage for liver disease increased but decreased for CVD
over the study period. Similar to the overall trend line, hospital stays with liver disease,
and bone loss showed negative differences in procedure usage over this period, which
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indicates a higher median number of procedures among HSWOH compared to HSWH.
Trends for differences in resource usage during hospital stays with cancer, CVD, and
diabetes had positive differences over time, which reflects a higher number of procedures
for HSWH compared to HSWOH (Figure 5.4A).
In figure 5.4B, similar to the overall (all-cause hospital stays) trend line, decreasing
trends of difference in median LOS were observed for hospital stays with cancer, CVD,
and liver disease. Increased differences in median LOS for hospital stays with bone loss
represent the increasing gap between HSWH and HSWOH over time in terms of hospital
LOS. Differences in median LOS were unchanged for diabetes after several fluctuations
over the years. All years’ positive differences in median LOS indicates that LOS were
consistently higher for HSWH over the study period for general hospital stays as well as
for hospital stays with five major HANA conditions (Figure 5.4B).
Figure 5.4C shows that differences in median costs for all-cause hospital stays
(overall) were decreased over the study period and became negative (lower costs for
HSWH) in 2009 and afterward. Decreased differences in median costs were also observed
during hospital stays for all major five HANA conditions. Differences in median costs were
positive (HSWH>HSWOH) for hospital stays with CVD and cancer, while it was negative
(HSWH<HSWOH) for liver disease and bone loss. There were regular fluctuations in
almost all trends line, but the drops in cost differences occurred for hospital stays with all
five major HANA conditions during the recession period (2008 and 2009) (Figure 5.4C).
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Figure 5. 4 Trends of differences in inpatient resource utilization and costs (median)
between hospital stays with and without HIV (HSWH-HSWOH) for hospital stays with
major HANA conditions, 2003 to 2015; (A) Number of procedures, (B) Length of stay
(LOS), and (C) Inpatient costs.
5.4.4 Multivariable Analyses
The results of the multivariable analyses are presented in Table 5.2 using the
exponential of β and 99% Confidence Interval (CI). Zero-inflated negative binomial model
[zero-model is presented in Appendix B (Table B.1)] represents the predictors of the
number of procedures used during hospital stays, and generalized linear models (GLMs)
represent the predictors of hospital LOS and costs. All the estimates presented in table 5.2
were statistically significant at the P-value of less than 0.01 unless otherwise stated.
Number of Procedures: In the unadjusted model, the relationship between the
number of procedures and hospital stays with HIV (HSWH) was negative (exp β<1). When
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controlled for the patient and hospital-level covariates, HSWH had a 30% lower utilization
of procedures compared to HSWOH. Each 10-year increase in patient’s age increased the
number of procedure counts by 3%.
In terms of covariates, females, African Americans, Hispanics, Medicare and
Medicaid beneficiaries, and uninsured had lower procedure usage compared to their male,
white, and privately insured counterparts, respectively. Weekend admission, inpatient stays
in rural hospitals, and in Midwest and South also had fewer procedure counts compared to
their respective reference categories. Besides, procedure usage increased for hospital stays
by non-metro patients, highest median income quartile, large bed size hospitals, and when
admission was elective, and that occurred in an urban teaching hospital, and West
compared to their respective reference categories. Also, longer hospital LOS were the
significant predictors of higher procedure use (Table 5.2).
Length of Stays: In the unadjusted model, the association of LOS with HIV and
age were positive (exp β>1). Similarly, controlling for the patient and hospital-level
covariates, the average length of stays was 32% higher for HSWH, and LOS increased
slightly by 1% per ten years of age.
African Americans, Medicare and Medicaid beneficiaries, uninsured, and higher
number of procedures were significant predictors of higher LOS during inpatient stays.
Non-metro patient location, higher-income quartiles, elective admission, medium bed size
hospitals, rural hospitals, and regions other than Northeast were significant predictors of
lower LOS compared to their respective reference categories. Also, the number of
procedures were strong predictors of LOS (Table 5.2).
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Inpatient Costs: In the unadjusted model, the relationship between inpatient costs
and HSWH and age were positive (exp β>1). Controlling for the patient and hospital-level
covariates, the associations of age and HIV with the costs were the same. HSWH had 13%
higher inpatient costs than HSWOH. A ten-years increase in age elevated the costs by 2%.
Females, Medicare and Medicaid recipients, uninsured, weekend admissions,
medium and large bed size hospitals, and hospitals from rural and South were the predictors
of lower inpatient costs compared to their reference categories. Hispanics, non-metro
patient location, higher-income quartiles, elective admissions, urban teaching hospitals,
and the West region were the predictors of higher costs during hospital stays. Also, hospital
LOS and number of procedures were strong predictors of inpatient costs (Table 5.2).
5.4.5 Multivariable GLMs for hospital stays with major HANA conditions
Table 5.3 represents the estimates for resource utilization and costs for the
independent variable, i.e., hospital stays with HIV and age, controlling for patient and
hospital-level covariates. Unlike the all-cause procedure model, age affects the procedure
usage negatively for hospital stays with major HANA conditions, except liver disease. For
hospital stays with CVD, cancer, diabetes, and bone loss, utilization of procedures
decreased by 3%, 2%, 1%, and 5% with per ten-year increase in age, respectively. The
positive associations of hospital LOS with age and HSWH in the all-cause LOS model
remained similar for all five major HANA conditions, even though the magnitude of the
relationships expressed by the exponential of β and 99% CI differs across the HANA
conditions (Table 5.3).
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Table 5. 2 Predictors of inpatient resource utilization and costs during hospital stays, 2003-2015 from the Generalized Linear Models
(GLM)a.

Number of Procedures
Variables

Unadjusted Model
Intercept
HSWH (Ref.= HSWOH)
Age (per 10 years)
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Adjusted Model
Intercept
HSWH (Ref.= HSWOH)
Age (per 10 years)
Patient-level characteristics
Sex
Male
Female
Race/ethnicity
White
African American
Hispanic
Others
Expected primary payer

Exp (β)*

99% CI
Min
Max
N= 69,633,686
(weighted 343 million)
1.34
1.34
1.34
0.79
0.78
0.81
1.05
1.05
1.05

Length of Stay (LOS)
Exp (β)*

99% CI
Min
Max
N= 69,633,686
(weighted 343 million)
4.04
4.03
4.04
1.63
1.62
1.65
1.04
1.04
1.04

Inpatient Costs
Exp (β)*

99% CI
Min
Max
N=65,582,213
(weighted 324 million)
10917
10910
10926
1.11
1.10
1.12
1.03
1.03
1.03

N=55,231,368
(weighted 272 million)
1.10
1.09
1.10
0.70
0.68
0.71
1.03
1.03
1.03

N=55,231,368
(weighted 272 million)
3.51
3.50
3.52
1.32
1.31
1.34
1.01
1.01
1.01

N=51,704,466
(weighted 255 million)
4144
4139
4148
1.13
1.12
1.14
1.02
1.02
1.02

1.00
0.89

0.89

1.00
1.00 ꝉ

1.00

1.00
0.97

0.97

0.97

0.95
0.99
1.05

1.00
1.05
0.99
1.04

1.05
0.99
1.04

1.00
1.00
1.03
1.03

1.00
1.03
1.03

1.01
1.03
1.03

1.00
0.95
0.99
1.04

0.89

0.95
0.99
1.04

1.00

1.05
0.99
1.04
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Private including HMO
Medicare
Medicaid
Self-pay
Others (incl. No charge)
Patient’s location
(rurality)b
Large metropolitan
Small metropolitan
Micropolitan areas
Not metropolitan or
micropolitan
Median Household
Income in ZIP
0-25th percentile
26th to 50th percentile
51st to 75th percentile
76th to 100th percentile
Readmission scores
Mortality scores
Hospital-level characteristics
Weekend admission
No
Yes
Elective admission
Non-elective

1.00
0.86
0.83
0.86
0.95

1.00
1.03
1.23
1.15

1.00
1.04
1.04
1.06
1.00
1.01

1.00
0.95
1.00

0.86
0.83
0.86
0.95

1.03
1.23
1.15

1.04
1.04
1.06
1.00
1.01

0.95

0.86
0.83
0.87
0.95

1.00
1.19
1.30
1.06
1.12

1.03
1.24
1.16

1.00
0.98
0.97
0.98

1.04
1.04
1.06
1.00
1.01

1.00
0.97
0.95
0.94
1.01
1.01

0.95

1.00
0.99
1.00

1.19
1.30
1.06
1.12

0.98
0.97
0.98

0.97
0.95
0.94
1.01
1.01

0.99

1.19
1.30
1.06
1.12

1.00
0.97
0.93
0.94
0.98

0.97
0.93
0.94
0.98

0.97
0.93
0.94
0.98

0.99
0.97
0.98

1.00
0.99
1.05
1.04

0.99
1.05
1.04

0.99
1.05
1.04

0.97
0.95
0.94
1.01
1.01

1.00
1.04
1.07
1.11
1.00
1.00

1.04
1.07
1.11
1.00
1.00

1.04
1.07
1.11
1.00
1.00

0.99

1.00
0.98

0.98

0.98

1.00
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Elective
1.24
1.24
1.24
0.98
0.98
0.98
1.30
1.30
1.30
Bed size
Small
1.00
1.00
1.00
Medium
1.14
1.14
1.15
0.95
0.95
0.95
0.97
0.97
0.98
Large
1.25
1.25
1.25
1.01
1.00
1.01
0.96
0.96
0.97
Location/teaching status
of the hospital
Urban non-teaching
1.00
1.00
1.00
Rural
0.66
0.66
0.66
0.97
0.97
0.97
0.97
0.96
0.97
Urban teaching
1.18
1.18
1.18
1.01
1.01
1.01
1.04
1.04
1.04
Region
Northeast
1.00
1.00
1.00
Midwest
0.96
0.96
0.96
0.88
0.88
0.88
0.99
0.99
0.99
South
0.97
0.97
0.97
0.92
0.92
0.92
0.95
0.95
0.95
West
1.02
1.02
1.02
0.88
0.88
0.88
1.22
1.22
1.22
LOS
1.03
1.03
1.03
N/A
1.07
1.07
1.07
Number of procedures
N/A
1.12
1.12
1.12
1.18
1.18
1.18
ꝉ
*All betas (β) were statistically significant at P<0.01, unless stated by superscript.
ꝉ
Estimate was not statistically significant at P<0.01.
(a) All models are controlled for year variables (2003 to 2015).
(b) Large metropolitan areas include central counties of metro areas (>1 million) and fringe counties of metro areas (≥1 million),
and small metropolitan areas contain counties in metro areas with 50,000-999,000 population. See methods section for details.

In Table 5.3, multivariable cost models for hospital stays with liver disease and
bone loss were very similar to general (all-cause hospital stays) cost models that HSWH
and age are positively associated with costs. However, cost models for CVD and Diabetes
are different from the general cost model; inpatient costs did not change significantly with
patient’s age. In the case of hospital stays with cancer, the multivariable model showed
inverse relationships of age and HSWH that we found in the general cost models. For
hospital stays with cancer, inpatient costs were significantly lower for HSWH and younger
(Table 5.3).

5.5 Discussion
The current study described hospital resource utilization and costs in the United
States for thirteen years and identified some critical issues. The procedure use during
hospital stays was lower among HSWH, but it increased substantially among older HSWH
compared to HSWOH. While the LOS and costs for HSWH were higher than that for
HSWOH, differences narrowed down over the study period among all age groups.
Multivariable analyses demonstrate that inpatient LOS and costs were significantly higher
among HSWH and older.
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Table 5. 3 Predictors of resource utilization and costs from the Generalized Linear Models (GLM)a for hospital stays with major
HANA conditions, 2003-2015.

Number of Procedures
Adjusted models
CVD
Intercept
HSWH
(Ref.= HSWOH)
Age (per 10 years)
Cancer
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Intercept
HSWH (Ref.=
HSWOH)
Age (per 10 years)
Diabetes
Intercept
HSWH (Ref.=
HSWOH)
Age (per 10 years)
Liver Disease

99% CI
Min
Max
N=40,276,849
(weighted 198 million)
1.84
1.83
1.85
0.63
0.61
0.65

Length of Stays (LOS)

Exp (β)*

Exp (β)*

Exp (β)*

0.97

0.96
0.97
N=9,118,172
(weighted 45 million)
1.48
1.47
1.49
0.76
0.72
0.80

1.01

1.01
1.01
N=9,118,172
(weighted 45 million)
3.52
3.50
3.54
1.43
1.38
1.48

1.00 ꝉ

0.98

0.97
0.98
N=15,408,908
(weighted 76 million)
1.42
1.41
1.43
0.59
0.56
0.63

1.02

1.02
1.02
N=15,408,908
(weighted 76 million)
3.40
3.38
3.41
1.26
1.22
1.31

0.98

0.98
0.98
N=14,454,669
(weighted 71 million)
4680
4669
4691
1.07
1.05
1.09

0.99

1.02

1.01

0.99
0.99
N=5,262,320
(weighted 26 million)

99% CI
Min
Max
N=40,276,849
(weighted 198 million)
3.36
3.35
3.37
1.32
1.30
1.34

Inpatient Costs

1.02
1.02
N=5,262,320
(weighted 26 million)

99% CI
Min
Max
N=37,742,702
(weighted 186 million)
5057
5050
5064
1.03
1.02
1.04
1.00
1.00
N=8,543,770
(weighted 42 million)
5552
5534
5570
0.98
0.96
1.00

1.01
1.01
N=4,926,126
(weighted 24 million)

Intercept
HSWH
(Ref.= HSWOH)
Age (per 10 years)
Bone Loss

0.98
0.80

0.99
0.84

3.22
1.51

1.03
1.03
N=13,648,868
(weighted 67 million)
1.85
1.83
1.86
0.51
0.48
0.55

1.02

1.03

0.97
0.77

3.20
1.47

3.24
1.55

5119
1.10

1.02
1.02
N=13,648,868
(weighted 67 million)
3.19
3.18
3.21
1.42
1.36
1.47

1.01

5101
1.08

5138
1.12

1.01
1.01
N=12,804,190
(weighted 63 million)
5020
5007
5033
1.12
1.09
1.15
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Intercept
HSWH
(Ref.= HSWOH)
Age (per 10 years)
0.95
0.94
0.95
1.03
1.03
1.03
1.01
1.01
1.01
ꝉ
*All betas (β) were statistically significant at P<0.01, unless stated by superscript
ꝉ
Estimate was not statistically significant at P<0.01
(a) HANA-specific models are controlled for sex, race/ethnicity, median household income, primary payer, patient’s location,
weekend, elective admission, bed size, location/teaching status of the hospitals, region, comorbidity scores, number of procedures,
length of stay, and year.

The number of procedures used during the U.S. inpatient stays is an essential
indicator of hospital resource utilization. This study found that on average HSWH used
fewer procedures than HSWOH, which may indicate delay or avoidance of nonurgent
procedures due to the risk of person-to-person transmission in healthcare settings from
performing invasive procedures and exposure-prone procedures (Flint et al., 2011;
Mitchell, Lewis, Maillard, Moore, & Weber, 2020; Polder et al., 1991). However, the aging
of PLWH might allow less flexibility to delay or avoid those procedures, because the virus
consistently activates the immune cells that make the individuals susceptible to
inflammation-induced diseases and diminishes their capacity to fight some diseases (Fauci
et al., 2010). Thus, the current study found disproportionate increase in procedure use
among elderly patients for HSWH compared to HSWOH. Consistent with the increasing
HSWH by older (Siddiqi, Olatosi, Ostermann, Zhang, & Khan), this study also showed an
increased number of procedures over the years for HSWH. We found no studies which
reported trends of procedures use during inpatient stays with all diagnoses; however, a
study reported increasing trends of the number of procedures among patients with the
Hepatitis C virus (Younossi et al., 2015). Studying procedure use is important because of
its role as a principal hospital cost driver (McDermott, Freeman, & Elixhauser, 2017;
Okunji et al., 2016). The number of procedures performed during inpatient stay contributes
to the longer length of stay, which may impact overall inpatient costs (Younossi et al.,
2015).
A longer duration of hospital stays is more common among the PLWH compared
to non-PLWH (Akgün et al., 2013; Pearce et al., 2012). While LOS is significantly higher
for HSWH, decreasing trends of differences in LOS between HSWH and HSWOH may
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indicate that the hospital resource use for PLWH is getting similar to that of other patients.
Previous hospital-based studies (Heslin & Elixhauser, 2016; Tai, Liu, & Merchant, 2015;
Zhao et al., 2007) and population-based studies (Yehia et al., 2010) demonstrated
decreasing trends of inpatient days among HSWH. This decrease among HSWH is
probably due to improved HIV care and services and presenting with similar conditions as
other hospital stays (Tai et al., 2015). However, this study observed overall higher length
of inpatient stays among HSWH compared to HSWOH. Longer duration of stays by the
symptomatic PLWH may contribute to keeping the average duration of stays up, when
hospital stays by asymptomatic PLWH are very similar to that of non-PLWH patients
(Rowell-Cunsolo et al., 2018).
Despite the positive effect of HIV infection on hospital LOS, the LOS decreased
over time for HSWH among all age groups, which may indicate LOS for HSWH is less
affected by the aging of PLWH. This may occur because LOS for HSWH is longer among
younger; thus, little change is observed with increasing age. This is the opposite of
HSWOH, where LOS increases with age. Similar to this finding, a previous study found
higher mean LOS among older patients (Weiss & Elixhauser, 2014). These findings are
the opposite of our hypothesis that HSWH have a higher burden of comorbidities and
longer inpatient stays compared to their HSWOH with increasing age. The first paper of
this series showed an overall lower prevalence of HANA conditions among any age groups
of PLWH compared to non-PLWH during their hospital stays, yet the differences were
getting narrower over time among older (Siddiqi et al.). This study demonstrates prolonged
hospital stays for HSWH but the higher impact of aging on HSWOH. Previous studies
showed that PLWH aged 50 years or older have higher hospitalization rates and length of
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stay compared to younger PLWH in the United States (S. A. Berry et al., 2012; Fleishman
et al., 2005; Tadros et al., 2012). However, these studies are lacked non-PLWH
comparators. The lack of studies comparing hospital stays across age between HSWH and
HSWOH made these study findings incomparable to the existing evidence.
Although previous studies showed increasing trends of inpatient costs over the
years for HSWH (Zhao et al., 2007), our study observed decreasing trends of inpatient
costs among HSWH over the study period. The sharp drops in inpatient resource utilization
and costs for HSWH during the recession period (2008 and 2009) suggest that HSWH were
disproportionately affected by the U.S. economic recession compared to HSWOH. In
addition, due to the availability of HAART and fewer hospitalization with AIDS-defining
illnesses, previous studies have projected lower health care costs for PLWH (Harling &
Wood, 2007; Hellinger, 1998; Meyer-Rath et al., 2013; Shapiro et al., 1999). However,
consistent with the previous studies (H. Krentz & Gill, 2015; Zingmond et al., 2017),
overall inpatient costs were found higher among HSWH compared to HSWOH during the
study period. The frequent and lengthy hospitalizations are common among some PLWH
that are considered as important cost predictors (S. A. Berry et al., 2012; Bozzette et al.,
2001; Guaraldi et al., 2013). Our study also found significantly higher LOS among HSWH
and identified LOS as a significant predictor of inpatient costs. A large portion of these
higher inpatient costs might be due to an increased proportion of HSWH by older patients
(Siddiqi et al., unpublished). Previous studies suggest that the average cost of HIV care is
consistently higher for older PLWH than younger PLWH (Gebo et al., 2010; Guaraldi et
al., 2013). With the aging of PLWH, despite a CD4 count equivalent to those of younger
patients, older patients still account for a higher burden of care and costs (H. Krentz & Gill,
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2015). The reduction of total care cost observed with increased CD4 cell count was
counterbalanced by the cost increase due to the increased age of the PLWH (Guaraldi et
al., 2013). While the current study observed a substantial increase in inpatient costs for
HSWOH over time among all age groups, costs for HSWH decreased over time among all
age groups except the elderly. The Ryan White HIV/AIDS Treatment Extension Act of
2009 might have a great contribution to reduce inpatient costs because it enables both
premium and cost-sharing coverage for the severely impacted areas or States through this
extension (Crowley & Kates, 2013). Also, this extension might enable HSWH to keep
inpatient costs lower than that of HSWOH in 2009 and afterward. An increase in overall
all-cause inpatient costs among older patients (B. Moore, Levit, & Elixhauser, 2014)
reflects the cost increase among HSWOH with age. Also, decreasing trends of median
inpatient costs for HSWH and increasing trends for HSWOH and older in recent years also
support the impact of aging on inpatient costs of HSWOH.
In our study, similar results from the models for hospital stays with major HANA
conditions demonstrate that the impact of the aging of PLWH on inpatient resource
utilization and costs does not vary for hospital stays with different major HANA
conditions, except few exceptions. As discussed earlier, with increased age, inpatient costs
for HSWH became similar to HSWOH; thus, our study did not observe substantial cost
variations with the aging of PLWH. Similar things also observed in cost models for major
HANA conditions. No significant variations were found between HSWH and HSWOH
with the aging during hospital stays with CVD and diabetes. Previous studies projected
higher resource utilization and costs as PLWH are living longer with multiple
comorbidities (Ward et al., 2020); thus future studies incorporating multiple HANA
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conditions are required to understand the effect of increased age-related comorbidities on
inpatient costs. However, the real impact of aging PLWH on inpatient resource use and
costs might be underreported in our study because of the higher hospital readmission by
the PLWH than their non-PLWH counterparts (S. Berry et al., 2016; Coelho et al., 2017).
Since NIS does not contain unique patient identifiers, it is not possible to identify
readmission and measure the true inpatient resource utilization and costs. Therefore,
hospital resource use patterns by the PLWH during hospital stays might be different from
the other health care settings.

5.6 Limitations
While this study provides a detailed picture of the impact of the aging PLWH on
U.S. inpatient stays, study findings should be interpreted with certain limitations
(Hashimoto et al., 2014; Sarrazin & Rosenthal, 2012). First, the unit of analysis of this
study is hospital stay, so all numbers and estimates represent the records of hospital stays,
and does not reflect individual-level information. NIS is not a longitudinal survey; thus,
there may be repeat hospitalization by an individual in a year or next (in case of pooled
data) with the same or different conditions. Patients with a high number of repeat hospital
stays may have skewed the findings. Unfortunately, the NIS did not contain unique patient
identifiers that would enable linking multiple hospitalizations by the same patient.
Nevertheless, given that the main objective of this study was to examine the association of
HIV and aging with hospital resource utilization and costs, the study results still provide
critical facts to inform the public health community. Second, this study excluded hospital
records that were discharged on the same day, and that indicated neonatal or pregnant
issues. Thus, the results are not reflective of all U.S. hospital stays, even though this study
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represent all-cause U.S. hospital stays. Also, the results are not reflective of hospital stays
in long-term care facilities, such as rehabilitation, psychiatric, alcoholism, and chemical
dependency hospitals, because the NIS collects data from U.S. short-term U.S. community
hospitals.
Third, the accuracy of claims data depends on the quality and consistency of coding
by participating hospitals. Thus, the ICD-9-CM codes we used to characterize patients’
illnesses may not accurately capture the primary reasons for patient’s hospitalization
because hospitals use these codes primarily for billing purposes. In this study, we described
the principal diagnosis as well as all-listed diagnoses that may minimize the impact of
coding bias substantially. Fourth, HCUP only provides hospital-wide cost-to-charge ratios,
which help to understand overall (all-cause) inpatient costs but may bias HANA-associated
costs in our study. Individual department- or disease-specific ratios might produce more
accurate cost estimates for the U.S. inpatient department; however, these ratios are not
available for NIS. Fifth, the number of diagnoses and procedures vary State by State; that
is, while some States provide as many as 74 diagnoses and 47 procedures, others may
provide as few as 9 diagnoses and 6 procedures. This could result in inconsistent prevalence
estimates. We checked the impact of this inconsistent data structure by conducting
sensitivity analyses. We calculated averages and reran the models after removing reporting
discrepancies across the States, and found similar results due to the relatively few cases
with a higher number of diagnoses and procedures. Finally, the analysis of a database
containing a large sample can increase the possibility of a type-I error, i.e., falsely
concluding that there is an important association where none exists (Lin, Lucas Jr, &
Shmueli, 2013). A statistical test with a large sample is likely to produce lower p-value,

135

showing significance but not necessarily clinical importance (Dahiru, 2008; Perera et al.,
2012). Therefore, we interpreted the study results emphasizing the 99% confidence interval
and clinical relevance of the associations.

5.7 Conclusions
This study finding confirmed our hypothesis of longer hospital stays and higher
costs by HSWH and increased procedures utilization for older HSWH. This study also
demonstrates that there is no additional impact of aging PLWH on inpatient length of stays
and costs for HSWH. Higher resource utilization and costs among HSWH by younger
adults deserve further investigation using individual-level data to assess whether the onset
of age-related comorbidities at the early age of PLWH contributes to this inpatient care
utilization. Future studies need to look into the lower utilization of procedures by HSWH
because this may indicate differential inpatient care utilization compared to HSWOH. The
source of this difference might be the avoidance of nonurgent procedures for some PLWH
due to the risk of person-to-person transmission in healthcare settings from performing
invasive procedures and exposure-prone procedures. In general, resource utilization and
costs increased with the older age, irrespective of the HIV status of the hospital stays. With
the aging of PLWH, the U.S. inpatient departments need to incorporate HIV specific
chronic disease management programs in inpatient care delivery to manage the future
increases in older PLWH and their age-related comorbidities. Policymakers,
administrators, and other stakeholders should investigate and focus on the types of surgical
procedures and comorbidities that incur longer inpatient stays and higher costs to make the
inpatient department more efficient as PLWH age in the United States.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS
This study demonstrates an increased presence of some age-related medical
conditions among HSWH, yet these higher comorbidities did not increase the length of
stays and costs for HSWH compared to HSWOH. These findings are reflective of the lower
impact of the aging of PLWH on inpatient care delivery. Lowering the gap in life
expectancy might also decrease the differences between hospital stays with and without
HIV in terms of inpatient resource utilization and costs. Nevertheless, the increased
presence of older patients with HIV and major age-related chronic conditions during
inpatient stays in recent years demonstrates the need for incorporating chronic disease
management programs in inpatient care delivery. The health care need might be different
for PLWH than the same-age non-PLWH during hospital stays because they might present
with multiple age-related comorbidities at a younger age, and those multi-comorbidities
and ART toxicities may results in frailty among younger PLWH. Thus, an adequate number
of HIV trained inpatient workforce and geriatric care providers should be in place for the
future. Studies using individual-level data that capture the onset of those chronic conditions
are needed to understand whether PLWH are having those age-related comorbidities earlier
than non-PLWH as they age.
Although some previous studies projected higher resource utilization and costs
among older PLWH due to long-term ART toxicities and multiple comorbidities, this study
only found increased procedure use with age; while, did not observe any differential trends
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for inpatient length of stays and costs by age among PLWH compared to non-PLWH. The
causes of this discrepancy can be two-folded: one, previous studies might not project for
inpatient care separately; second, higher readmission or frequent stays among PLWH
might underestimate the average length of stays and costs. Future studies capturing every
hospital stay of the individual patient and using an appropriate non-PLWH control group
will be able to give us more accurate results about the changing demand for inpatient
resources by the aging of PLWH. Policymakers, hospital administrators, and other
stakeholders should carefully observe the older patients with those disproportionately
increased chronic conditions to understand how age-related comorbidities contribute to the
resource utilization and costs during inpatient stays.
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APPENDIX A
SUPPLEMENT TABLES AND FIGURES FOR PAPER 1
Table A. 1 List of all diseases for five major types of HIV-associated non-AIDS (HANA)
conditions.
Conditions

CCS code

Cardiovascular Disease (CVD)
Heart valve disorders
Essential hypertension
Hypertension with complications and secondary hypertension
Acute myocardial infarction
Coronary atherosclerosis and other heart disease
Pulmonary heart disease
Other and ill-defined heart disease
Conduction disorders
Cardiac dysrhythmias
Cardiac arrest and ventricular fibrillation
Congestive heart failure; non-hypertensive
Acute cerebrovascular disease
Occlusion or stenosis of precerebral arteries
Other and ill-defined cerebrovascular disease
Transient cerebral ischemia
Late effects of cerebrovascular disease
Peripheral and visceral atherosclerosis
Aortic; peripheral; and visceral artery aneurysms
Aortic and peripheral arterial embolism or thrombosis
Other circulatory disease
Phlebitis; thrombophlebitis and thromboembolism
Varicose veins of lower extremity
Syncope
Cancer

96
98
99
100
101
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
245

Cancer of head and neck

11
157

Cancer of esophagus
Cancer of stomach
Cancer of colon
Cancer of rectum and anus
Cancer of liver and intrahepatic bile duct
Cancer of pancreas
Cancer of testis
Cancer of bronchus; lung
Cancer; other respiratory and intrathoracic
Cancer of bone and connective tissue
Melanomas of skin
Other non-epithelial cancer of skin
Cancer of breast
Cancer of uterus
Cancer of cervix
Cancer of ovary
Cancer of other female genital organs
Cancer of prostate
Cancer of testis
Cancer of other male genital organs
Cancer of bladder
Cancer of kidney and renal pelvis
Cancer of other urinary organs
Cancer of brain and nervous system
Cancer of thyroid
Hodgkin`s disease
Non-Hodgkin`s lymphoma
Leukemias
Multiple myeloma
Cancer; other and unspecified primary
Secondary malignancies
Malignant neoplasm without specification of site
Diabetes
Diabetes mellitus without complication
Diabetes mellitus with complications
Liver Disease

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

Hepatitis

6
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49
50

Biliary tract disease
Liver disease; alcohol-related
Other liver diseases
Bone Loss

149
150
151

Osteoarthritis
Other non-traumatic joint disorders
Spondylosis; intervertebral disc disorders; other back problems
Osteoporosis
Pathological fracture
Other bone disease and musculoskeletal deformities
Fracture of neck of femur (hip)

203
204
205
206
207
212
226

H O S PITAL IZAT IO N a , b RAT E S (PE R 100)
20-34
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65+

All
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2014 2015*

Figure A. 1 Hospitalization rates per 100 PLWH across age groups, 2003 to 2015 (single
HIV hospitalization by a PLWH).
*Total number of hospitalizations in 2015 is for the first three quarters (January to
September), however, the approximate rates were calculated by multiplying the number
of PLWH by ¾ to make the rates consistent with other years.
a

Source: HIV surveillance report, vol. 16-28, Center for Disease Control and Prevention
(CDC).
b

Excludes hospital stays by less than 18 years old, same-day discharges (LOS=0), and
that with a diagnosis code for pregnancy, labor, delivery, or neonatal cases.
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Table A. 2 Patient- and hospital-level characteristics of hospital stays, 2003, 2009, and 2015.
2003
Characteristics

160

Overall
Admission sourcea
Emergency Room
Another hospital
Another facility
incl. long term care
Court/law
enforcement
Routine/birth/other

2009

HIVHIV+
HIVHIV+
Unweighted Weighted Unweighted Weighted Unweighted Weighted Unweighted Weighted
n
%
n
%
n
%
n
%
5505953
99.19
45765
0.81
5490815
99.15
46798
0.85
3050951
214836
100753

55.59
3.95
1.82

33214
1195
670

72.76
2.64
1.45

653480
54027
32752

55.80
4.47
2.83

12988
580
434

72.22
3.14
2.35

5728

0.10

67

0.15

1366

0.12

59

0.34

2108079

38.54

10481

23.00

432235

36.78

4067

21.94

0.81

Overall

5490815

99.15

46798

0.85

3813082

2015 (Q1-Q3)ꝉ
99.19
31179

Transfer
Indicator
Not a transfer

5077648

92.77

44074

94.86

3458880

91.25

28938

93.43

268468

4.82

1525

3.24

228643

6.03

1391

4.49

131513

2.41

873

1.89

102935

2.72

644

2.08

2009

Transferred in from
a different acute
care hospital
Transferred in from
another type of
health facility

Control/ownerb
Government,
685391
12.73
10668
23.16
455238
11.94
5766
18.49
nonfederal
Private, non-profit
3932248
72.74
29356
63.77
2773865
72.75
21117
67.73
Private, invest-own
774188
14.53
5856
13.07
583979
15.32
4296
13.78
(a) Many missing values (4,345,625) in 2009, thus there are vast differences in frequency (n)
(b) Categories were dissimilar, therefore incomparable over the study periods
ꝉ This study analyzed data for quarter 1 to quarter 3 (January to September 2015), to avoid the transition in ICD codes from ICD9-CM to ICD-10-CM codes effective on October 1, 2015.
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APPENDIX B
SUPPLEMENT TABLES AND FIGURES FOR PAPER 2
TRENDS OF PROCEDURE USE
Mean # of Procedures, HIV-

Mean # of Procedures, HIV+

1.80
1.70

MEAN

1.60
1.50
1.40
1.30
1.20
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Figure B. 1 Trends of average procedure used during hospital stays, 2003 to 2015
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TRENDS OF LENGTH OF STAY
Mean LOS, HIV-

Mean LOS, HIV+

7.50
7.00

MEAN #DAYS

6.50
6.00
5.50
5.00
4.50
4.00
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Figure B. 2 Trends of the average length of hospital stays (number of days), 2003 to
2015.

T RE NDS O F INPAT IE NT CO S T S
Mean Costs, HIV-

Mean Costs, HIV+
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15311

US DOLLAR
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10000
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Figure B. 3 Trends of inpatient costs during hospital stays (US dollar), 2003 to 2015.
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Table B. 1 Predictors of number of procedure use during hospital stays, 2003-2015 from the Zero-Inflated Negative Binomial (ZINB)
Generalized Linear Models (GLM)a.

Number of Procedures (NPR)
Variables

Exp (β)*

Unadjusted Model

Zero-model (NPR=0)

99% CI
Exp (β)*
(OR)
Min
Max
N= 69,633,686
(weighted 343 million)
1.34
1.34
0.00
0.78
0.81
0.62 ꝉ
1.05
1.05
3.65

99% CI
Min

Max

0.06
3.63

6.68
3.66

1.34
0.79
1.05

Adjusted Model

N=55,231,368
(weighted 272 million)
1.10
1.09
1.10
0.70
0.68
0.71
1.03
1.03
1.03

N=55,231,368
(weighted 272 million)
0.40
0.40
0.41
0.91
0.82
1.00
1.16
1.16
1.16

1.00
0.89

0.89

1.00
1.12

1.12

1.13

0.95
0.99
1.05

1.00
0.96
0.80
0.78

0.96
0.79
0.78

0.97
0.80
0.79
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Intercept
HSWH (Ref.= HSWOH)
Age (per 10 years)

Intercept
HSWH (Ref.= HSWOH)
Age (per 10 years)
Patient-level characteristics
Sex
Male
Female
Race/ethnicity
White
African American
Hispanic
Others

1.00
0.95
0.99
1.04

0.89

0.95
0.99
1.04
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Expected primary payer
Private including HMO
Medicare
Medicaid
Self-pay
Others (incl. No charge)
Patient’s location (rurality)b
Large metropolitan
Small metropolitan
Micropolitan areas
Not metropolitan or micropolitan
Median Household Income in ZIP
0-25th percentile
26th to 50th percentile
51st to 75th percentile
76th to 100th percentile
Readmission scores
Mortality scores
Hospital-level characteristics
Weekend admission
No
Yes
Elective admission
Non-elective
Elective
Bed size

1.00
0.86
0.83
0.86
0.95
1.00
1.03
1.23
1.15
1.00
1.04
1.04
1.06
1.00
1.01

1.00
0.95
1.00
1.24

0.86
0.83
0.86
0.95

1.03
1.23
1.15

1.04
1.04
1.06
1.00
1.01

0.95

1.24

0.86
0.83
0.87
0.95

1.00
1.33
1.14
1.16
1.15

1.32
1.13
1.15
1.14

1.34
1.15
1.17
1.16

1.03
1.24
1.16

1.00
1.04
0.65
0.71

1.04
0.65
0.71

1.04
0.66
0.72

1.04
1.04
1.06
1.00
1.01

1.00
0.95
0.95
0.86
0.99
1.01

0.94
0.94
0.86
0.99
1.01

0.95
0.95
0.87
0.99
1.01

0.95

1.00
1.15

1.14

1.15

1.24

1.00
0.0
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Small
1.00
1.00
Medium
1.14
1.14
1.15
0.82
0.82
0.83
Large
1.25
1.25
1.25
0.77
0.77
0.78
Location/teaching status of the hospital
Urban non-teaching
1.00
1.00
Rural
0.66
0.66
0.66
1.63
1.62
1.64
Urban teaching
1.18
1.18
1.18
0.72
0.72
0.73
Region
Northeast
1.00
1.00
Midwest
0.96
0.96
0.96
1.51
1.50
1.52
South
0.97
0.97
0.97
1.31
1.30
1.31
West
1.02
1.02
1.02
1.07
1.06
1.08
LOS
1.03
1.03
1.03
0.76
0.76
0.76
Number of procedures
N/A
N/A
ꝉ
*All betas (β) were statistically significant at P<0.01, unless stated by superscript
ꝉ
Estimate was not statistically significant at P<0.01
(a) All models are controlled for year variables (2003 to 2015)
(b) Large metropolitan areas include central counties of metro areas (>1 million) and fringe counties of metro areas (≥1 million),
and small metropolitan areas contain counties in metro areas with 50,000-999,000 population. See methods section for details.

